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ABSTRACT 
 
Haematopoietic stem cells (HSCs) can migrate to the injured kidney and aid in tissue 
repair, however clinical success remains poor and is partially attributed to limited HSC 
recruitment. This study determined the molecular mechanisms governing HSC 
recruitment to the ischaemia-reperfusion (IR) injured kidney, whether this recruitment 
could be enhanced and also any immuno-modulatory effects HSCs may be having on 
surrounding injured microvasculature. HSC adhesion was significantly enhanced to the IR 
injured kidney compared to sham; this recruitment was governed by CD49d/VCAM-1 and 
CD44/HA. KC or SDF-1α pre-treatment enhanced HSC adhesion to the IR kidney.  KC and 
SDF-1α also increased CD44 and CD49d surface clusters on HSCs respectively, and 
therefore increased HSC adhesion to HA and VCAM-1. Following injection into IR injured 
mice, HSCs improved blood flow and kidney function in the injured kidney compared to 
sham. This may be related to inflammatory modulation, as neutrophil recruitment and 
number of platelet microthrombi were reduced following HSC administration. This is the 
first study to show that pre-treatment of HSCs increases their recruitment to the site of 
injury, and that recruitment of HSCs can reduce inflammatory cell infiltration following 
injury. 
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1 General Introduction 
  
1.1 Kidney disease and dysfunction 
1.1.1 Acute Kidney Injury 
Acute kidney injury (AKI) is common and arises from multiple initiating insults including 
ischaemia-reperfusion (IR) injury, glomerulonephritis, cardiovascular surgery, shock and 
sepsis.  It is characterised as a sudden and prolonged decline in glomerular filtration rate 
(GFR), which leads to an inability to remove metabolic waste, sustain fluid balance and 
electrolyte homeostasis (Devarajan 2006).  AKI affects 5% of all hospitalised patients and 
if untreated can develop into end-stage renal disease, therefore requiring dialysis or renal 
transplantation (Winterberg and Lu 2012).  Although a common condition, prognosis is 
poor and has not changed much over the past 40 years due to very few successful 
therapies being developed.  Evidence suggests AKI predisposes a person to accelerated 
chronic kidney disease (CKD) (Basile 2007).  Although the kidney has regenerative 
capacity, these mechanisms become overwhelmed during sustained periods of renal 
injury.  The lack of an effective pharmacological therapeutic intervention has led to AKI 
becoming a major emerging healthcare problem, particularly in an ageing population.  An 
increased hospital stay is associated with severe AKI, especially if renal replacement 
therapy is required (Chertow et al. 2005).  This clearly has a huge economic impact on 
healthcare resources. 
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1.1.2 Ischaemic Acute Kidney Injury 
The kidneys receive almost a quarter of cardiac output and it is disproportionately 
distributed to aid good urinary concentration; however, this does make kidney function 
particularly susceptible to changes in blood flow.  The kidney is made up of many tiny 
filtration units (nephrons) that act to sieve the blood (Figure 1.1).  As previously stated, IR 
injury is one of the main causes of AKI and it develops following a sudden transient drop 
in total or regional blood flow to the kidney.  It occurs in clinical practice in association 
with sepsis, shock, severe trauma and major cardiovascular surgery, which leads to a 
range of clinical manifestations (Stroo et al. 2009).  Patients with diabetes, congestive 
heart failure, liver cirrhosis or chronic renal failure are most at risk from ischaemic AKI.  
Once developed, ischaemic AKI therapy is predominantly supportive and continues to be 
associated with significant morbidity and mortality (Thadhani et al. 1996; Song and 
Humes 2009).  Studies in rats have shown that after weeks or months, surviving animals 
develop CKD and renal failure, as marked by increased tubulointerstitial fibrosis (Forbes 
et al. 2000; Basile et al. 2001).  AKI causes many changes to renal structure and function; 
this has been documented by most published groups as a substantial decrease in GFR 
shown by a 7-10 fold increase in serum creatinine.  This is one of the most serious 
functional changes in ischaemic renal injury, as even small changes are associated with 
increased mortality (Coca et al. 2007). 
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Figure 1.1. The kidney is made up of many functional units known as nephrons. The nephron is made up of three distinct parts: 1) the central 
filtration unit, the glomerulus; 2) a tubule that runs through the proximal, distal and intermediate segments of the kidney, that reabsorbs and 
secretes solutes to modify the passing filtrate; and finally 3) a duct that carries the urine into the collecting duct system prior to the bladder. 
There are up to a million nephron units per fully-functional human kidney. During AKI, the latter part of the proximal tubule, known as the S3 
segment, is most affected by the hypoxic environment.  This diagram was adapted from images published by the Algonquin College, Canada.  
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Clinically, ischaemic AKI is split into four different stages: 1) the initiation phase; 2) the 
activation phase; 3) the extension phase and 4) the maintenance stage. 
 
1. During the “initiation phase”, injury is first caused by the restricted oxygen and 
nutrient supply during ischaemia (Greek. isch- restriction, haema- blood).  Due to 
the decrease in blood flow, tissue metabolism is reduced and therefore restricts 
the resynthesis of energy-rich phosphates, e.g. adenosine 5’-triphosphate (ATP) 
and phosphocreatine.  As cellular levels of ATP fall, hypoxanthine accumulates in 
ischaemic tissue.  High levels of hypoxanthine react with the oxygen, via the 
enzyme xanthine oxidase, producing reactive oxygen species (ROS) (Figure 1.2).  
These molecules cause local endothelial damage.   
 
2. The “activation stage” swiftly follows and corresponds with the increased ROS 
numberss; this propagates renal inflammation by increasing adhesion molecule 
expression and enhances pro-inflammatory cytokine release from the vasculature 
(Eltzschig and Collard 2004). 
 
3. The third stage of ischaemic AKI is known as the “extension phase”.  Although 
blood flow returns during this phase, it is paradoxically the phase where most 
tissue injury occurs.  Red blood cells (RBCs), platelets and leukocytes adhere to 
the impaired area once blood flow is resumed (Eltzschig and Collard 2004).  Large 
numbers of adherent pro-inflammatory cell types severely reduce blood flow, 
thus cell death continues to rise, particularly in the susceptible corticomedullary 
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region.  Furthermore, post-resumption of blood flow, neutrophils in the 
vasculature become activated and produce higher levels of ROS, causing further 
oxidative stress (Tapuria et al. 2008).  
 
4. Lastly the “maintenance stage” is where cells undergo repair and re-establish 
cellular and tubular integrity if possible; however during longer periods of 
ischaemia these innate processes are not powerful enough to fully reverse cellular 
injury and require external treatment options. 
 
Endothelial dysfunction plays a central role in ischaemic AKI and is a common feature 
observed in other ischaemic organs, such as the heart, brain and liver (Patel et al. 2001; 
Nadar et al. 2005; Kavanagh et al. 2010).  Early on in AKI, the swelling of endothelial cells 
(ECs) in the renal vasculature leads to the narrowing of the vessel lumen, contributing to 
the “no-reflow” hypothesis.  Flores and colleagues were the first to demonstrate that 
endothelial swelling was an important part of ischaemic AKI, as reducing the lumen size 
hinders microvascular clearance (Flores et al. 1972).    
 
Further contributing to the smaller lumen size, the renal endothelium attenuates its 
release of endothelial nitric oxide synthase (eNOS) after an ischaemic insult, thereby 
reducing the generation of nitric oxide (NO), which is a potent vasodilator (Yamasowa et 
al. 2005).  It has been argued that continued constriction in the afferent arterioles 
feeding the glomerulus is central to the impaired GFR seen in AKI (Oken 1984).  
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NO can also inhibit platelet aggregation and this, plus other anti-coagulant substances, 
that act to reduce fibrin formation are released by the resting endothelium; however 
after ischaemia their production is haltered, promoting a pro-coagulant phenotype post-
IR injury.  Therefore clot formation is increased due to the increased deposition of fibrin, 
as seen in renal IR injury (Enestrom et al. 1988), contributing to a reduced blood 
perfusion, particularly at the corticomedullary junction.  Continued arteriole constriction, 
along with clot formation and the accumulation of platelets, leukocytes and red blood 
cells within the microvasculature, clogs and further compresses the peritubular 
capillaries, reducing blood flow. 
 
Blood flow within the kidney is differentially distributed (Figure 1.3) and during IR injury, 
blood flow from medullary regions is redirected to the cortex, which contains the 
glomeruli, to preserve their blood flow and function (Badr and Ichikawa 1988).  This 
redirection of blood flow reduces the oxygen partial pressure to 10% of its normal levels 
(Yamamoto et al. 1984).  Therefore, the most affected areas during ischaemic AKI are the 
outer medullary and corticomedullary regions, especially the lower descending part the 
proximal tubule, the S3 segment.  When blood flow to the tissue is resumed, it returns to 
40-50% of the normal range due to vascular congestion, resulting in prolonged cellular 
injury (Molitoris and Sutton 2004).  These alterations in blood flow contribute 
significantly to the continual worsening of kidney function over the following 24-48 hours 
(Regner and Roman 2012).  Permanent damage and even loss of peritubular capillaries 
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has also been recorded after ischaemia, which has been associated with development of 
tubulointerstitial fibrosis and increased blood pressure (Basile et al. 2001).   
 
Collective evidence therefore demonstrates that damage to the microcirculation is a 
major target of IR injury (Figure 1.4).  It follows that the development of new strategies to 
treat ischaemic AKI must involve approaches that improve renal microcirculatory 
haemodynamics, reduce pro-inflammatory cell recruitment and focus on endothelial 
repair. 
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Figure 1.2. Alterations in the cellular metabolism after ischaemia-reperfusion injury. The ischaemic period is predominated by a large 
reduction in ATP synthesis; this propels the cell into pro-apoptotic and oxidative phenotypes, leading to a complex series of events including 
the disruption of the cytoskeleton and cellular ionic homeostasis (Bonventre and Weinberg 2003).  Reperfusion causes the conversion of 
accumulated hypoxanthine into ROS, resulting in DNA damage and more specifically repressing protective gene products.  Large amounts of 
oxidative damage to endothelium occur, resulting in an upregulation of cytokines that help recruit and activate other cell types to 
exacerbate injury.  Diagram adapted from ‘Update on Mechanisms of Acute Kidney Injury’ (Devarajan 2006).  
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Figure 1.3.  Different areas of oxygenation within the kidney. The effects of an ischaemic 
insult vary in the different regions of the kidney.  This is because the normal ranges of 
oxygen partial pressures differ between the outer renal cortex and the inner medulla.  
The outer cortex receives the majority of the blood flow that the kidney receives, 
therefore exposing the endothelium here to more oxygen.  The outer medulla receives a 
relatively small proportion of blood flow, which explains the lower partial pressure of 
oxygen see here.  During IR injury, a reduction in total blood flow can be reduced to 40-
50% of normal figures, further reducing the decreased flow seen in the medulla 
(Lieberthal 1997).  Diagram taken from ‘Hypoxia of the renal medulla – its implications for 
disease’ (Brezis and Rosen 1995). 
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Figure 1.4.  Effects of IR injury on the microvasculature. Cytokines, leukotrienes and ROS are released from the activated endothelium and 
cells during IR injury.  Many of these released chemical mediators enhance neutrophil adhesion, which are the major exacerbators of IR injury.  
There are many effects of IR injury on the surrounding microenvironment and some of these are outlined above. 1. vascular congestion from 
RBC , leukocytes and other cell types; 2. endothelial cell swelling; 3. leukocyte adhesion; 4. thrombosis formation; 5. upregulation of adhesion 
molecules, e.g. VCAM-1 and ICAM-1; 6. vasodilatation due to perturbed eNOS activity.  All these effects cause a decrease in renal perfusion, 
which causes significant surrounding tissue hypoxia (Singbartl et al. 2001).  This phenomenon has been described in both animal models of 
ischaemic AKI and in the human condition (Sutton et al. 2002).   
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1.2 Inflammatory Cell Types at the Ischaemia-Reperfusion Injury Interface 
 
1.2.1 Inflammatory Response 
IR injury initiates an inflammatory reaction.  Inflammation is a localised protective 
reaction to a source of irritation, injury or infection and is mediated by the immune 
system.  Depending on the situation, the immune system has either the innate or 
adaptive response.  The innate response is the first line of defence and plays an 
important role in ischaemic AKI.  It requires no prior exposure to the insult and is 
activated by toll-like receptors (TLRs).  These are a large family of transmembrane 
proteins that serve to recognise a wide range of pathogen-specific molecular structures 
(Akira et al. 2006).  When infection or tissue damage occurs, TLRs on resident 
parenchymal cells are activated and then secrete chemoattractants, causing rapid 
leukocyte recruitment to the site of injury.  Once these leukocytes (mainly neutrophils 
and macrophages) are recruited, they can clear pathogens, invading microorganisms and 
any damaged cells by engulfment.  To complement the innate immune response, the 
body has an adaptive immune response, which includes the other leukocyte sub-sets, 
mainly T- and B-cells.  The adaptive immune response occurs up to 10 days post-
injury/infection.  B-cells produce specific antibodies against a particular pathogen and 
have immunological memory; therefore, if there is another exposure to the same 
pathogen, a specific immune response will be more rapid.  The efficiency of the 
inflammatory response is dependent on the highly orchestrated movement and actions 
of many different inflammatory cell types.  
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1.2.2 Different Leukocyte Populations Contribute at Different Time Points in IR Injury 
During renal IR injury, there is an influx of inflammatory cells in response to the original 
insult.  Cytokines and chemokines are released from the injured kidney; these are small 
secreted molecules that act to activate and attract cells and will be further discussed in 
section 1.3.2.  When circulating leukocytes are activated by these factors, they become 
more rigid and subsequent firm adhesion to the injured endothelium occurs, contributing 
to the vascular congestion. (Akcay et al. 2009).  Different subtypes of leukocytes may 
contribute different effects to IR injury (Linas et al. 1988; Klausner et al. 1989).   
 
1.2.2.1 Neutrophils Govern Early Stages of Renal IR Injury 
Neutrophil influx and adhesion is now considered a hallmark of substantial IR injury, 
including that of the kidney (Linas et al. 1988; Kelly et al. 1994; Linas et al. 1995; Rabb et 
al. 1995; Kelly et al. 1996).  Soon after the ischaemic insult, several studies have shown 
that adherent post-ischaemic neutrophils are mainly located in the medullary regions, 
which is not surprising as these are the areas of most injury (Willinger et al. 1992).  After 
adherence and chemotaxis into the tissue, infiltrating neutrophils can release ROS that 
damage the surrounding areas (Linas et al. 1988).  To further support this, creatinine 
levels have been shown to be positively correlated with the number of neutrophils at the 
time of ischaemia.  Blocking the neutrophil adhesion receptor, E-selectin, or using anti-
neutrophil serum in vivo, improves injury scores and kidney function (Singbartl and Ley 
2000).  Other studies have shown that by reducing neutrophil infiltration, tissue injury is 
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ameliorated (Paller 1989; Kelly et al. 1994).  Although there are many studies like these 
showing that neutrophils are involved in the progression of AKI, injury is still seen in 
patients who are neutropenic, which suggests that neutrophil depletion alone is not 
sufficient to protect against AKI (Franca et al. 2013). 
 
1.2.2.2 Later Stages of AKI are Characterised by Macrophage and T-lymphocyte 
Infiltration 
Later stages of renal IR injury are characterised by macrophages and T-lymphocytes, 
which predominate over neutrophils (Klausner et al. 1989; Takada et al. 1997).  
Macrophages are a source of pro-inflammatory molecules such as TNF-α, IL-1β, and iNOS, 
all of which have been shown to propagate renal disease (Nikolic-Paterson and Atkins 
2001).  Macrophage-mediated effects on the renal medulla after IR injury have been 
noted in both mouse and rat models (De Greef et al. 2001; Jo et al. 2006).  Regarding T 
lymphocytes, one study demonstrated that mice that lacked both CD4+ and CD8+ T-cells 
were protected from renal IR injury.  When naïve CD4+ and CD8+ T cells were injected 
back into the IR animal, renal damage occurred; this data suggests a role for T cells in 
ischaemic injuries (Rabb et al. 2000).  Similar results were also seen in a cisplatin model of 
AKI (Liu et al. 2006). 
 
1.3 Leukocyte-Endothelial Adhesion Cascade 
Leukocyte adhesion to endothelial cells is a main contributor of IR injury, as their 
presence determines the duration of damage (Buras and Reenstra 2007).  Leukocytes 
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arresting from flow was initially proposed by Cohnheim over 135 years ago (Cohnheim 
1877).  Since then, our understanding of leukocyte recruitment has improved.  The 
leukocyte-endothelial adhesion cascade, which was initially proposed by Butcher (1991), 
involves four main steps: tethering, rolling, firm adhesion and transmigration; an 
overview of this is illustrated in Figure 1.5. 
 
1.3.1 Rolling Phase Governed by Selectins 
Capture and slow rolling of passing leukocytes is essential if these cells are to stably 
adhere to the injured endothelium.  Slow rolling largely mediated by a cell-surface 
glycoprotein family called selectins.  These are categorised into E-selectin, P-selectin and 
L-selectin (Rosen and Bertozzi 1996).  The only ligand known to interact with all three 
selectins is P-selectin glycoprotein 1 (PGSL-1) (Katayama et al. 2003; Sperandio et al. 
2003).   
 
Under baseline conditions, E-selectin expression is negligible; however after injury, E-
selectin expression by the inflamed endothelium increases, taking several hours to reach 
maximal expression (McEver 1991).  E-selectin can also bind to glycosylated CD44 and E-
selectin ligand 1 (ESL1) (Steegmaier et al. 1995; Dimitroff et al. 2001).   
 
P-selectin is stored in the Weibel-Palade bodies of endothelial cells and in the 
membranes of platelet α-granules.  After renal IR injury, P-selectin is quickly upregulated 
(< 10 minutes) on the endothelial surface and can interact with PGSL-1 on passing 
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leukocytes; this interaction is of low affinity and therefore cannot support stable 
adhesion, but rather allows leukocytes to roll on the endothelium (Norman et al. 1995).  
Both E-selectin and P-selectin are up-regulated on the endothelial surface during renal 
ischaemia (Eppihimer et al. 1997; Molitoris and Marrs 1999).  Reduction of E- and P-
selectin using mutant animals and function-blocking antibodies in models of ischaemic 
AKI have reduced injury; most likely due to decreased leukocyte adhesion (Singbartl et al. 
2000; Singbartl and Ley 2000).   
 
L-selectin is not expressed on endothelial cells, but on all monocytes, neutrophils, 
lymphocytes and haematopoietic progenitor cells (Sackstein 1997).  The main role of L-
selectin is to govern naïve T cell homing into lymphoid tissues (Gallatin et al. 1983) and 
has been shown to functionally interact with E- and P-selectins (Lawrence et al. 1994).  
Redundancy in selectin roles has been proposed in certain situations, which may explain 
why, following IR-induced AKI in L-selectin -/- mice, no changes in adherent leukocytes or 
renal injury levels were reported (Rabb et al. 1996). 
Chapter 1: General Introduction 
 
17 
 
 
Figure 1.5.  The leukocyte-endothelial adhesion cascade.  This multi-step adhesive cascade was characterised by 4 main stages: rolling; 
activation; firm adhesion; and lastly migration (Butcher 1991).  The start of this cascade involves the selectin family to firstly cause the 
slowing of the leukocytes from the circulation and initiate their rolling on the endothelium; secondly, the increases in chemokine 
concentrations trigger leukocyte activation and they subsequently flatten; activated leukocytes then make strong connections with the 
endothelium through integrin receptors, such as immunoglobulin cell adhesion molecules, ICAM-1 and VCAM-1; and lastly once firm 
adhesion takes place, these flattened cells can migrate towards cell junctions and transmigrate through the endothelial layer into the tissue 
using a variety of EC adhesion molecules.  Further insights into this mechanism have been dissected by using in vitro flow models and in vivo 
intravital techniques; there is thought to be sub-steps within this process including slow rolling, adhesion strengthening, intraluminal 
crawling and migration through basement membrane.  Diagram adapted from Ley and Tedder (Ley and Tedder 1995).   
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1.3.2 Activation of Rolling Leukocytes Governed by Chemoattractants 
Selectin-mediated rolling allows the leukocyte to ‘sample’ the surrounding environment 
and transmit those signals through G-protein-coupled receptors (GPCRs) (Alon and Ley 
2008).  In the context of inflammation, cytokines are produced by the activated 
endothelium and they interact with their corresponding receptor on target cells, 
including neutrophils or stem cells (SCs).  Cytokines are small 7-30 kDa secreted proteins 
that principally act to regulate immune and haematopoietic cell proliferation and activity.  
Cytokines can be grouped broadly into interleukins (IL), colony-stimulating factors, 
interferons, chemokines and growth factors.  Secreted chemokines are extracellular 
signalling molecules that create a chemotactic gradient for surrounding cells and can also 
modulating all areas of the adhesion cascade by causing changes in integrin affinity and 
avidity (Ley et al. 2007).  The cytokine family targets cells over a range of distances and 
can further activate the cells which secreted them.  Following GPCR activation by a 
cytokine, rapid inside-out signalling results in almost instantaneous integrin activation 
(Shamri et al. 2005).  Several cytokines and chemokines are involved in this process but 
within this study we looked only at IL-1, KC (murine IL-8), SDF1α and TNF-α. 
 
1.3.2.1 Interleukin-1β 
Interleukins (IL) were the first shown cytokines to be released from leukocytes.  Local 
production of IL-1β and/or TNF-α by polymorphonuclear neutrophils increases E- and P-
selectin expression on endothelium.  This increases leukocyte binding and infiltration into 
injured tissues, therefore promoting further injury (Rice and Bevilacqua 1989; Weller et 
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al. 1992).  More recently, injured endothelium has shown elevated IL-1β gene expression 
and been shown to release IL-1β into the circulation 4 hours post-reperfusion (Jo et al. 
2006).  Upon endothelial activation, IL-1β is released in its inactive form and is cleaved by 
the pro-inflammatory enzyme, caspase-1. After cisplatin induced AKI, IL-1β plasma 
concentrations were increased in WT mice, but by using caspase-1-/- mice, IL-1β levels 
were reduced (Faubel et al. 2007).  However, direct blocking of its receptor IL-1R does not 
affect injury markers (Haq et al. 1998), thereby questioning the involvement of IL-1β in 
AKI. 
 
1.3.2.2 Keratinocyte-derived Chemokine 
Keratinocyte-derived chemokine (KC; CXCL1; murine functional homologue of human IL-
8) is a strong leukocyte chemoattractant and is released by a variety of cells, including 
leukocytes and endothelial cells (Yoshimura et al. 1987; Schroder and Christophers 1989).  
KC production can be increased by pre-treating with IL-1 or TNF-α (Detmers et al. 1990).  
KC acts to recruit both neutrophils and T-lymphocytes to the site of inflammation 
(Frangogiannis 2007) and has also been shown to trigger monocyte arrest on 
atherosclerotic endothelium (Huo et al. 2001).  The main chemokine receptor for KC is 
CXCR2, but it can also interact with CXCR1.  When a CXCR2 inhibitor, repertaxin, is used in 
a model of rat renal transplantation, neutrophil infiltration is reduced and renal function 
is preserved (Cugini et al. 2005).  Intravital microscopy shows that leukocyte rolling in 
CXCR2-/- murine cremaster venules have an increased velocity compared to WT mice 
(Morgan et al. 1997), implicating this receptor in the slow rolling stage of the leukocyte 
adhesion cascade.  KC levels are increased in serum readings 2 hours after AKI (Molls et 
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al. 2006).  This could be useful as an early biomarker for AKI, so that patients could be 
subjected to treatment before any substantial or irreversible damage is done.   
 
1.3.2.3 Stromal Cell Derived Factor-1α 
Stromal cell derived factor-1α (SDF-1α; CXCL12) is a chemokine that has been extensively 
studied with regards to its role in the regulation of cell migration and inflammation.  Its 
receptor, CXCR4, is present on all immune cells and those of the central nervous system.  
CXCR4-deficient mouse embryos have several lethal defects, including the bone marrow 
being devoid of progenitor cells (Ratajczak et al. 2006).   SDF-1α was originally purified 
from bone marrow (BM) stromal cell releasate, which established a high chemokine 
concentration in the BM (Sweeney et al. 2002).  Surratt and colleagues (2004) have 
shown that this high concentration of SDF-1α acts to retain CXCR4+ neutrophils in the BM 
under normal conditions.  SDF-1α is upregulated during many tissue injuries, including 
kidney IR (Togel et al. 2005) and disrupts the BM concentration gradient, consequently 
causing neutrophil and progenitor cell egress (Hattori et al. 2001).  Until recently, CXCR4 
was thought to be the sole receptor of SDF-1α, but CXCR7 has also been identified and 
shown to dimerise with CXCR4 to regulate its activity (Sierro et al. 2007). 
 
1.3.2.4 Tumour Necrosis Factor-α 
Tumour necrosis factor-α (TNF-α) is released from infiltrating leukocytes and can activate 
the endothelium and stimulate the production of many other cytokines and chemokines, 
including KC and IL-1β (Detmers et al. 1990).  It is involved in the acute phase of 
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inflammation and is deregulated in many diseases, including cancer (Charles et al. 2009).  
Raised levels of TNF-α are shown in chronic end-stage renal disease patients on 
haemodialysis and they correlate with their life-expectancy (Balakrishnan et al. 2004).  
Elevated levels were also seen in patients with AKI, but at a lower extent to those of a 
chronic nature (Ficek et al. 2006).  Reducing circulating TNF-α concentration causes 
decreased leukocyte rolling, adhesion and vascular leakage in ocular inflammation 
(Koizumi et al. 2003).  TNF-α has been shown to be increased after myocardial IR injury 
and further exacerbates damage by producing ROS leading to coronary endothelial 
dysfunction (Zhang et al. 2006). 
 
1.3.3 Firm Adhesion Governed by Integrins 
Integrins are a superfamily of cell adhesion transmembrane receptors.  They are made up 
of an α- and a β-chain and can bind to extracellular matrix (ECM) components, cell-
surface ligands and some soluble molecules.  There are eighteen α-integrins and eight β-
integrins that can dimerise to form 24 distinct heterodimer integrins.  These receptors 
can switch between low- and high-affinity states according to the state of the local 
environment, i.e. cytokine concentrations, to mediate stable adhesion to their 
endothelial counter-ligands (Hynes 2002).  The functions of the α4β1 integrin VLA-4 (very 
late antigen-4) and the β2 integrins have been widely investigated and are discussed 
below.    
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1.3.3.1 CD49d 
CD49d is the α4 chain which can bind to the β1 chain, CD29 to form the integrin, VLA-4 
(α4β1).  This integrin is found on most leukocytes and mainly interacts with vascular cell 
adhesion molecule-1 (VCAM-1) on endothelial cells or fibronectin within the ECM.  This 
integrin is best known for its role in lymphocyte adhesion to its counter-ligand VCAM-1 
on the inflamed endothelium (Elices et al. 1990).  Studies have shown that VLA-4/VCAM-1 
is essential for the release of neutrophils from the BM into the periphery and this process 
is regulated by the SDF-1α/CXCR4 pathway.  SDF-1α enhances neutrophil binding to 
VCAM-1 coated plates and injecting antibodies against both CXCR4 and VCAM-1 further 
enhanced neutrophil mobilisation compared to that seen when each antibody is 
administered separately (Petty et al. 2009).  This is most likely due to SDF-1α initiating the 
clustering of VLA-4 via GPCR signalling (inside-out signalling), as previously seen in 
lymphocytes (Grabovsky et al. 2000).  These results show the importance of crosstalk 
between chemokines and adhesion molecules.  Similar crosstalk has also been shown 
regarding human SC adhesion and transmigration (Peled et al. 2000).  
   
1.3.3.2 CD18 
CD18 is the β2 subunit for three separate integrins, associating with αL (CD11a), αM 
(CD11b) or αx (CD11c) to form Mac-1, LFA-1 and integrin αxβ2 respectively (Chakravorty 
et al. 1999).  Inflammatory mediators, such as platelet activating factor (PAF) and 
leukotrienes, can induce CD18 expression on neutrophils within 2 minutes, which allows 
rapid adhesion of neutrophils to the endothelium (Granger and Kubes 1994).  β2 integrins 
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on mature leukocytes can bind to ICAM-1 (intercellular adhesion molecule-1) expressed 
on the endothelium (Springer 1994).  Expression of renal ICAM-1 is increased on the 
endothelium in response to ischaemic injury (Ichikawa et al. 1997).  ICAM-1 deficient 
mice are protected from acute renal IR injury (Kelly et al. 1996), implicating the role of 
ICAM-1 in worsening acute tubular necrosis.  This protective effect of blocking ICAM-1 
was also seen by Rabb et al. (1995), as administering monoclonal ICAM-1 blocking 
antibodies up to 2 hours post-ischaemia can reduce injury.   
 
1.3.4 Non-Integrin CD44 Based Leukocyte Adhesion 
CD44 is a type I transmembrane glycoprotein expressed on a variety of cell types, 
including leukocytes and endothelial cells.  It is encoded by a single gene with multiple 
splice sites, resulting in the expression of various splicoforms.  All splicoforms have a 
hyaluronan (HA) and osteopontin binding site, which are the major ligands for CD44.  
Also, interactions with VLA-4 can enhance firm adhesive endothelial contact (Nandi et al., 
2004).  CD44 is involved in leukocyte activation, haematopoiesis, and SC migration when 
modified.  Under normal conditions, CD44 is minimally expressed in the kidney but after 
renal inflammation expression is markedly increased, especially on glomerular cells 
(Burne et al. 2001).  Rouschop et al. (2005) discovered that endothelial CD44 governs 
neutrophil trafficking in their renal IR injury model; blockade or deficiency of endothelial 
CD44 caused a decrease in the number of infiltrating neutrophils into the ischaemic 
kidney tissue, improved renal function and reduced renal fibrosis. 
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1.3.5 Transmigration 
Following firm adhesion, leukocytes must migrate through the endothelium and into the 
underlying inflamed tissue stroma with minimal disruption to the vessel wall.  
Transendothelial migration (TEM) is known as the point of no return regarding 
inflammation, as all previous steps in the leukocyte-endothelial cascade can be reversed.  
Paracellular transmigration is a well-described process involving cell movements through 
cellular junctions in the endothelium monolayer; this is the most common way cells cross 
the endothelial barrier.  It has been shown that neutrophils can migrate through an 
endothelial cell, but this event is rare (Feng et al. 1998). 
 
1.3.6 Platelets 
Another cell type that plays a role in IR injury is the platelet. They are discoid-shaped 
cells, with their diameter measuring between 0.5 - 3μm.  In mammals, platelets are 
anucleated cells that originate from BM-derived megakaryocytes and circulate within the 
body, ready to respond to losses in vessel integrity.  For years it was thought that 
platelets could only adhere to the exposed subendothelial collagen matrix, but now it is 
understood that under high shear stress inflammatory conditions, such as IR injury, GPIb 
on the platelet surface can interact with von Willebrand factor (vWF) on intact but 
activated endothelium early after reperfusion (Chintala et al. 1994; Clemetson and 
Clemetson 2008).   
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During IR injury, endothelial cells synthesize tissue factor and bind soluble fibrinogen. 
This, along with platelet inhibition by endothelial NOS and PGI2 production being 
perturbed, promotes platelet aggregation (Frenette et al. 1998; Yamasowa et al. 2005).  
Platelet accumulation is inversely proportional to blood flow (Laws et al. 1983).  Once 
attached to the activated endothelium through P-selectin (Massberg et al. 1998), 
platelets release IL-1β and soluble CD40-ligand, which acts upon the endothelium to 
support further platelet adhesion and maintain the stability of the developing thrombus 
(Massberg et al. 2002; Theilmeier et al. 2002).  Also, when thrombin-activated platelets 
were co-incubated with human intestinal endothelial cells (EC), the ECs became activated 
and released more IL-8 coupled with an upregulation of ICAM-1 and VCAM-1 expression, 
all of which promotes leukocyte-endothelium adhesion (Danese et al. 2004).  
 
Therefore, it is not surprising that platelets have been shown to be involved in the 
pathogenesis of IR injury. Platelet adhesion has been shown to increase with increasing 
reperfusion times whereas, without injury, platelet adhesion is negligible (Carvalho et al. 
1974).  When platelets are depleted in a coronary artery occlusion-reperfusion rabbit 
model, there was a reduced infarct size and improved heart function (Golino et al. 1987).  
Platelets can also bind to leukocytes, via P-selectin and P-selectin glycoprotein ligand-1 
(PGSL-1), to form heterotypic aggregates in the circulation and in microvascular beds 
(Weyrich et al. 2003).  Activated platelets help to recruit neutrophils to sites of 
inflammation in experimental models of AKI (Singbartl et al. 2000).  Platelets also release 
a concoction of inflammatory mediators, such as PAF, SDF-1α and various cytokines, 
which all promote a pro-inflammatory environment.   
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1.4 Injury Diagnosis, Renal Repair and Current Treatments 
 
1.4.1 Injury Diagnosis 
Despite our increased understanding of AKI over the last decade, diagnosis of this 
condition is still poor.  This is mainly due to very few sensitive early biomarkers of injury, 
the heterogeneity of the disease and not being able to detect the severity to give the 
most suitable treatment (Tsagalis 2011).  The kidney receives 25% of cardiac output and 
facilitates the high GFR required for regulating the body’s fluid and electrolyte balance.  
After renal IR injury, there is a drop in blood flow and consequently a fall in GFR, which 
produces an increase in nitrogenous waste products in the blood, such as urea and 
creatinine (Thadhani et al. 1996).  Currently, serum creatinine is the most common 
indicator of kidney function that is used clinically: it has been suggested that creatinine 
should be used to differentiate between different degrees of kidney damage so that the 
appropriate treatment can be given accordingly (Bellomo et al. 2004).  There is now an 
increased recognition that even relatively small rises in serum creatinine are associated 
with poor prognosis, with high rates of morbidity and mortality (Chertow et al. 2005; 
Ostermann et al. 2008).  
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1.4.2 Renal Repair Following Ischaemia-Reperfusion Injury 
The kidney is a highly complex organ made up of many cell types.  Even though the cell 
turnover rate of the kidney is much lower than other organs, such as the gut and skin, the 
kidney still has auto-regenerative capacity (Iwatani and Imai 2010) and can recover from 
short periods of kidney damage.  Due to the large transport demands and the 
architectural arrangement of the kidney, cells of the kidney are likely to experience toxic 
insults and ischaemia.  Proximal tubules in particular can be susceptible to such damage 
but have been shown to undergo repair after short periods of ischaemic damage; the 
apoptotic epithelial cells generate signals that initiate the repair response (Toback 1992).  
Some groups have shown that in both human and animal models of AKI, the tubular cells 
which surround the injury start to change their phenotype and begin to proliferate more 
quickly than usual (Witzgall et al. 1993; Abbate et al. 1999).  However when injury is more 
substantial the kidney cannot repair itself, which results in persistent tubulointerstitial 
inflammation and fibroblast proliferation; both of which cause fibrosis to develop.  Due to 
the kidneys innate repair processes being overwhelmed, external assistance is required. 
 
1.4.3 Existing Treatment Options 
Once AKI develops, supportive measures aside, there is no treatment available to 
effectively treat or prevent it.  Severity differs between patients who have AKI, but in 
critically ill patients mortality rates are as high as 50% (Karsou et al. 2000).  Patients who 
experience AKI require dialysis or subsequently progress to CKD.  The number of people 
suffering from AKI and CKD is increasing and in 2006, $23 billion was spent on their 
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medical care, as calculated by the U.S. Renal Data System.  Available therapies at the 
moment cannot enhance kidney repair or regeneration.  Renal replacement therapies 
such as dialysis are used, but this only helps the excretory function of the kidney and 
although it is life sustaining, it is an extremely exhausting and invasive procedure that 
dramatically reduces average life-expectancy (Owen et al. 1993).  Therefore, there is an 
urgent need for better renal replacement therapies. 
 
Using animal models, drugs such as mannitol, loop diuretics, dopamine and calcium 
channel blockers have been partially successful in promoting diuresis, as urine production 
is altered due to increases in endothelial permeability, but results have not been 
replicated in humans (Agmon and Brezis 1993).  Human AKI is a very heterogeneous in its 
functional changes therefore therapies affecting more than one pathway are of particular 
interest.  Something that has been used in an attempt to reduce the risk of ischaemic AKI 
is ischaemic preconditioning (IPC).  IPC refers to causing non-lethal tissue ischaemia for a 
very short period of time to protect against a future prolonged ischaemic insult: this was 
first tested in mice and had extremely positive results with a decreased number of 
infiltrating neutrophils and macrophages in the kidney (Kinsey et al. 2010).  Cross-
clamping of the common iliac artery to induce remote ischaemic preconditioning (RIPC) in 
patients undergoing abdominal aortic aneurysm repair has been investigated: the 
incidence of AKI was reduced by 23%, determined by creatinine serum concentrations (Ali 
et al. 2007).  Similar beneficial effects have also been seen in patients undergoing 
multivessel coronary artery bypass graft surgery who received RIPC in the form of three 
5-minute cycles of ischaemia by use of a blood pressure cuff (Zhou et al. 2010).  The ideal 
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therapy for kidney disease would be something that would target the heart of the 
problem therefore removing all of the secondary effects. 
 
1.5 Stem Cells as a Source for Regenerative Medicine 
 
1.5.1 The Different Progenitor Cells of the Bone Marrow 
Given the poor prognosis of AKI, SC -based therapy has been heralded as a favourable 
option for the management of renal disease progression; this is mainly due to many 
reports showing the plasticity of SCs, thus making them a promising aid to regeneration 
and organ recovery.  SCs are defined by having the dual-capacity to self-renew and also to 
produce a more mature differentiated daughter progeny.  SCs drive normal development 
and as this progresses, lineage-restricted progenitor cells create the tissues and organs of 
the body.  During late embryonic development, SCs migrate from the foetal liver to the 
BM (Christensen et al. 2004).  During adulthood, SCs still play a role in the maintenance of 
tissue and organ homeostasis:  the BM is responsible for maintaining haematopoiesis and 
contains a mixture of immature and maturing cells.  The immature cells include 
mesenchymal stem cells (MSCs); endothelial progenitor cells (EPCs); and haematopoietic 
stem cells (HSCs).  Several studies have shown that BM-derived SCs (BMSCs) can be 
beneficial in several organ injuries, including the heart, kidney, brain, liver and gut (Orlic 
et al. 2001; Kale et al. 2003; Deng et al. 2005; Kavanagh et al. 2010; Kavanagh et al. 
2013).  Furthermore, using BMSCs to treat AKI is encouraging due to the adaptable 
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nature of these cells according to their environment (Bussolati et al. 2009).  Most studies 
investigating SCs in organ repair have looked at MSC and HSC BM- subsets. 
 
1.5.2 Mesenchymal Stem Cells 
The term ‘mesenchymal stem cells’ was first coined by Caplan (1991) for the ability of 
these BM-derived cells to differentiate along several mesenchymal lineages.  These cells 
are less abundant than their haematopoietic counter-part and are not easy to define due 
to the lack of specific marker proteins; this has been the main hindrance in completely 
understanding MSCs full potential.  Currently, the most popular way to define them is by 
their capability of differentiating into specialised mesenchymal cells, such as osteocytes, 
chondrocytes and adipocytes, and also by their ability to adhere to plastic (Meirelles Lda 
et al. 2009).  As well as being able to differentiate into these different types of cells, MSCs 
can provide stromal support for HSCs within the BM (Bensidhoum et al. 2004) and are 
capable of differentiating into glomerular and tubular epithelium and interstitial cells 
when in the presence of the embryonic kidney (Yokoo et al. 2005).   
 
Regarding their regenerative potential, MSC benefits are not wholly dependent on MSC 
differentiation into tissue parenchyma.  There has been much speculation about MSCs 
having paracrine effects on the surrounding tissue; Togel and colleagues (2007) observed 
that after MSC infusion into a rat model of renal IR injury, there was an improvement in 
renal function after 24 hours.  This effect was not due to differentiation into epithelium 
or endothelium but due to an altered expression in inflammatory mediators, such as 
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VEGF, IGF-1 and HGF.  Also, injecting MSCs overexpressing the Akt1 survival gene into the 
myocardium following an acute myocardial infarction improved cardiac function in less 
than 72 hours post-MSC injection (Gnecchi et al. 2005).  Due to differentiation and fusion 
events being uncommon, it was proposed that this improvement was due to paracrine 
protective factors being released (Gnecchi et al. 2006).   
 
1.5.3 Haematopoietic Stem Cells 
HSCs were first identified by Till and McCulloch in the early 1960s as ‘colony forming 
units’ and were defined as being able to form within the spleen of irradiated mice and 
differentiate into several blood lineages (Till et al. 1964). HSCs are multipotent SCs that 
are self-renewing and can differentiate to produce myeloid and lymphoid adult blood 
cells (Figure 1.6).  Krause and colleagues (1994) have shown that by transplanting a single 
male HSC into a lethally-eradiated female mouse replenished all of the blood cells.  HSCs 
are a relatively rare population of cells, constituting 1 in 105 cells in the BM and can be 
identified and purified by isolating c-kit+ Sca1+ Lin- (KSL) populations from the BM.  In 
humans, HSCs are most commonly identified by being CD34+ (Civin et al. 1984), however 
roughly 90% of mouse HSCs do not express this marker making it unfeasible to use CD34 
for isolating murine HSCs (Osawa et al. 1996).  Although in adult life, HSCs reside in the 
bone marrow, they can migrate out of the BM and circulate in the blood, trafficking to 
different organs during homeostasis and trauma (Wright et al. 2001; Massberg et al. 
2007; Si et al. 2010).  It has been proposed that <400 HSCs circulate in the mouse 
circulation and are important for homeostatic maintenance (Wright et al. 2001).  
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HSCs have received a great deal of attention with regard to their regenerative capacity, as 
they are not confined to producing cells of just the haematopoietic lineage.  Numerous 
laboratories have shown that HSCs can differentiate into cells of a non-haematopoietic 
origin, therefore replenishing lost cell types in different injured organs (Lagasse et al. 
2000; Graf 2002; Sata et al. 2002; Kale et al. 2003; Lin et al. 2003; Bailey et al. 2004).  
However, the mechanism is still under investigation.  
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Figure 1.6.  The haematopoietic system.  HSC differentiation begins in the bone medulla 
and each stage is governed by a variety of signals.  HSCs can produce all cells that make 
up the blood and the process into a terminally differentiated cell is outlined above.  CMP: 
common myeloid progenitor; CLP: common lymphoid progenitor; MEP, megakaryocyte–
erythrocyte progenitor; GMP: granulocyte-macrophage progenitor; LMPP: lymphoid 
primed multipotent progenitor; EP: erythrocyte progenitor; MkP: megakaryocyte 
progenitor; GP: granulocyte progenitor; MacP, macrophage progenitor; Pro-B: progenitor 
B cell; Pro-T: progenitor T cell; Pro-NK: progenitor natural killer. 
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1.5.4 HSC Regeneration by Differentiation, Cell Fusion and Paracrine Mechanisms 
Once at the injury site, there are three main theories to explain how HSCs produce an 
effect: differentiation; fusion; or via paracrine mechanisms.  Differentiation was initially 
the most common theory and has stemmed from the studies of sex-mismatched 
transplantations in humans: female kidneys were transplanted into male recipients and 
later in life developed acute tubular necrosis (ATN), kidney biopsies were taken and cells 
containing the Y chromosome were found (Gupta et al. 2002).  Poulsom and colleagues 
(2001) also showed similar results in their human gender mis-matched experiments.  In a 
CKD model, which uses male mice deficient in fumarylacetoacetate hydrolase (Fah) to 
produce a build up of acid causing chronic proximal tubule damage, it was found that 
nine months post female Fah+ bone marrow transplantation there were 25-50% renal 
tubule cells that were positive for Fah (Held et al. 2006).  This showed that engraftment 
of BM cells to improve kidney function can occur.  Researchers have also explored the 
possibility that these progenitor cells may be fusing with other surrounding cells.  Terada 
et al. (2002) was the first to hypothesise that BM cells and embryonic stem (ES) cells 
could spontaneously fuse in vitro, as the BM cells adopt a more ES cell phenotype.  
However, the Sca1+Lin- fraction did not increase fusion events, suggesting that HSCs do 
not undergo such occurrences.  Some studies have demonstrated fusion events in the 
first week or the first month after folic acid or IR kidney injuries (Fang et al. 2005; Li et al. 
2007), although fusion occurred in very small percentages.   
 
Ever-increasing evidence suggests HSCs are able to contribute to tissue repair via 
paracrine anti-inflammatory mechanisms.  In our lab, the HPC-7 HSC cell line has shown 
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to reduce the number of leukocytes in a murine model of liver IR injury and also intestinal 
IR injury (Kavanagh et al. 2013).  Biziuleviciene and colleagues (2007) have shown 
reduced oedema and TNF-α release after HSC administration into a paw oedema model 
of mouse inflammation.   
 
Investigations that have used HSCs in renal IR injury have had a poor recruitment of cells 
(Lin et al. 2003; Li et al. 2010), which may be the reason for poor renal recovery following 
injury.  Therefore, ways in which to enhance such recruitment would most likely lead to 
enhanced beneficial results.  
 
1.5.5 HSC Recruitment to Adult Peripheral Tissues 
Jia and colleagues stated that the movement of SCs is critical for repair in adulthood (Jia 
et al. 2012).  Certain techniques have been employed to understand HSC trafficking; 
intravital microscopy (IVM) has been one of the main ones, as it allows the direct 
visualisation of a single cell’s movement in a particular organ of an anaesthetised animal 
(Furlani et al. 2009; Kavanagh et al. 2010; Lo Celso et al. 2011; Kavanagh et al. 2012).  
Although SC homing to the BM has been extensively studied (Frenette et al. 1998; 
Lapidot and Petit 2002; Avigdor et al. 2004), SC homing to injured sites is still in its 
infancy.  This is mainly due to low endogenous HSC numbers.  Therefore many studies 
have used exogenously-derived HSCs to understand such trafficking, for example 
Massberg and colleagues (2006) infused 1.5 x 105 HSC into a murine thrombosis model.  It 
has been hypothesised that the way in which BM-derived SCs adhere to the injured 
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endothelium is similar to that of differentiated BM cells (Lapidot and Petit 2002); 
therefore many studies have been conducted on that premise. 
 
It was primary studies by Tavassoli and Hardy (1990) that first suggested that membrane 
lectin-carbohydrate interactions were involved between circulating HSCs and 
endothelium.  A few years later, haematopoietic progenitor cells were shown to exhibit a 
similar repertoire of surface adhesion molecules to leukocytes, expressing 1 and 2 
integrins which could bind to their endothelial counter-ligands, VCAM-1 and ICAM-1 
respectively (Turner et al. 1995) and their adhesion can be regulated by cytokines 
(Kinashi and Springer 1994).   
 
Studies have shown that without the β1 integrin, haematopoietic cell migration to the 
foetal liver is impaired in pre-natal stages (Hirsch et al. 1996).  Also, HSCs home to sites of 
new vessel growth to promote angiogenesis, and this recruitment is dependent on the 
α41/VCAM-1 pathway (Jin et al. 2006).  Similar interactions also mediate HSC 
recruitment to BM: there is a 50% reduction in HSC numbers within the BM after 
inhibiting VCAM-1 or α4 subunits, thus implicating an important role for this integrin in 
HSC homing (Papayannopoulou et al. 1995).  During periods of ischaemia, fusion events 
between HSCs and murine cardiomyocytes occur through α41/VCAM-1 interactions 
(Zhang et al. 2007) and work from our group demonstrated a critical role for the CD49d 
(α4 subunit of α41 integrin) / VCAM-1 interaction in mediating HSC recruitment to 
injured murine liver in vivo (Kavanagh et al. 2010).  It is not known whether CD49d is 
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universally responsible for retaining HSCs in all injured vascular beds, including the 
kidney. 
 
In IR injured mouse gut, HSC recruitment has shown to be independent of α41 activity 
but dependent upon the 2 integrin CD18.  Interestingly, in an IR injured cremaster 
muscle, both CD49d and CD18 have a role in facilitating HSC adhesion to the injured 
vasculature (Kavanagh et al. 2013).  The non-integrin cell-surface glycoprotein molecule 
CD44 has been implicated in HSC homing to the BM (Dimitroff et al. 2001).  In our 
previous IR-injury models, we have not found a role of the non-integrin cell-surface 
glycoprotein molecule CD44 in assisting HSC adhesion. 
 
Many of the factors responsible for maintaining HSCs within the BM are also used by 
peripheral organs to recruit HSCs.  One of the most potent candidates responsible for 
retaining HSCs within the BM is the extensively studied G-protein coupled chemokine 
receptor CXCR4 and its ligand SDF-1α.  Osteoblasts are a local source of this HSC-
attracting chemokine (Jung et al. 2006).  SDF-1α gradients are incredibly important with 
regard to the recruitment and localisation of HSCs: hypoxic conditions upregulated local 
SDF-1α expression through the increased actions of hypoxia inducible factor-1α (HIF-α) 
(Ceradini et al. 2004).  When there is an altered oxygen tension, such as in ischaemic 
injuries, there is an increase in SDF-1α release from the damaged endothelium and 
CXCR4+ HSCs egress from the BM and home to the injured tissue (Togel et al. 2005).  
Another rich source of SDF-1α is activated platelets. Platelets adhere to inflamed 
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vasculature and release SDF-1α which then induces the accumulation of human CD34+ 
progenitor cells (Stellos et al. 2008).  Blocking platelet adhesion or platelet-secreted SDF-
1α in a murine arterial thrombosis model eradicated almost all HSC adhesion in vivo 
(Massberg et al. 2006).  The endothelial surface presents SDF-1α to the local 
environments and it can act to coordinate the actions of many adhesion molecule 
receptors, including VLA-4, LFA-1 and CD44 (Peled et al. 2000).   Avigdor and colleagues 
(2004) have shown that human CD44+ HSCs cooperate with SDF-1α and this improves 
transendothelial migration in the BM.  Blocking its receptor inhibits progenitor cell 
homing and engraftment in NOD/SCID mice (Peled et al. 1999).   
 
1.5.6 HSCs in the Injured Kidney. 
SCs need to be able to localise to the injured kidney if they are to have a beneficial effect 
in repairing AKI.  Both Park and Akashi and colleagues (Park et al. 2002; Akashi et al. 
2003) stated that their isolated HSCs could retain their developmental plasticity and that 
their gene expression was different to less primitive BM-derived cells, which may govern 
the pluripotent nature of HSCs.  Data from the same lab produced the first report 
showing that a pure population of HSCs could differentiate into renal tubule cells thus 
contributing to kidney regeneration after IR injury (Lin et al. 2003).  In these experiments, 
the renal artery was clamped for 15 minutes which produced tubule damage including 
epithelial cell detachment from basement membrane, loss of proximal tubule (PT) brush 
border and an increase in tubular cell death as assessed by increases in BrdU staining.  
2000 LacZ+ HSCs were transplanted into the female recipient 2 hours post-reperfusion 
and 4-12 weeks later the injured animals that received HSCs had a stripe of LacZ+ cells in 
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the S3 segment of the proximal tubule, where most damage occurs post-IR injury.  Some 
of the LacZ+ cells in this area expressed a sodium/phosphate cotransporter type 2, which 
is located in the brush border of the proximal tubule, indicating that some of the 
transplanted HSCs had adopted a renal phenotype.  However, only very few of the 
transplanted HSCs actually adhered (8.3±2.3%) and even fewer took on the PT 
phenotype.  No creatinine or blood urea nitrogen (BUN) experiments were conducted to 
show any improvement in function and judging from the poor HSC engraftment and even 
poorer phenotypic changes it would be unlikely for this kidney to show any clinically 
relevant improvements.   
 
Li and colleagues in 2010, administered human haematopoietic stem/progenitor cells 
(HSPCs) 24 hours post-renal IR injury.  At day 3, HSPCs underwent a phenotypic switch to 
a more endothelial characteristic (Li et al. 2010) and at day 7, 90% of mice survived 
compared to 50% in the vehicle-treated group.  HSPCs were primarily located in the 
peritubular region, as assessed by immunostaining, and these HSPCs were still evident on 
days 14 and 28 after IR injury (Li et al. 2010). 
 
More recently, Li et al. (2012) showed that by treating human CD34+ haematopoietic 
stem/progenitor cells (HSPCs) with cytokines, growth factors and deacetylation inhibitors 
they can be induced towards a more committed renal lineage.  These treated HSPCs can 
form tubular structures in 3-dimensional cultures, similar to the control renal inner 
medullary collecting duct (IMCD) differentiated cells.  In these studies, sex-mismatched 
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BM transplanted animals received an intravenous injection of 5 x 106 treated HSPCs 2 
hours after 35 minutes ischaemia, which improved renal morphology and function.  
However, very few tubular epithelial cells possessed the Y chromosome, indicating low 
HSPC engraftment from the male donor; this suggested that beneficial effects may be 
exerted through paracrine mechanisms.  Conditioned media from these treated cells 
contained VEGF, IGF-1 and HGF and these alone can reduce injury markers 24 hours after 
renal IR injury, further supporting the paracrine theory.  In agreement with this study, 
injection of MSCs following renal ischaemia in rats reduced injury markers and this could 
be reversed by selectively knocking down VEGF within the MSC (Togel et al. 2007; Togel 
et al. 2009).  One point to mention concerning the Li et al. (2012) study would be that 
after intravenous injection of HSPCs, these cells localise to the lungs, liver and even home 
back to the BM thereby explaining low numbers of direct cell engraftment. 
 
Using a mixture of BMSCs or HSCs in specifically treating renal IR injury has had mixed 
results: Poulsom and colleagues (2001) showed that BM-derived cells could contribute to 
the repair of the renal parenchyma by adopting a renal phenotype, although the exact 
source(s) of these cells was unknown.  Within this study, changes in SC phenotype and 
marginal improvements in morphology were seen, although engraftment into tubules 
after ischaemic injury was poor.  This low level of engraftment has also been seen in 
experiments by Lin and colleagues (2003), showing that cell engraftment/differentiation 
mechanisms are contributing very little to overall renal regeneration.  Several other 
studies have shown that the BMSC role in repair is negligible (Duffield et al. 2005; Lin et 
al. 2005). 
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Discrepancies in the contribution to renal regeneration are most likely due to poor 
recruitment of HSCs, mainly due to the majority being lost to non-injury sites.  Therefore, 
understanding how to increase the homing and adhesion of these SCs to the site of injury 
would be extremely beneficial.  Currently, there are no papers describing HSC 
recruitment mechanisms to the IR-injured kidney. 
 
1.6 Summary 
AKI usually occurs after shock, transplantation, sepsis and vascular surgery.  It is unlikely 
to happen in isolation and frequently occurs in critically ill patients.  Published mortality 
rates for intensive care unit patients with AKI are between 30 and 70%.  When kidney 
injury is extensive, its intrinsic repair programs are insufficient.  As there is such a high 
mortality rate and financial burden coupled with limited effective treatments against AKI, 
the use of SC therapy to repair such an injury is an exciting alternative.   
 
In human studies, it has been shown that extrarenal cells can participate in renal tubule 
regeneration (Gupta et al. 2002), which supports findings seen in injured livers and hearts 
after cell/organ transplants (Alison et al. 2000; Jackson et al. 2001; Orlic et al. 2001).  
Despite emerging clinical evidence that these SCs can improve a variety of inflammatory 
disorders, benefits are either minor or transitory (Lanzoni et al. 2008; Dai and Kloner 
2011).  This has been partially explained by low numbers of HSCs actually adhering within 
the local microcirculation of injured organs.  Therefore, when delivered by the preferred 
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systemic route, poor homing and a subsequent low efficiency of tissue engraftment 
occur, processes that are essential for HSCs to mediate repair (Karp and Leng Teo 2009).   
 
If SCs do hold promise in the context of regenerative diseases or the repair of renal injury, 
what is clear is that strategies to enhance, inhibit or modulate HSC migration is of utmost 
importance.  However, there is a lack of published literature that has addressed this and 
the molecular adhesive events that govern their recruitment within injured non-BM sites 
are currently unknown.  It is possible that BMSCs utilise the same classes of adhesion 
molecules used by mature leukocytes for recruitment to inflamed sites.  As most renal 
repair occurs during the first week post-injury, this research therefore primarily focuses 
on the molecular adhesive mechanisms that govern the recruitment of HSCs to sites of 
renal injury immediately after HSC infusion.  This study will also determine what local 
inflammatory factors may be responsible in mediating HSC adhesion and whether once 
present within the injured tissues, HSCs are beneficial for treating renal IR injury.  
Understanding the recruitment mechanisms and enhancing this process will hopefully 
prevent non-specific HSC adhesion to extrarenal organs and potentially lead to a more 
rapid, efficient and longer lasting tissue repair.   
 
1.7 Aims and Hypotheses 
The major hypothesis for this thesis is that HSCs home to the injured kidney after IR injury 
via organ specific recruitment mechanisms, and that HSC adhesion can be modulated.  
More specifically, the aims and hypotheses of this research were as follows: 
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1. Aim: Develop a viable model of murine AKI for intravital monitoring of labelled 
HSC trafficking through the injured microvasculature in vivo 
2. Hypothesis: Renal IR injury promotes HSC adhesion to the injured 
microvasculature in vitro and in vivo 
3. Hypothesis: Blockade of adhesion molecules would decrease HSC recruitment in 
the injured mouse in vivo 
4. Hypothesis: The injured kidney releases inflammatory substances that can 
enhance HSC adhesion both in vitro and in vivo 
5. Aim: Develop an extensive model of murine AKI for visualisation of endogenously 
labelled platelets and neutrophils in the peritubular capillaries in vivo 
6. Hypothesis: HSC recruitment produces anti-inflammatory effects that reduce both 
platelet microthrombi and neutrophil numbers and this attenuates injury 
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2 Materials and Methods 
 
2.1 Materials 
2.1.1 Antibodies 
Various antibodies were used within this study and these are outlined in the below table.  
Exp
t
 Antibody Conj Clone Origin Target Company Conc
n 
Flow 
cytometry 
and 
Clustering 
IgG control FITC IgG2b Rat Mouse eBioscience 1:50 
IgG control PE IgG2b Rat Mouse eBioscience 1:50 
Anti-CD18 FITC GAME-46 Rat Mouse Santa Cruz 1:50 
Anti-CD44 PE IM7 Rat Mouse eBioscience 1:50 
Anti-CD49d FITC MFR4.B Rat Mouse eBioscience 1:50 
Anti-CXCR2 PE 242216 Rat Mouse R&D sys. 1:16 
Anti-CXCR4 FITC 2B11 Rat Mouse eBioscience 1:50 
Immuno 
LE-AF IgG 
control 
N/A IgG2a Rat Mouse Cambridge 
Bioscience 
1:50 
Anti-CD42b N/A Xia.B2 Rat Mouse EmFret 1:50 
IgG control 488 - Goat Rat Life Tech. 1:50 
HSC 
blocking 
LE-AF IgG  N/A IgG2b Rat Mouse Cambridge 
Bioscience 
80 μg/ml 
LE-AF Anti-
CD18 
N/A GAME-46 Rat Mouse BD Pharm. 80 μg/ml 
LE-AF Anti-
CD44 
N/A IM7 Rat Mouse Cambridge 
Bioscience 
80 μg/ml 
LE-AF Anti-
CD49d 
N/A R1-2 Rat Mouse Cambridge 
Bioscience 
80 μg/ml 
Anti-CXCR2 N/A 242216 Rat Mouse R&D sys. 50 μg/ml 
Anti-CXCR4 N/A 2B11 Rat Mouse R&D sys. 40 μg/ml 
In vivo 
blocking 
LE-AF IgG N/A IgG2b Rat Mouse Cambridge 
Bioscience 
Varies 
depending on 
treatment 
Hyaluron-
idase 
N/A Type VI-S Bovine Mouse Sigma 10mg 
(enzymatic 
activity of 
3000-15000 
units per mg) 
LE-AF Anti-
CD44 
N/A IM7 Rat Mouse Cambridge 
Bioscience 
100μg 
LE-AF Anti-
CD104 
N/A 429/ 
MVCAM.A 
Rat Mouse Cambridge 
Bioscience 
70μg 
Anti-Ly6G 660 RB6-8C5 Rat Mouse eBioscience 60 μg 
Anti-CD41 N/A MWReg30 Rat Mouse BD Pharm 40 μg 
IgG 488 - Goat Rat Life Tech. 80 μg 
IgG 568 - Goat Rat Life Tech. 80 μg 
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2.1.2 Common Materials 
A number of materials were used repeatedly in this thesis and these are presented in the 
below table for clarity.  
 
 Abbreviation Company Location 
Acetone - Fisher Scientific Leicestershire, UK 
Bovine Serum Albumin BSA Sigma Poole, UK 
5’6-carboxyfluorescein diacetate 
succinimidyl ester 
CFSE Molecular Probes 
(Life technologies) 
Paisley, UK 
D-Valine MEM - Promocell UK 
Dimethyl Sulpoxide DMSO Sigma Poole, UK 
Hanks’ Balanced Salt Solution HBSS Sigma Poole, UK 
Heat inactivated Fetal Bovine 
Serum 
FBS Life Technologies Paisley, UK 
Gelatin (Type I from porcine skin) - Sigma Poole, UK 
Glutaraldehyde  Sigma Poole, UK 
Interleukin 1 beta IL-1β Peprotech London, UK 
Keratinocyte Chemokine KC Peprotech London, UK 
Ketamine - Amersham 
Bioscience and 
Upjohn Ltd 
Buckinghamshire, UK 
L-Glucose - Sigma Poole, UK 
L-Glutamine (Glutamax™) - PAA Labs Somerset, UK 
Pencillin - PAA Labs Somerset, UK 
Phosphate Buffered Saline PBS Life Technologies Paisley, UK 
Propidium Iodide PI Sigma Poole, UK 
Sodium ethylene tetraacetic acid Na.EDTA Sigma Poole, UK 
Sodium Chloride NaCl Sigma Poole, UK 
Stem-Pro 34-SFM - Life Technologies Paisley, UK 
Streptomycin - Life Technologies Paisley, UK 
Stromal Derived Factor 1 alpha SDF-1α Peprotech London, UK 
Trypsin-EDTA - Life Technologies Paisley, UK 
Tumour Necrosis Factor 1 alpha TNF-α Peprotech London, UK 
Xylazine Hydrochloride - Millpledge 
Pharmaceuticals 
Nottinghamshire, UK 
 
2.2 Cell Culture, Cell Isolation and Cell and Supernatant Preparation 
2.2.1 Cell Counting 
For all cell counting, a standard Neubauer haemocytometer was used and Trypan Blue 
(9:1) was added to exclude dead cells.  90µL of Trypan Blue was added to 10μl of cell 
suspension and approximately 20μl of the resulting suspension was viewed using a 
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haemocytometer under a x10 objective.  The number of cells that had not taken up the 
blue stain (viable cells) were counted in the four grid 1 x 1mm2 fields.  The average count 
from the four grids was calculated and multiplied by 1 x 105 to yield the number of cells 
per ml. 
 
2.2.2 Haematopoietic Progenitor Cell-5 and -7 (HPC-5 and HPC-7) 
Intravital studies monitoring HSC trafficking to sites of injury have been limited due to 
difficulties in isolating sufficient numbers for detection following systemic infusion.  We 
have found that approximately 5000 primary murine HSCs, defined as being c-Kit+, Sca-1+ 
and lineage negative (Lin-; KSL cells), can be obtained from one adult mouse.  This is too 
low for intravital or even in vitro adhesion assays – pooling cells from mice would require 
an unacceptable number of donor mice to be culled for individual intravital or endothelial 
experiments.  Therefore, an adult and embryonic murine HSPC line, HPC-5 and HPC-7 
respectively, were used in this study (gift from Professor L Carlsson, Umea University, 
Sweden).  HPC-5 are an immortalised adult murine SC line, created from adult BM genetic 
modification (Pinto do et al. 1998).  HPC-7 are an immortalised embryonic SC line, but 
they were generated by transfection with the LIM-Homeobox gene, Lhx2 into a lethally 
irradiated mouse (Pinto do et al. 2001).  Crucially, HSCs generated in this way are 
extremely similar to primary HSCs: they can fully reconstitute haematopoiesis when 
injected into a lethally irradiated host (Pinto do et al. 2002) and display many of the 
critical characteristics of primary HSCs, including expression of c-kit and Sca-1 on their 
surface and being and lineage negative.  Furthermore, HPC-5 and HPC-7 express surface 
adhesion molecules known to be expressed on primary HSCs and we have previously 
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used them to model hepatic and intestinal recruitment intravitally (Kavanagh et al. 2010; 
Kavanagh et al. 2012).  HPC-5 and HPC-7 were maintained in Stem Pro 34 SFM 
supplemented with the manufacturer’s supplement, L-glutamine, penicillin and 
streptomycin.  In addition to stem cell factor (SCF), HPC-5 cells are dependent on IL-6 and 
were cultured in the presence of 10ng/ml murine IL-6.  Both progenitor cells were 
maintained daily at a density of 1.0-1.2 x 106 cells/ml in Stem-Pro media with the above 
additives. 
 
2.2.3 Culture of Immortalised Murine Renal Endothelium 
Isolation of primary murine endothelial cells (ECs) is typically very difficult and requires 
elaborate time consuming purification techniques (Marelli-Berg et al. 2000).  Therefore, 
immortalised murine renal ECs (a gift from Dr. J. Steven Alexander, LSU-HSC, USA) were 
used to conduct in vitro static adhesion assays.  These renal ECs were maintained in 
growth media at 33°C: the growth media consists of D-Valine MEM supplemented with 
10% FBS, 50U/ml penicillin, 50U/ml streptomycin, 2mM L-Glutamine, 1% vitamin mix and 
10% interferon-γ.  Once cells had grown to confluence, cells were enzymatically 
dissociated using Trypsin-EDTA, washed in complete media and then split 1 in 3.  For 
static adhesion assays, a confluent flask of renal EC was enzymatically dissociated using 
Trypsin-EDTA, washed, and then one third resuspended in experiment medium.  1.5ml of 
this resulting cell suspension was then added to each well of a 24 well plate and 
incubated at 37°C ready for experimentation once confluent. 
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2.2.4 CFSE-Labelling of Cells 
Cells were centrifuged (1200rpm, RT, 5 minutes) and 2ml of pre-warmed PBS with 0.1% 
albumin in PBS (PBSA) was added before centrifuging again.  The cell pellet was 
resuspended in 2ml of PBSA and an additional 2ml of 10µM CFDA-SE solution was added, 
giving a final staining concentration of 5µM; this was then incubated for 15 minutes at 
37°C in the dark.  Cell labelling is achieved by using CDFA-SE, which is a non-fluorescent, 
cell-permeable fluorescein derivative; this is modified inside cells by endogenous 
esterases, which causes the molecule to become fluorescent.  Modification by these 
intracellular enzymes also renders the modified molecule cell impermeant.  Stock CFDA-
SE was diluted to 10mM in DMSO and aliquoted for future use.  After the 15 minute 
incubation, the reaction was hydrated with 6ml of the appropriate cell medium and was 
then washed twice by centrifugation (1200rpm, room temperature (RT), 5 minutes).  
Stained cells were then allowed 5 minutes to allow any non-reacted CFDA-SE to diffuse 
out of cells.  Cells underwent a final wash in medium before being suspending at the 
appropriate concentration in culture medium.  
 
2.2.5 Cell Adhesion Molecule Blocking  
To identify critical surface adhesion molecules involved in the recruitment of HSCs to the 
kidney, HPC-7 were pre-treated with 0.1% PBSA containing 80μg/ml of the blocking 
antibody.  Low endotoxin azide-free (LE-AF) antibodies, including IgG2b, anti-CD18, anti-
CD44 and anti-CD49d, were used to block the corresponding adhesion molecules function 
on the HPC-7 surface.  FACS studies have already been performed within our lab in order 
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to ensure 80μg/ml is an adequate dose to ensure complete blockade of the respective 
antigen (Kavanagh 2009).  Anti-CXCR2 and anti-CXCR4 function blocking monoclonal 
antibodies were also used to block chemokine receptor activity on HPC-7 at 
concentrations of 50μg/ml and 40μg/ml respectively, as suggested by the supplier.  For 
some studies, animals received a bolus injection of anti-CD44, anti-VCAM-1 or 
hyaluronidase to understand if these endothelial counter-ligands are responsible for HSC 
adhesion to the injured kidney in vivo.  Hyaluronidase type VI-S from bovine testes 
(Sigma-Aldrich, UK) has an enzymatic activity of 3000-15000 units per mg and is relatively 
pure in comparison to an U.S.P standard.  Control animals received an intra-arterial bolus 
of the corresponding dose of rat IgG or PBS.  Animals were surgically prepared as 
described in section 2.3.2 and immediately following ischaemia, the bolus injection of 
antibody, enzyme or PBS in 100µl was administered via the carotid artery.  In vivo 
antibody or enzyme doses were consistent with concentrations published in the literature 
using the same antibody or enzyme (John and Crispe 2004; Belcher et al. 2005; Orito et 
al. 2007). 
 
2.2.6 HPC-7 and Kidney Pre-treatments with Inflammatory Factors 
Recombinant murine IL-1β, KC, SDF-1α, TNF-α, plus a combination of KC and SDF-1α were 
used to pre-treat HPC-7 or the exposed sham kidney.  Cytokines and chemokines were 
made at a stock concentration of 10µg/ml in PBS containing 0.1% BSA.  Cytokines and 
chemokines were used experimentally at 25ng/ml, 50ng/ml and 125ng/ml for HPC-7 pre-
treatments and were made up in Stem Pro medium.  For topical applications, 2ml of 
200ng/ml of KC or SDF-1α was used to treat a healthy kidney and was made up in PBS.  
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1mL of fresh 200ng/ml chemokine was added to the bath at 1 hour, 2 hour and 3 hour 
time points to replace the media lost by evaporation or by absorption by the kidney.  
H2O2 was also used to pre-treat HPC-7 at 100μM for 5 minutes or 1 hour; this was made 
up in Stem Pro medium.  After HPC-7 pre-treatment with cytokines, chemokines or H2O2, 
HPC-7 were washed, centrifuged (1200rpm, RT, 5 minutes) and were resuspended in 
Stem Pro medium.  H2O2 concentration of 100μM was used due to previous 
experimentation showing that this concentration did not cause HPC-7 apoptosis and 
enhanced their adhesion to the IR injured gut (Kavanagh et al. 2012).  
 
 
2.3 Monitoring HSC Trafficking in vivo using Intravital Microscopy 
2.3.1 Animals 
Animal experiments were completed with prior approval of the local ethics committee 
and the United Kingdom Home Office, in accordance with the Animal Scientific 
Procedures Act of 1986 under Project Licence 40/3336 (Dr. Neena Kalia).  Male 8-12 
weeks old C57Bl/6 mice were obtained from Harlan, UK.  All animals had ad libitum 
access to food and water.  The 3 R’s of animal research, replacement, reduction and 
refinement, were heavily thought of during this work: endothelial assays were utilised 
during preliminary investigations into HSC adhesion to replace in vivo work; a trusted 
HSPC line to understand their trafficking mechanisms replaced the use of many donor 
animals needed for primary HSC sorting and this in turn reduced the number of animals 
needed for this project; animals were closely monitored for temperature and respiration 
Chapter 2: Materials and Methods 
 
52 
 
changes in order to refine and improve the way in which the animal experimentation is 
carried out.  Something that has been promoted very recently is the use of power 
calculations: these were not used in this body of work but would have been useful in the 
initial design of in vivo experiments.  Power calculations calculate the sample size 
required to accept or reject the hypothesis, giving greater validity to the results that are 
attained; this therefore give the scientist an indication of how likely the hypothesis is to 
be accepted and if it is ethically sound and scientifically responsible to continue with such 
a hypothesis.  When performed correctly, these calculations could reduce the number of 
animals used in experiments.  I would implore scientists to investigate the use of power 
calculations for continued animal work.    
 
2.3.2 Surgical Preparation 
Anaesthesia was induced by intra-peritoneal administration of ketamine (100 mg/kg 
Vetalar) and xylazine hydrochloride (10 mg/kg) delivered in 0.9% saline.  Maintenance of 
anaesthesia was delivered intra-peritonally as not to disrupt blood volume.  These mice 
underwent a tracheostomy to assist breathing and carotid artery cannulation with 
polyethylene portex tubing (Smiths Medical, Hythe, UK) to assist breathing and to allow 
administration of labelled cells, antibodies or FITC-BSA.  A midline laparotomy was 
performed by cutting along the linea alba, an avascular fibrous structure found between 
the left and right rectus abdominis muscles, to prevent any bleeding.  The intestines were 
then exteriorised and kept moist so that the left kidney could be seen. 
Chapter 2: Materials and Methods 
 
53 
 
 
2.3.3 Induction of Renal Ischaemia-Reperfusion Injury 
Following a midline laparotomy, unilateral ischaemia was induced by the application of 
an atraumatic vascular clamp to the left renal pedicle for 45 minutes.  The clamp was 
then removed and the left kidney was allowed to reperfuse for 60 minutes, as this has 
been shown to produce a significant amount of damage (Mashiach et al. 1998).  During 
the last 30 minutes of reperfusion the left kidney was exteriorised for intravital 
monitoring.  To exteriorise the left kidney, a flank laparotomy was performed and a 
cautery was used to remove the peritoneum.  The left kidney was always imaged due to 
the fact it is easier to exteriorise, due to no large organs (i.e. liver) causing any 
obstructions and it also has a longer renal pedicle due to the extended left renal vein.  
 
2.3.4 Intravital Microscopy Kidney Preparation to Understand HSC Trafficking 
This imaging modality is frequently used to visualise the microcirculation of solid organs.  
However, using intravital microscopy for imaging the renal microcirculation in mice is 
challenging and as a result, there are limited studies of this nature.  This is primarily due 
to the difficulties associated with exteriorising the mouse kidney, minimizing the effects 
of respiratory movements and having the correct optics and cameras to get high 
resolution, dynamic, real-time images.  We have established several murine renal 
preparations that allow continuous intravital monitoring of the renal microcirculation in 
vivo.  Firstly we used an upright fluorescent intravital microscope to view HPC-7 
recruitment to the kidney (Figure 2.1.A-B).  However, the most recent preparation gives 
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the clearest view of the superficial peritubular capillaries with minimal respiratory 
movement (Figure 2.1.C-D).  The initial intravital prep consisted of the kidney was gently 
teased out using a cotton bud, removing the renal capsule and being secured by its 
peritoneal fat onto a bed of agar.  The newer prep involved making a flank incision and 
then using the cautery to remove peritoneum to show the kidney.  The kidney was 
popped out using gentle manipulation, the kidney capsule was removed using forceps 
and then the mouse was placed on its side allowing the mouse body weight to gently 
press the kidney to the petri-dish creating a flat surface to image; this was the prep that 
was then used throughout the whole of my experiments in the rest of results chapters 3, 
4 and 5.  Animals undergoing sham procedures during all preps were exposed to the 
same surgical manipulation of the kidney except the clamp wasn’t applied.  
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Figure 2.1. Kidney prep using the upright (A, B) and the inverted (C, D) microscope.  (A) 
The initial prep used on the upright microscope involved visualising the left kidney due to 
the vessels being slightly longer on this side.  After a flank incision, the kidney is 
manipulated outside the body and is pinned either side of the renal pedicle into a bed of 
agar.  (B) The kidney is viewed from above and this microscope gets a clear image by 
focusing its field of view onto the flattest part of the kidney.  However the kidney hasn’t 
got a complete field of view that is flat so the image loses clarity towards the edges.  (C) 
After IR/sham injury has occurred, a flank laparotomy incision is made with the cautery to 
expose the kidney.  The kidney is then manipulated out of the hole with a cotton bud to 
prevent any further injury and the capsule is carefully removed.  (D) The mouse is lies on 
its left side on a petri-dish causing the kidney to become pressed against the flat edge, 
giving a larger flat area to view without losing sharpness. 
 
C D 
A B 
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2.3.5 Quantification of Cell Trafficking in vivo 
Using the x10 objective, one renal field of view (413µm x 308µm) towards the renal lower 
pole was focussed and a 10 second digital video at 200ms was taken as a control before 
the administration of cells.  2 x 106 CFSE-labelled HPC-5 or HPC-7 were administered 
through the carotid as a 100µl bolus at 60 minute post-reperfusion.  1 minute recordings 
were taken from the same pre-selected field of view every 5 minutes until 120 minutes 
post-reperfusion and then every 10 minutes for the following 40 minutes (i.e. until 160 
minutes post-reperfusion).  At the end of each intravital experiment, five fields of view 
were taken of the left kidney to ensure the events taking place in the recorded pre-
selected field of view were representative of the whole organ.  All recordings were stored 
digitally using Slidebook software (Intelligent Imaging Innovations, Denver, US) and 
analysed offline.  Quantification of cell trafficking using an intravital set-up has been well 
documented within the area of microcirculatory research (Lim et al. 2002; Au et al. 2008; 
Kavanagh et al. 2010).  Rolling cells in the peritubular capillaries are extremely rare to see 
in the renal microcirculation and so only adherent and free flowing cells were counted.  
Adherent cells were those that had been still/non-moving for 30 seconds or more; free-
flowing ones were non-static or static for less than 30 seconds.  Cells that entered the 
monitored field of view after the 30 second recording were classed as free-flowing, as it 
couldn’t be certain if they remained adherent beyond 30 seconds.  Adherent cells 
throughout all focus planes were counted.  Results are expressed as mean adherent or 
mean free flowing cells per field (CPF) per minute at each time point ±SEM.  The mean 
speed (μm/s) of cells trafficking through the renal microvasculature was also calculated 
using Slidebook imaging software. 
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2.3.6 Quantification of HSC Recruitment in Major Organs ex vivo 
After completed intravital experiments, animals were culled and the left injured and right 
non-injured contralateral kidney were removed and observed ex vivo for labelled HSC 
recruitment using an Olympus IX81 inverted microscope.  IR and CL kidneys were washed 
twice with 0.9% saline to remove traces of blood and were placed on a petri dish so that 
the flat vascular surface could be visualised.  The initial field was blindly chosen in the 
bottom right hand corner of the tissue and the subsequent five fields of view were 
selected to give complete organ coverage (Figure 2.2).  Fluorescent cells were counted 
manually using in-house blinded counting software (courtesy of Dr. Dean Kavanagh). 
 
 
 
 
 
 
 
2.3.7 Blood Flow Measurements 
We combined intravital microscopy with laser speckle microscopy to calculate renal 
blood flow during injury and sham experiments.  The Moor FLPI laser speckle camera 
(Moor Instruments, UK) was used to determine renal surface blood flow within exposed 
IR injured and sham kidneys as described previously (Holstein-Rathlou et al. 2011).  When 
Figure 2.2.  Pre-determined pattern for 
counting fields of view on organs.  This 
pattern was used to count adhering cells 
in different organs during ex vivo 
analysis.  The first point was always 
positioned towards the right bottom 
region of the organ 
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the laser is targeted on the tissue it produces a speckle pattern; continued movement, 
like that from blood flow, produces a more intensely fluctuating pattern.  High levels of 
flow corresponded with a white to red colour; areas of lower flow were depicted with a 
blue to purple colour.  Recordings were made every 15 minutes throughout the ischaemic 
and reperfusion phases, using the same region of interest, and an arbitrary unit of flux 
was obtained. 
 
 
2.4 Monitoring Inflammatory Cells using Confocal Intravital Microscopy 
2.4.1 Intravital Preparations 
To monitor endogenous inflammatory cells during IR injury, I decided to use the new 
confocal microscope that is connected to the upright Olympus microscope, as it has 
better resolution.  A new prep was designed to provide a better image than the initial 
upright prep used during results chapter 1; this involved exteriorsing the kidney through 
the flank incision like before, but putting the mouse on its side with the kidney resting on 
the petri dish creating a flat surface in which to image (Figure 2.3.A-B).    
 
2.4.2 Surgical Preparation 
Mice were surgically prepared as previously described.  Maintenance of anaesthesia was 
maintained by intra-peritoneal administration of ketamine (100 mg/kg) and xylazine 
hydrochloride (10 mg/kg) was delivered in 0.9% saline, as not to disrupt blood volume.  
These mice underwent a tracheotomy to assist breathing and carotid artery cannulation 
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with polyethylene portex tubing (Smiths Medical, Hythe, UK).  Endogenous platelets were 
labelled by adding 40μl Alexa Fluor 594 with 20μl rat anti-murine CD41 (GPIIb) antibody 
and this was made up to 100μl with saline and then injected via the carotid cannula.  To 
visualise neutrophils in vivo, 30μl of pre-conjugated anti-mouse Ly-6G eFluor® 660 was 
made up to 100μl with saline and also injected via the carotid cannula.  Antibodies 
circulated for 5 minutes before further surgery was performed: a midline laparotomy was 
performed by cutting along the linea alba, an avascular fibrous structure found between 
the left and right rectus abdominis muscles, to prevent any bleeding.  The intestines were 
then exteriorised and kept moist so that the left kidney could be seen and clamped for 45 
minutes like before and then allowed to reperfuse for 6 hours.  HPC-7 were introduced 
into the IR injured animal at 1 hour reperfusion.  Five fields of view were taken at 1 hour, 
4 hours and 6 hours reperfusion and the number of platelet microthrombi and 
neutrophils, along with the size and intensity of each platelet microthrombi, were 
quantified using Slidebook analysis software and ImageJ. 
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Figure 2.3.  Monitoring inflammatory cell recruitment after renal IR injury using the 
confocal upright intravital microscope.  A new kidney intravital preparation was 
designed for use on the confocal upright intravital microscope.  This involved using a 
larger petri-dish with holes cut out for air holes and carotid tubing.   The mouse was 
prepared as before on the inverted prep (Figure 2.1.C-D).  Briefly, the trachea and carotid 
are cannulated to assist breathing and administration of antibodies and cells.  After IR 
injury or sham surgery, the left kidney is exteriorised through a flank incision and the 
capsule is carefully removed.  The mouse is placed on a large petri-dish and secured in 
place with surgical tape.  The lid of the petri-dish is placed on top so that the kidney light 
touches the lid providing a flat surface in which to image (Figure 2.3.A-B).  
 
 
A B 
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2.5 Quantification of Injury 
2.5.1 FITC-BSA  
During IR injury the integrity of the vessel is lost therefore giving vascular leakage.  
Therefore to measure the integrity of the vessels, a fluorescent molecule can be 
introduced and this allows easy visualisation of blood flow and if any injury is present 
(Kalia et al. 2002).  200µl of FITC-conjugated bovine serum albumin (FITC-BSA) was 
injected intra-arterially.  FITC-BSA was made by mixing 10% FITC on celite, BSA and 10ml 
of bicarbonate pH 9.0 buffer overnight at 4°C.  Afterwards this was centrifuged (12 000 
rpm, 4°C, 10 minutes) and any conjugated or unconjugated BSA was separated by dialysis 
(12,000MW cut off; Spectrum Laboratories, CA, USA).  Prepared FITC-BSA was frozen and 
stored until use in 1ml eppendorfs. 
 
2.5.2 Creatinine and Urea Levels  
To biochemically confirm that renal injury has occurred, blood samples were obtained 
from mice subject to sham or IR procedures at 6 hours reperfusion.  Urea is a waste 
product that is normally excreted in the urine, but during kidney malfunction and disease 
is it retained within the blood.  Serum creatinine is a well known indirect marker of GFR 
and is widely used to assess kidney function.  Using a 26G needle containing 100μl of acid 
citrate dextrose (ACD) to prevent clot formation, blood was removed via descending 
aorta puncture and then centrifuged (1000g, 4°C, 10 minutes).  The supernatant (serum) 
was then aliquoted and stored at -80°C.  Samples were analysed by the Pathology 
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department at the Queen Elizabeth hospital, Birmingham, UK, with increased levels of 
serum creatinine and urea being directly proportional to the extent of renal injury.   
 
 
2.6 Techniques to Quantify Cell Adhesion in vitro 
2.6.1 Frozen Tissue Stamper-Woodruff Assay 
The Stamper-Woodruff static adhesion assay was used to examine HPC-5 and HPC-7 cell 
adhesion to snap frozen murine kidney sections (Stamper and Woodruff 1976).  C57BL/6 
mice were subjected to renal IR injury or sham surgery as previously described in section 
2.3.  Ischaemia was induced for 45 minutes and then reperfused for 120 minutes.  After 
reperfusion, the left injured, right non-injured contralateral or sham kidneys were 
removed, snap frozen in liquid nitrogen, and stored at -80°C until ready for sectioning.  
Cryo-M-bed (Bright Instruments, Cambridge, UK) was used to embed the kidneys on a 
cork disc and 10µm sections were cut using a Bright Instruments cryostat and mounted 
on X-tra™ adhesive microscope slides (Surgipath, Peterborough, UK).  These slides were 
then fixed for 20 minutes using acetone and then stored at -20°C until use.  Two kidney 
sections were put onto one slide, carefully placed so that they had only touched the 
blade once, so it didn’t affect the tissues adhesive capabilities (Mann et al., 2009).  To 
prepare the kidney sections for the assay, slides were fixed in 100% acetone for 5 
minutes, washed in PBS and sections were encircled using a wax immunology pen 
(Immedge; Vector Laboratories, Peterborough, UK).  HPC-5 and HPC-7 were labelled with 
CFDA-SE as previously described.  Some HPC-7 were pre-treated with IL-1β, KC, SDF-1α or 
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TNF-α (25ng/ml in complete Stem Pro 34 SFM) for 5 minutes or for 30 minutes with 
media conditioned by an injured or sham kidney.  After pre-treatments, 5 x 104 CFSE-
labelled HPC-7 in 100μl were added to each section and these slides were incubated on a 
humidified tray on a laboratory rocker for 20 minutes to allow any HSC adhesion to occur.  
Slides were then fixed for 5 minutes in 100% acetone and subsequently washed three 
times in PBS.  Slides were dried and coverslips were applied using Gel Mount aqueous 
mounting medium (Sigma, UK).  Once dry, slides were analysed using a Zeiss Axiovert 
Microscope (Carl Zeiss, Herefordshire, UK).  Five fields of view were selected from each 
tissue sections using a set field pattern, as previously described (Figure 2.2).  Fluorescent 
cells were counted manually using blinded counting software Counter.exe; this software 
was developed by Dr. Dean Kavanagh, Birmingham, UK.  Results are expressed as mean 
adhesion per field ±SEM. 
 
2.6.2 Immobilised Counter-Ligand Adhesion Assay 
96-well plates (Nunc, Rochester, USA) were coated with 50μl of recombinant murine (rm) 
ICAM-1, rmVCAM-1 or 0.5mg/ml rmHA for 1 hour.  Wells were then washed, blocked 
using 10mg/ml heat-denatured BSA.  HPC-7 were blocked with LE-AF CD16/32 function-
blocking antibody for 30 minutes before pre-treating HPC-7 for 5 minutes at 37°C with 
25ng/ml of IL-1β, KC, SDF-1α or TNF-α, made up in complete Stem Pro 34 SFM.  Pre-
treated HPC-7 were subsequently washed and resuspended in 100μl of complete Stem-
Pro 34 SFM and exposed to the immobilised proteins for 20 minutes at 37°C.  Wells were 
washed thoroughly with PBS to remove any unbound cells.  Adherent HPC-7 were fixed 
with 2% glutaradehyde at RT for 15 minutes.  Wells were washed and 100µl PBS was 
Chapter 2: Materials and Methods 
 
64 
 
added for imaging adherent cells on an inverted Olympus IX81 microscope.  Five fields of 
view were selected from each well using a set field pattern as previously described 
(Figure 2.2).  HPC-7 were counted manually using blinded counting software, 
Counter.exe.  Results are expressed as mean adhesion per field ±SEM. 
 
2.6.3 Renal Endothelial Cell Static Adhesion Assay  
The immortalised murine renal ECs (gift from Dr. J. Steven Alexander, LSU-HSC, USA) 
were cultured to confluence in gelatin-coated wells in a 24 well plate (BD Biosciences).  At 
confluence, monolayers were treated for 4 hours with 100ng/ml TNF-α.  Following 
washing with 0.1% PBSA, 1x105 HPC-7 cells were added for 20 minutes.  Some HPC-7 
were pre-treated with IL-1β, KC, SDF-1α or TNF-α (25ng/ml in complete Stem Pro 34 SFM) 
for 5 minutes or for 30 minutes with media conditioned by an injured or sham kidney.  
Wells were washed with PBS and fixed with 2% glutaraldehyde in PBS for 15 minutes at 
RT.  Five fields of view were selected from each tissue sections using a set field pattern 
(Figure 2.2) and were imaged using fluorescent microscopy (Olympus IX81; Olympus, UK).  
Fluorescent cells were counted manually using blinded counting software, Counter.exe.  
Results are expressed as mean adhesion per field ±SEM. 
 
2.6.4 Immunohistochemistry on 6 hour Reperfused Tissue Sections 
After 6 hours reperfusion experiments, the left kidneys were removed and snap frozen in 
liquid nitrogen and stored at -80°C ready for sectioning.  As stated above, Cryo-M-bed 
was used to embed the kidneys on a cork disc and 10µm sections were cut using a Bright 
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Instruments cryostat and mounted on X-tra™ adhesive microscope slides.  These slides 
were then fixed for 20 minutes using acetone and then stored at -20°C until use. To 
prepare the kidney sections for the assay, slides were fixed in 100% acetone for 5 
minutes, washed in PBS and sections were encircled using a wax immunology pen 
(Immedge; Vector Laboratories, Peterborough, UK). A primary antibody against CD42b 
and a control IgG antibody were applied to sections for 3 hours at 4°C.  Slides were then 
thoroughly washed with PBS on a rocker and a secondary fluorescent antibody, Alexa 
488, was applied to each section for 1 hour at 4°C.  Any unbound fluorescent secondary 
antibody was thoroughly washed off with several PBS washes, followed by dehydration 
steps with acetone prior to applying coverslips using Gel Mount aqueous mounting 
medium (Sigma, UK).  Once dry, slides were analysed using a Zeiss Axiovert Microscope 
(Carl Zeiss, Herefordshire, UK).  Five fields of view were selected from each tissue sections 
using a set field pattern, as previously described (Figure 2.2).  Fluorescent cells were 
counted manually using blinded counting software Counter.exe (downloaded gratis from 
http://www.dephilon.com/Counter.exe).  This software was developed by Dr. Dean 
Kavanagh.  Results are expressed as mean adhesion per field ±SEM. 
 
 
2.7 In vitro Techniques to Dissect the Effects of Injury and Cytokines on HPC-7 
Adhesion and Free-Flowing Numbers 
2.7.1 Conditioned Media Preparation from Injured and Sham Kidneys 
In order to determine whether factors released from injured kidney could potentially 
modulate expression of adhesion molecules and therefore alter the amount of SC 
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adhesion.  The kidney was clamped for 45 minutes and allowed to reperfuse for 60 
minutes, or sham-operated, as previously described.  The whole kidney was then 
removed and put into 2ml DMEM medium and incubated at 37°C for 24hours from the 
point of reperfusion.  Following incubation, the tissues were homogenised using an 
electronic tissue homogeniser (Power Gen 125; Fisher Scientific, Leicestershire, UK).  The 
homogenate was then centrifuged at 1200rpm for 5min and the resulting supernatant 
was sterile filtered using a 0.22µm filter (Millipore, Watford, UK).  This filtrate was then 
aliquotted and stored at -20°C until needed. 
 
2.7.2 Determination of Protein Content within Conditioned Media  
To determine whether there was a variation in the levels of proteins contained within the 
conditioned media from injured kidney compared to sham, a Coomaissie stained gel was 
prepared.  Conditioned media samples were removed and added to an equal volume of 2 
x Laemmli sample buffer (Reducing: 20% glycerol, 10% β-mercaptoethanol, 4% SDS, 
50mM tris, trace Brilliant Blue R; Non-reducing: 20% glycerol, 4% SDS, 50mM tris, trace 
Brilliant Blue R) for whole cell protein studies.  SDS is an anionic detergent which 
denatures proteins and applies a negative charge to each protein in proportion to its 
mass.  This was then boiled for 5 minutes at 100°C.  Denatured proteins were separated 
by electrophoresis through sodium dodecyl sulphate polyacrylamide gels (10% and 15%).  
Pre-stained molecular weight markers (Bio-Rad, Hemel Hempsted, UK) were run 
alongside the samples.  Following electrophoresis, the gels were stained with a 
Coomassie stain (10% acetic acid, 45% methanol, trace CBBR-250 stain) for 1 hour at 
Chapter 2: Materials and Methods 
 
67 
 
room temperature.  This was then de-stained with several washes of de-stain (10% acetic 
acid, 45% methanol). 
 
2.7.3 Adhesion Molecule Clustering 
To examine the effects of KC and SDF-1α on HPC-7 adhesion receptor clustering, HPC-7 
were treated for 5 minutes with 25ng/ml KC and/or SDF-1α at 37°C and then fixed with 
2% glutaraldehyde for 15 minutes at room temperature.  Following fixation, Fc receptors 
were blocked using CD16/32 antibody for 30 minutes.  Cells were washed with warm 
0.1% PBSA and centrifuged (1200rpm, RT, 5 minutes) and subsequently incubated with 
primary LE-AF anti-CD49d or LE-AF anti-CD44 for 1 hour on ice.  Cells were washed and 
centrifuged again and then incubated with an Alexa Fluor® 488 goat anti-rat IgG 
secondary antibody for 30 minutes on ice.  Cells were added to air-dried washed lysine 
coverslips for 1 hour.  These cells were then mounted onto coverslides ready for imaging 
using confocal microscopy (Leica TCS-SP2) and 90 cells were imaged per treatment group.  
Areas of adhesion molecule clustering were identified using the “Find Maxima” plugin in 
ImageJ (NIH, NH, US), using a noise tolerance level of 20 to separate clusters from 
background. 
 
2.7.4 Micropipette Assay 
The deformability of HPC-7 following cyto/chemokine pre-treatment was assessed using 
a micropipette assay as previously described (Tse et al. 2005).  HPC-7 were pre-treated 
with 25ng/ml of IL-1β, LC, SDF-1α and TNF-α for 5 minutes.  Cells were then washed with 
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warm 0.1% PBSA and centrifuged (1200rpm, RT, 5 minutes) and fixed with 2% 
glutaraldehyde and were placed in a chamber made up of two coverslips separated by a 
U-shaped gasket and placed on a microscope stage held at 37°C.  A micropipette with an 
internal diameter of approximately 5m was introduced into the chamber from the open 
side, and a fixed aspiration pressure of 1000Pa (10cmH2O) was applied by lowering a 
water reservoir connected to the pipette. Video recordings were made of HPC-7 
aspirated into the pipette and the time taken to enter the pipette was measured offline.  
Typically 50 cells were tested in each sample. 
 
 
2.8 FACS-Based Studies 
2.8.1 HPC-7 Cell Surface 
HPC-7 were analysed using flow cytometry to identify changes in cell surface expression 
of CD18, CD44, CD49d, CXCR2 and CXCR4.  1 x 106 HPC-7 were pre-treated for 5 minutes 
with PBS or 25ng/ml KC and/or SDF-1α.  Subsequently, cells were fixed with 5% formalin 
at RT for 20 minutes.  HPC-7 were blocked with LE-AF CD16/32 function blocking antibody 
to reduce subsequent non-specific antibody binding.  Cells were then incubated with 
fluorochrome-conjugated primary antibody for 30 minutes at 4°C.  Cells were 
subsequently washed and resuspended in 300μl 0.1% PBSA and supplemented with 0.6μl 
of 0.5mg/ml propidium iodide (PI).  PI is a red fluorescent nuclear and chromosome 
counterstain; it is does not permeate live cells so can therefore be used to distinguish 
between live and dead cells from a general population.  After cytokine and chemokines 
pre-treatment, the amount of F-actin was also quantified by using FITC-Phalloidin (Life 
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Technologies, UK). Phalloidin is isolated from the deadly Amanita phalloides mushroom 
and competes with the binding sites of F-actin, therefore giving an indication of the 
quantity of F-actin within a cell.  Post pre-treatment, HPC-7 were washed and fixed with 
5% formalin at RT for 20 minutes.  Cells were washed, centrifuged (1200rpm, RT, 5 
minutes) and then resuspended in 0.1% Triton X-100 in PBS for 5 minutes.  After washing 
several times, HPC-7 were resuspended in 2μM of FITC-conjugated Phalloidin for 1 hour 
at RT and then washed and resuspended with 300μl 0.1% PBSA before analysis.  Cells 
fluorescence was subsequently interrogated using flow cytometry on a BD FACSCalibur 
cytometer (Becton Dickinson, USA).  Cell counting was terminated following the 
collection of 10 000 live events and data was analysed with CellQuest (Becton Dickinson, 
USA) by calculating the median average value from each repeat and then doing a one-
tailed t-test (when only two groups) or a one-way ANOVA with Dunnett’s post-tests 
(when more than two groups) on these values to determine any significance. 
 
2.9 Statistics 
Unpaired Student t-tests were used to make comparisons between two experimental 
groups for static adhesion assays, FACS data, changes in velocity and deformability.  For 
more than two experimental groups, a one-way ANOVA followed by Dunnett’s post-tests 
were carried out.  For in vivo experiments, area-under-curve (AUC) calculations were 
performed to identify any significant differences between treatments.  Analysis of free-
flowing cells and blood flow data were analysed using a two-way ANOVA with Bonferroni 
post-tests.  Values were considered significant when p<0.05. 
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3 Recruitment of HSCs by Ischaemia-Reperfusion Injury 
 
3.1 Introduction and Hypotheses 
3.1.1 Introduction 
AKI is a common disease and with limited treatment options it continues to have a high 
rate of morbidity and mortality.  IR injury is one of the most common causes of AKI and 
results in cell death, inflammation and altered cell metabolism.  One of the main 
pathophysiological consequences post-renal IR injury is the loss of vascular endothelial 
cells (Molitoris and Sutton 2004).  Li et al., (2010) showed that HSPCs incorporate into 
post-ischaemic renal tubules and begin to adopt a more endothelial phenotype; HSPCs 
express endothelial marker CD146 and lose expression of progenitor cell markers CD133 
and CD45.  Although these experiments show promising protective effects of HSCs, 
clinical success is poor and is partially attributed to small numbers of HSCs actually being 
recruited to the kidney.  Experimental studies suggest that this is primarily due to non-
specific entrapment of SCs within non-injured regions, such as the liver or lungs (Karp and 
Leng Teo 2009).  The general consensus is that to improve the therapeutic efficacy of 
these cells, increasing their delivery to and recruitment within the injured kidney is key.  
Since systemic infusion of SCs is the preferred route of administration, capture of 
trafficking HSCs is dependent upon firm interactions with endothelial cells within the local 
renal microcirculation.  The kinetics of HSC recruitment within the IR injured mouse 
kidney has not been previously investigated directly in vivo.  This could be partly due to 
the difficulty associated with imaging the mouse kidney using intravital microscopy (IVM).  
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This chapter therefore aimed to establish an experimental model of acutely injured 
mouse kidney for intravital observations of HSC recruitment. 
 
3.1.2 Aims and Hypotheses 
For the work included in this chapter, the main aims and hypotheses were: 
1. Aims:  Establish a kidney preparation that will allow SC adhesion to be monitored 
using static adhesion assays in vitro and continuous IVM of the renal 
microcirculation in IR injured and sham / non-injured anaesthetised mice in vivo.   
2. Hypothesis: HSC adhesion to snap frozen IR injured kidney sections would be 
significantly greater than that to snap frozen contralateral and sham non-injured 
kidney tissue.  
3. Hypothesis: The number of HSCs adhering to the injured renal microcirculation in 
vivo will be significantly greater than that to the sham non-injured renal 
microvasculature. 
 
3.2 Methods 
The methods used in this chapter are described in detail in Chapter 2.  Briefly, Stamper-
Woodruff static adhesion assays were conducted to view the adhesion of the adult HSC 
line, HPC-5, and the embryonic HSC line, HPC-7, to injured renal tissue.  Briefly, the left 
kidney was subjected to 45 minutes of ischaemia and 2 hours reperfusion.  The left 
injured kidney, the right non-injured contralateral kidney (CL) and non-injured sham 
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kidneys were snap frozen in liquid nitrogen.  HPC-5 and HPC-7 were stained with CFSE 
and then 1 x 105 cells were exposed to frozen tissue sections.  For intravital in vivo 
studies, anaesthetised mice were surgically prepared by cannulation of the carotid artery 
and intubation of the trachea.  Following laparotomy, the left renal pedicle was clamped 
to induce ischaemic injury as above.  Thereafter, 2 x 106 CFSE labelled HPC-5 and HPC-7 
were introduced via the carotid artery.  Initially, the first kidney preparation was 
conducted on an upright IVM set-up.  We subsequently utilised the inverted IVM as the 
exteriorised kidney was flatter, more still and subject to less manipulation; this therefore 
generated better quality images of circulating and adhesive labelled cells.  On both the 
upright and inverted IVM renal preparations, one field of view was selected and 
monitored for 60 seconds every 5 minutes, until the final 30 minutes where the adhesion 
and free-flowing cells were monitored every 10 minutes.  Observations were made for a 
total of 90 minutes.  Cells were quantitated in vivo within the microcirculation as either 
adherent (static for ≤ 30 seconds) or free-flowing (visible in the field, but not adherent).   
 
3.3 Results 
3.3.1 HPC-5 adhesion is not increased to IR injured kidney tissue sections in vitro 
 Adhesion of HPC-5 did not increase to IR sections compared to tissue from sham animals.  
There were also no significant differences in HPC-5 adhesion between CL renal sections 
and the non-injured sham sections (Cells per field (CPF): IR: 7.40±1.50; CL: 6.40±1.81; 
Sham: 16.20±5.29; Figure 3.1.A-D).  Interestingly, less adhesion was observed on the IR 
and CL tissue sections in relation to sham sections. 
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3.3.2 HPC-7 adhesion is increased to IR injured kidney tissue sections in vitro 
Significantly (p<0.05) increased HPC-7 adhesion was observed in vitro to both injured and 
CL renal section taken from IR injured mice compared to sham tissue (CPF: IR: 
42.00±9.88; CL: 48.004.81; Sham: 13.00±5.00; Figure 3.2.A).  Interestingly, adhesion on 
the IR injured kidney was very similar to that observed on the non-injured CL taken from 
the injured mice.  Representative images of the tissue sections are shown and it’s clear 
that the IR injured renal tissue architecture (Figure 3.2.C) looks more disturbed and 
damaged than the healthy tubular anatomy observed in the sham controls (Figure 3.2.B) 
and the non-injured contralateral kidney (Figure 3.2.D). 
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Figure 3.1.  HPC-5 do not adhere more so to IR injured kidney sections.  Kidney sections 
were isolated from sham and IR-treated animals and 1 x 105 CFSE-labelled HPC-5 were 
applied to each section for 20 minutes.  HPC-5 adhesion was quantified from 5 fields of 
view per section using a pre-selected pattern and an average for each tissue section was 
calculated.  There were no significant differences in HPC-5 to frozen sections of IR injured, 
non-injured CL tissue compared to controls.  Results are shown in panel A.  
Representative images are shown of sham (panel B), non-injured contralateral (panel C) 
and IR injured (panel D) renal sections.  Plots represent mean adhesion ±SEM of at least 4 
separate experiments; no significance using one-way ANOVA and Dunnett’s post-test. 
A 
100μm 
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Figure 3.2.  The number of adherent HPC-7 is increased to frozen IR injured kidney 
sections in vitro.  Kidney sections were isolated from sham and IR-treated animals and 1 x 
105 CFSE-labelled HPC-7 were applied to each section for 20 minutes.  HPC-7 adhesion 
was quantified from 5 fields of view per section using a pre-selected pattern and an 
average for each tissue section was calculated.  A significant increase in HPC-7 to frozen 
sections of IR injured and non-injured CL tissue was observed compared to controls.  
223% more HPC-7 adhered to IR injured tissue compared to sham-operated kidney.  
Results are shown in panel A.  Representative images are shown of sham (panel B), non-
injured contralateral (panel C) and IR injured (panel D) renal sections.  Plots represent 
mean adhesion ±SEM of at least 4 separate experiments; *p < 0.05 (one-way ANOVA and 
Dunnett’s post-test). 
 
A 
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3.3.3 Adherent and free-flowing HPC-5 numbers in vivo do not change in IR injured 
animals 
Initial experiments were conducted using an upright IVM set-up (Figure 3.3.A). No 
significant differences were observed in the number of adherent HPC-5 to the injured 
renal microvasculature compared to sham (AUC: IR: 84.67±23.92; Sham: 134.20±8.34; 
Figure 3.3.B-D), which is consistent with the previous SW assay results.  No significant 
differences in the number of free-flowing HPC-5 were observed in the IR injured kidney 
compared to those seen in the sham controls (CPF: IR: 29.33±6.17; Sham: 35.33±7.97; 
Figure 3.3.E).   
 
3.3.4 Adherent and free-flowing HPC-7 numbers in vivo are significantly increased in 
the renal IR injured model 
Using the upright microscope and corresponding kidney preparation, HPC-7 adhesion was 
significantly (p<0.001) increased within the peritubular microcirculation in vivo in injured 
animals compared to shams (AUC: Sham: 80.67±17.86; IR: 192.00±46.05; Figure 3.4.A).  
Free-flowing non-adherent HPC-7 trafficking in the peritubular capillaries was also 
monitored.  Significantly (p<0.001) more HPC-7 were seen homing to the kidney upon 
initial administration after IR injury when compared to the numbers observed in the non-
injured kidney microvasculature (CPF: IR: 37.83±9.94; Sham: 17.00±6.36; Figure 3.4.B).  
The high numbers of free flowing HPC-7 in the kidney were only observed when first 
administered; thereafter, only occasional circulating cells were identified.   
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Figure 3.3.  Renal IR injury does not promote changes in HPC-5 adhesion and the 
number of free-flowing HPC-5. Adhesion of HPC-5 to the renal peritubular capillaries was 
examined using intravital microscopy.  Animals were subjected to 45 minutes ischaemia 
and 1 hour reperfusion prior to receiving an intra-arterial bolus of 2 x 106 CFSE-labelled 
HPC-7.  One field of view was selected and 1 minute recordings every 5 minutes starting 
from the point of infusion (60 minutes post-reperfusion).  After 2 hours reperfusion, 
recordings were taken for 1 minute every 10 minutes for the remaining 30 minutes.  
Using the upright intravital microscope and the corresponding prep (panel A), HPC-5 
adhesion is not significantly altered in animals subjected to renal IR injury when 
compared to sham treated controls (panel B; black line: sham treated animals; grey line: 
renal IR injured animals).  There were no significant changes to the number of HPC-5 
circulating through the injured microvasculature compared to the sham controls (panel C; 
black line: sham treated animals; grey line: renal IR injured animals).  Representative 
images of HPC-5 adhesion to sham (panel D) and IR injured animals (panel E) are shown 
(in and out of focus cells are counted).  Non-adherent free-flowing HPC-5 were also 
analysed in each 1 minute recording.    Plots represent a mean adhesion ±SEM of at least 
4 separate experiments; *** p < 0.001.  Panel B: area under the curve calculations; panel 
C: two-way ANOVA with bonferroni post-tests.  
A B 
C 
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Figure 3.4.  Renal IR injury enhances the adhesion of HPC-7 to the injured 
microvasculature in vivo.  Adhesion of HPC-7 to the renal peritubular capillaries was 
examined using intravital microscopy.  Animals were subjected to 45 minutes ischaemia 
and 1 hour reperfusion prior to receiving an intra-arterial bolus of 2 x 106 CFSE-labelled 
HPC-7.  One field of view was selected and 1 minute recordings every 5 minutes starting 
from the point of infusion (60 minutes post-reperfusion).  After 2 hours reperfusion, 
recordings were taken for 1 minute every 10 minutes for the remaining 30 minutes.  
Using the upright intravital microscope and the corresponding prep; HPC-7 adhesion is 
significantly raised in animals subjected to renal IR injury when compared to sham 
treated controls (panel A; black line: sham treated animals; grey line: renal IR injured 
animals).  Non-adherent free-flowing HPC-7 were also analysed in each 1 minute 
recording.  There were significantly more HPC-7 circulating through the injured 
microvasculature compared to the sham controls but only at the point of infusion (panel 
B; black line: sham treated animals; grey line: renal IR injured animals).  Representative 
images of HPC-7 adhesion to sham (panel C) and IR injured animals (panel D) are shown 
(in and out of focus cells are counted).  Plots represent a mean adhesion ±SEM of at least 
5 separate experiments; *** p<0.001.  Panel A: area under the curve calculations; panel 
B: two-way ANOVA with bonferroni post-tests respectively).  
A B 
C D 
Sham IR 
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3.3.5 The number of adherent HPC-7 in vivo is significantly increased to the injured 
kidney with the new kidney intravital preparation 
To improve the quality and reproducibility of intravital images, studies were also 
conducted on an inverted IVM set-up (Figure 3.5.A).  Using this new prep, HPC-7 
adhesion was again significantly (p<0.001) increased within injured kidney compared to 
the sham control (AUC: Sham: 221.90±20.62; IR: 367.30±21.16; Figures 3.5.B-D).  Ex vivo 
analysis demonstrated that the adhesive events observed in the single pre-selected area 
during IVM were paralleled by those occurring in other randomly selected regions of the 
same kidney, with significantly (p<0.05) increased adhesion in the injured and CL kidney 
of IR injured mice compared to sham (CPF: Sham kidney: 11.04±1.70; IR kidney: 
20.75±3.07; Sham CL kidney: 11.30±4.03; IR CL kidney: 27.20±4.11; Figures 3.5.E). 
 
3.3.6 Free-flowing HPC-7 numbers in vivo are significantly increased at the point of 
cell infusion 
The inverted IVM set-up demonstrated that at the point of HPC-7 infusion (60 minutes 
post-reperfusion), the number of free-flowing cells were again significantly (p<0.001) 
increased in injured animals compared to sham animals (CPF: IR: 134.40±29.11; Sham: 
75.80±7.83; Figure 3.6.A).  This effect was not seen at any other time point.  Since this 
may result from increased renal blood flow following IR injury, laser speckle contrast 
microscopy was used to determine blood flow in sham and injured kidneys.  At 60 
minutes post-reperfusion, renal blood flow was significantly (p<0.05) decreased in injured 
mice compared to sham mice (Flux: IR kidney: 1719.20±312.97; sham kidney: 
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2739.57±21.97; Figure 3.6.B-C).  Furthermore, HPC-7 velocity was also measured in vivo 
and was significantly (p<0.01) reduced in the injured microcirculation compared to the 
microcirculation in sham animals (Figure 3.6.D). 
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Figure 3.5.  Renal IR injury enhances the adhesion of HPC-7 to the injured 
microvasculature in vivo.  HPC-7 adhesion to the renal peritubular capillaries was 
examined using intravital microscopy.  Animals were subjected to 45 minutes ischaemia 
and 1 hour reperfusion prior to receiving an intra-arterial bolus of 2 x 106 CFSE-labelled 
HPC-7.  One field of view was selected and 1 minute recordings every 5 minutes starting 
from the point of infusion (60 minutes post-reperfusion).  After 2 hours reperfusion, 
recordings were taken for 1 minute every 10 minutes for the remaining 30 minutes.  To 
get a stiller and crisper prep, the prep was altered and the inverted intravital microscope 
was used instead (panel A); HPC-7 adhesion to the vasculature is significantly increased 
after renal IR injury compared to non-injured sham control animals (panel B; black line: 
sham treated animals; grey line: renal IR injured animals).  Representative images of 
CFSE-labeled HPC-7 in sham (panel C) and IR injured (panel D) renal microcirculation are 
shown (both in focus and out of focus cells are counted).  These recorded events were 
paralleled by those occurring in other randomly selected regions of the injured kidney 
and there was also a significantly higher number of adherent HPC-7 in the non-injured 
right contralateral kidney compared to the right sham kidney (panel E) compared to the 
sham control.  Plots represents a mean adhesion ±SEM of at least 4 separate 
experiments; * p<0.05, ** p<0.01, *** p < 0.001. Panel B: Area under the curve 
calculations); panels E and F: unpaired t-test.  
 
 A 
 
B 
E 
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Figure 3.6. More free-flowing HPC-7 are seen in the injured kidney immediately upon 
HPC-7 infusion.  After renal IR injury, the number of free-flowing HPC-7 seen flowing in 
the injured renal vasculature significantly increases compared to the non-injured sham 
animal (panel A).  This effect is limited to the first 1 minute recording only. Blood flow 
(measured as flux) was significantly reduced in IR injured mice at the time of HPC-7 
infusion (panel B).  Representative images from the laser-speckle microscopy results 
determining blood flow in sham (panel C; upper row) and IR injured kidney (panel C; 
lower row) are shown.  HPC-7 velocity in vivo was significantly reduced in IR injured renal 
microcirculation compared to that in sham animals (panel D).  Plots represent a mean 
adhesion ±SEM of at least 4 separate experiments; * p < 0.05, ** p < 0.01, *** p < 0.001.  
Panel A and B: two-way ANOVA with bonferroni post-tests; panel C: unpaired t-test. 
A B 
C 
D 
Sham Sham 
IR IR 
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3.4 Major Findings for Chapter 3 
 
FINDING HOW? 
1 Established murine renal IR injury model In vivo: Intravital microscopy 
2 
HPC-5 do not adhere to IR-injured kidney more so than 
sham 
In vitro: Stamper-Woodruff 
In vivo: Intravital microscopy 
3 HPC-7 adhere more to IR-injured kidney than sham 
In vitro: Stamper-Woodruff 
In vivo: Intravital microscopy 
4 HPC-7 adhere more to CL kidney than sham 
In vitro: Stamper-Woodruff 
Ex vivo: Intravital microscopy 
5 
After IR injury, more HPC-7 are seen free-flowing in the 
kidney in the first minute 
In vivo: Intravital microscopy 
6 Blood flow continues to be reduced in the IR kidney 
In vivo: Laser speckle 
contrast microscopy 
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3.5 Discussion 
A great deal of excitement surrounds the idea of BM-derived stem/progenitor cells as 
many studies have shown that they have regenerative potential or therapeutic ability in 
the kidney.  However, following systemic infusion, their recruitment by the renal 
microcirculation is an essential pre-requisite.  Although previous histological studies have 
demonstrated that HSCs can incorporate into IR injured kidney and confer benefit, no 
studies have currently used IVM to directly monitor the kinetics of HSC homing 
immediately upon infusion.  Stroo and colleagues (2009) injected BM-derived KSL cells 
but monitored their presence in mouse renal sections 24 hrs post-infusion.  Similarly, Kale 
et al., (2003) and Lin et al., (2003) monitored KSL cells in IR injured renal sections 7 days 
and 4-12 weeks post-infusion respectively.  Understanding how circulating HSCs traffic 
through the injured environment is important and may allow us to develop therapeutic 
strategies to enhance recruitment, thus hopefully improving the efficacy to which they 
regenerate.   
 
Using IVM, we generated novel data demonstrating that HSC adhesion was increased in 
IR injured kidneys compared to sham controls.  Intravital images are usually acquired 
from one pre-selected field of view and this same region is imaged throughout the 
duration of the experiment; this limits the area in which adhesive events are observed.  
Therefore, the static adhesion assay using frozen tissue sections allows a greater area to 
be visualised.  Both in vivo and in vitro assays demonstrated that renal IR injury was 
sufficient to promote the recruitment and adhesion of HPC-7 to the injured 
microvasculature.    
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To our knowledge, we are the first lab to use this method to describe the kinetics of SC 
homing to the kidney.  One of the challenges to renal IVM in mice has been the difficulty 
in exteriorising and stabilising the kidney due to its anatomical location; most renal 
pathologies often involve damage to structures deeper in the kidney, particularly to the 
glomerular capillaries.  Only the peritubular capillaries can be visualised intravitally, thus 
making IVM studies for glomerular diseases near impossible; however, since IR injury also 
damages the peritubular capillaries (Basile et al. 2001), viewing the surface of the kidney 
has proved invaluable for monitoring injury mediated SC -endothelial interactions in vivo.  
We firstly used an upright Olympus microscope to monitor the surface peritubular 
capillaries from above.  Although we did image SCs trafficking through the kidney with 
the upright IVM, we further modified this method using an inverted set-up to enable 
clearer images of the renal microcirculation to be obtained; this resulted in almost double 
of the adherent CFSE-labelled HPC-7 numbers that we were able to detect.  Also, a far 
greater number of free-flowing HPC-7 were counted.   
 
It is well accepted that performing in vivo trafficking studies using primary HSCs is not 
easy because of the difficulty in isolating large enough numbers so that they can be 
quantified after their infusion.  These cells are extremely rare within the mouse BM 
(roughly 5000 per animal) so in this thesis, HSC lines were used.  Unlike our studies which 
used HPC-7 cells, previous studies described above have used primary HSCs isolated from 
donor mouse BM.  However, much smaller numbers of cells were injected (eg.  5 x 103 for 
Kale and colleagues (2003); 2 x 105 for Lin and colleagues (2003)), which are possible to 
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obtain from donor mice and is sufficient for histological type studies.  However, for 
imaging dynamic cell trafficking intravitally a much larger dose of cells (1-2 x 106) is 
required, hence the need for a cell line in these studies.  HPC-7 are a well-accepted 
representative cell line of pure HSCs and have been widely used for investigating the 
control of HSC growth and differentiation at a molecular and cellular level (Pimanda et al. 
2008; Wilson et al. 2009).  Furthermore, this cell line can restore haematopoiesis in 
lethally irradiated mice (Pinto do et al. 2002).  We have demonstrated that increased 
numbers of HPC-7 adhere to IR injured kidney microvessels, when compared to sham 
controls.  Our data is in line with the findings of Stroo and colleagues (2009) that HSCs 
preferentially migrate to the ischaemic kidney.  Interestingly, HPC-5 did not show a 
preference in their adhesion to either IR injured kidney or sham controls in any of our 
studies.  The variation in homing and adhesion of these two HSC cell lines could be due to 
differences in surface adhesion molecule expression (Pinto do et al. 1998; Ivanova et al. 
2002).  Differences in the BM homing capabilities of embryonic and adult HSCs have also 
been noted (Perlingeiro et al. 2001). However, it has been previously shown that HPC-5 
can also be recruited to the IR injured liver in vivo (Kavanagh et al. 2010), therefore 
showing that HPC-5 cells do have the capability of homing and adhering to an acute 
ischaemic injury; this shows that there is some tissue specificity with regards to SC 
trafficking. 
 
Although the findings of Stroo et al. (2009) regarding HSC recruitment to the IR kidney 
are in agreement with our studies, they did not observe a similar increase in HSC 
adhesion to the CL non-injured kidney.  Meldrum et al. have shown that unilateral renal 
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IR injury causes a significant increase in TNF-α mRNA and protein expression in the IR and 
CL kidney in similar amounts after 1 hour reperfusion, compared to sham, as assessed by 
RT-PCR and ELISA assays respectively (Meldrum et al. 2002).  TNF-α is a pro-inflammatory 
agent and can enhance neutrophil infiltration and cytokine release, leading to an 
increased adhesion molecule expression on the endothelium (Devarajan 2006).  These 
results could therefore explain our increases in HSC numbers seen in the CL kidney after 
renal IR injury, showing that the CL kidney experiences a biologically significant injury 
after unilateral renal IR injury.  In the study by Stroo and colleagues, HSC numbers within 
the kidneys were quantified after 24 hours, so it is possible that any remote inflammation 
has already peaked or the HSCs that may have been adherent initially have migrated 
elsewhere.  However, Lin and colleagues (2003) have also noted donor-derived HSCs in 
the non-injured CL kidney, but after a 2 week reperfusion period.  Our results do question 
the use of the non-clamped CL kidney as an internal control, which it is often used as 
when assessing renal injury (Stern et al. 2004; Melo-Filho et al. 2010).    
 
Interestingly, the number of free-flowing HPC-7 cells observed circulating through the 
kidney was significantly increased but only at the point of infusion in IR injured mice.  
Some studies have demonstrated that blood flow increases following an inflammatory 
insult, which may explain the increased numbers of adherent cells (Hopkins and 
Damewood 1974; Sekizuka et al. 1988).  Others report that reperfusion of previously 
ischaemic tissue results in blood velocity decreasing due to vascular congestion as a result 
of adhesion of activated leukocytes and slowing of red blood cell flow (Cristol et al. 1993; 
Lieberthal 1997).  We combined IVM with laser speckle microscopy in order to correlate 
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the HSC adhesive events with renal blood flow.  The Moor FLPI laser speckle camera 
(Moor Instruments, UK) was used to determine renal surface blood flow within exposed 
IR injured and sham kidneys.  Flow/flux measurements were taken prior, during and after 
the 45 minute ischaemic period.  Using this non-invasive, quick and simple technique, we 
observed a significant decrease in blood flow within the ischaemic kidney at 60 minutes 
reperfusion, the point at which HSC infusion takes place, compared to the sham control.  
The data also confirmed that our IR injury is robust due to the presence of no blood flow 
within the renal microcirculation during the ischaemic period.  Furthermore, our 
individual cell tracking analysis program demonstrated that HPC-7 flowing through the 
injured kidney did so at a significantly lower pace.   
 
In conclusion, although there is increasing evidence that HSCs are beneficial following 
renal injury, the efficacy of such therapies is hypothesis to be proportional to the degree 
of cell recruitment which can be achieved.  Enhancing the effectiveness of regenerative 
processes may therefore depend on identifying and then modulating the adhesive 
mechanisms that underpin SC trafficking.  In this chapter we present novel data that renal 
IR injury can mediate active recruitment and subsequent adhesion of HPC-7 and that 
these events can be reproducibly monitored in real-time using fluorescent IVM.  This 
chapter and other studies from the Kalia lab (Kavanagh et al. 2013) demonstrate that the 
kinetics of HSC recruitment is similar to the well described adhesion cascade for 
neutrophils (Becker et al. 1999; Chan and Watt 2001).  The following chapter will examine 
in depth the adhesive mechanisms governing HSC recruitment to the IR injured mouse 
kidney.
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4 Mechanisms of Haematopoietic Stem Cell Recruitment to the IR Injured Kidney 
 
4.1 Introduction and Hypotheses 
4.1.1 Introduction 
Despite emerging clinical evidence that HSCs can improve a variety of inflammatory 
disorders, benefits are either minor or transitory (Lanzoni et al. 2008; Dai and Kloner 
2011); this has been partially explained by low numbers of HSCs actually adhering within 
the local microcirculation of injured organs after injection (Camargo et al. 2006).  When 
delivered by the preferred systemic route, SCs exhibit poor homing and a subsequent low 
efficiency of tissue engraftment occur, showing that these processes are essential for SCs 
to mediate repair (Karp and Leng Teo 2009).  After a myocardial infarction the progenitor 
cell retention is less than 5% (Aicher et al. 2003) and although Lin and colleagues (2003) 
showed that HSCs could engraft within the IR injured kidney tubules, the number of 
recruited cells were low, most likely resulting in a sub-maximal therapeutic benefit.  Poor 
homing, combined with the fact that HSCs are rare cells, <0.01% of BM, has likely limited 
their clinical utility and success.  If SC therapy is to be realised for various diseases, a 
better understanding of the adhesive mechanisms underlying their recruitment to the 
injured tissue bed would be advantageous. 
 
In the previous chapter, we have shown that our HSC line, HPC-7, preferentially adheres 
to the IR kidney, as demonstrated using both in vitro and in vivo assays.  However, the 
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adult HSC line, HPC-5, did not preferentially bind to the injured kidney.  Therefore we 
continued to use HPC-7 to determine the molecular mechanisms governing their 
recruitment to sites of renal IR injury.   
 
Currently, our knowledge of the adhesive mechanisms mediating the recruitment of 
transplanted HSCs to injured kidney is limited.  HSCs possess a similar repertoire of 
surface adhesion molecules to leukocytes; HSCs express - and -based integrin 
heterodimers, which bind to their endothelial counter-receptors, VCAM-1 and ICAM-1 
respectively (Turner et al. 1995).  Recent work from our group has shown the importance 
of both CD49d (α4 subunit of α41 integrin) and CD18 (β2 integrin) in mediating HSC 
recruitment to injured tissues (Kavanagh et al. 2010; Kavanagh et al. 2013).  The role of 
either of these integrins in HSC recruitment following renal IR injury is unknown.  A role 
for CD18 is likely since ICAM-1 has been shown to be highly expressed on the renal 
endothelium post-ischaemia and plays an important role in mediating inflammatory 
leukocyte adhesion.  Furthermore, blocking ICAM-1 with monoclonal antibodies in vivo 
protects animals from ischaemic AKI (Kelly et al. 1996).   
 
Interestingly, the non-integrin CD44 has shown contrasting results with regards its role in 
SC trafficking (Khaldoyanidi et al. 1996; Vermeulen et al. 1998; Oostendorp et al. 2000; 
Avigdor et al. 2004).  The main ligand for CD44 is HA, which is expressed in the ECM of 
most tissue beds (Goodison et al. 1999).  Also, CD44 is highly expressed in the kidney 
after IR injury (Goransson et al. 2004).   
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The first part of this chapter initially determined the molecular adhesive mechanisms 
governing HSC recruitment to IR injured murine renal microcirculation in vivo.  Expression 
of CD49d, CD18 and CD44 are expressed on the HPC-7 surface (Kavanagh et al. 2010) and 
due to the expression of their counter-receptors being heightened during renal IR injury, 
as well as having a role in the leukocyte-adhesion cascade, these receptors and their roles 
in SC homing to the injured kidney were determined.  
 
In addition to upregulated surface adhesion molecules during injury, chemokines 
released from the activated endothelium are also essential for activation of circulating 
cells, such as leukocytes (Granger and Senchenkova 2010).  The chemokines IL-8 and SDF-
1α are heavily implicated within this process, and the latter has been noted to be 
essential in SC trafficking.  It has also been shown that IL-8 or its murine homologue, KC, 
is heavily increased during the very early stages of ischaemic AKI (Molls et al. 2006).  The 
roles of these inflammatory chemokines in promoting HSC homing to a healthy kidney 
were investigated in the second part of this chapter, as well as deciphering if their 
counter-receptors aid in HSC recruitment to the injured kidney.   
 
4.1.2 Aims and Hypotheses 
The main aims and hypotheses of this chapter are: 
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1. Hypothesis: Individual blockade of adhesion receptors (CD18, CD44, CD49d) can 
significantly decrease HPC-7 adhesion to the IR injured kidney in vivo 
2. Hypothesis: Blocking endothelial counter-receptors  via an intra-arterial injection 
will reduce HPC-7 adhesion to the IR injured kidney in vivo 
3. Aims: Establish a murine prep that enables the healthy kidney to be immersed by 
the chemokine in question 
4. Hypothesis: KC and SDF-1α act as guidance cues to enhance HPC-7 homing  
5. Hypothesis: CXCR2 and CXCR4 have a major role in HPC-7 trafficking to the 
injured kidney 
 
4.2 Methods 
The methods used in this chapter are described in detail in chapter 2.  Briefly, to assess 
which HSC surface adhesion molecules have a role in trafficking to the injured kidney in 
vivo, our viable HSC cell line, HPC-7, were incubated with 80μg/ml function-blocking 
monoclonal antibodies (CD18, CD49d, CD44) against the specific adhesion molecule in 
question prior to injection into the carotid artery.  After this, the recruitment of these 
cells to the injured kidney was monitored intravitally.  To understand which counter-
ligands the HPC-7 receptors are interacting with, an in vivo monoclonal antibody (anti-
VCAM-1 or anti-CD44) or enzyme (hyaluronidase) was injected at 1 minute reperfusion.  2 
x 106 CFSE-stained HPC-7 were then injected at 60 minutes post-reperfusion and 
recruitment of these cells to the injured kidney was monitored intravitally. 
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As both KC and SDF-1α are released from the injured kidney, their role in regulating HPC-
7 homing to the kidney was determined.  To initially decipher if they could be having a 
role, the expression of their receptors, CXCR2 and CXCR4 respectively, on the HSC cell 
surface was determined using flow cytometry.  A novel preparation was designed in 
which the healthy non-injured kidney was continuously bathed in either chemokine for 4 
hours prior to SC administration and the number of adherent and free-flowing cells were 
subsequently quantified intravitally.  Blood flow was also monitored in this set of 
experiments using laser-speckle microscopy. 
 
After each intravital experiment, the animal was sacrificed and the left (sham/IR/treated) 
and right (non-injured CL) kidney were removed and adherent CFSE-labelled HPC-7 were 
quantified in five fields of view to obtain an average adherent cell count: this was used to 
make sure the HPC-7 events monitored in the one pre-selected field of view during 
intravital experiments was a true representation of events taking place in other regions of 
the kidney.  
 
4.3 Results 
4.3.1 Blocking HSC surface expression of CD18 does not have a role in HPC-7 
adhesion to the injured kidney 
Using flow cytometry, we have previously demonstrated that HPC-7 express CD18, CD49d 
and CD44 (Kavanagh et al. 2010).  Blocking CD18 on HPC-7 did not significantly decrease 
the number of adherent HPC-7 to the injured kidney (AUC: Anti-CD18: 268.3±10.65; IgG: 
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282.3±20.69; Figure 4.1.A).  Also, free-flowing HPC-7 numbers in the IR kidney after 
blocking CD18 were not significantly different compared to cells treated with an IgG 
control (Figure 4.1.B).  Ex vivo analysis of both IR injured and CL non-injured kidneys also 
confirms that CD18 does not have a role in HSC recruitment to the kidney (Figure 4.1.C-
D).  
 
4.3.2 CD49d has an important role in HPC-7 adhesion to the injured kidney 
Blocking CD49d significantly (p<0.01) decreased HPC-7 adhesion to the injured kidney 
(AUC: anti-CD49d: 164.9±36.68; IgG: 282.3±20.69; Figure 4.2.A).  After CD49d blockade, 
there was a significant (p<0.001) decrease in the numbers of free-flowing HPC-7 seen in 
the IR kidney, this effect is only seen during the first intravital recording when HPC-7 are 
infused (CPF: anti-CD49d IR kidney: 52.80±12.02; IgG IR kidney: 73.00±11.36; Figure 
4.2.B).  Ex vivo analysis shows there is a significant decrease in HPC-7 adhesion to IR 
injured (p<0.05) and CL non-injured (p<0.01) kidney (CPF: anti-CD49d IR kidney: 
10.44±1.076; IgG IR kidney: 15.50±1.895; Figure 4.2.C; anti-CD49d CL kidney: 
12.00±1.388; IgG CL kidney: 20.60±2.145; Figure 4.2.D).   
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Figure 4.1.  Adhesion of HPC-7 to renal IR injury does not require CD18.  Surface HPC-7 
expression was blocked by incubating cells with 80μg/ml of a CD18 function-blocking 
monoclonal antibody for 30 minutes prior to administration into the animal model of 
renal IR injury. Animals were subjected to 45 minutes ischaemia and 1 hour reperfusion, 
and then received an intra-arterial bolus of 2 x 106 CFSE-labelled CD18-blocked HPC-7.  
One field of view was selected and 1 minute recordings every 5 minutes started from the 
point of infusion (60 minutes post-reperfusion).  After 2 hours reperfusion, recordings 
were taken for 1 minute every 10 minutes for the remaining 30 minutes.  HPC-7 adhesion 
to the renal peritubular capillaries was examined using intravital microscopy.  HPC-7 
adhesion to the injured vasculature is not significantly altered after blocking HPC-7 
surface expression of CD18 compared to IgG controls (panel A; black line: IgG treated 
HPC-7; grey line: anti-CD18 treated HPC-7).  The number of free-flowing cells was also 
quantified and there were no significant differences at any time points (panel B).  Ex vivo 
analysis confirms that there is no difference in HPC-7 adhesion to the IR injured kidney 
(panel C) and also in the non-injured right contralateral kidney (panel D).  Plots represent 
a mean adhesion ± SEM of at least 4 separate experiments.  Panel A: area under the 
curve calculation; panel B: two-way ANOVA with bonferroni post-tests; panels C and D: 
unpaired t-test. 
C D 
B A 
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Figure 4.2.  Adhesion of HPC-7 to renal IR injury requires CD49d.  Surface HPC-7 
expression was blocked by incubating cells with 80μg/ml of a CD49d function-blocking 
monoclonal antibody for 30 minutes prior to administration into the animal model of 
renal IR injury.  HPC-7 adhesion to the renal peritubular capillaries was examined using 
intravital microscopy.  HPC-7 adhesion to the injured vasculature is significantly 
decreased after blocking HPC-7 surface expression of CD49d compared to IgG controls 
(panel A; black line: IgG treated HPC-7; grey line: anti-CD49d treated HPC-7).  The number 
of free-flowing cells was also quantified and there was a significant decrease in free-
flowing HPC-7 at the point of infusion only (panel B).  Ex vivo analysis of the IR kidney 
confirms there is an overall decrease in the number of adherent HPC-7 after anti-CD49d 
treatment (panel C) and also in the non-injured right contralateral kidney (panel D).  IgG 
controls were the same cohort as used in Figure 4.1 to reduce the number of animals 
used.  Plots represent a mean adhesion ±SEM of at least 5 separate experiments; * 
p<0.05; ** p<0.01; *** p<0.001. Panel A: area under the curve calculation; panel B: two-
way ANOVA with bonferroni post-tests; panels C and D: unpaired t-test. 
A B 
D C 
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4.3.3  HPC-7 adhesion is significantly reduced by in vivo blockade of VCAM-1 
Administration of an anti-VCAM-1 antibody, one of the counter-ligands to CD49d, intra-
arterially significantly (p<0.001) reduced HPC-7 adhesion when compared to intra-arterial 
administration of an IgG control (AUC: anti-VCAM-1: 209.9±16.06; IgG: 312.6±15.79; 
Figure 4.3.A).  VCAM-1 appears to also have a role in HPC-7 trafficking to the injured 
renal microvasculature (CPF: anti-VCAM1: 99.80±16.50; IgG: 134.3±15.01; Figure 4.3.B).  
Ex vivo analysis of the IR injured and CL non-injured kidney again confirms that blocking 
VCAM-1 significantly (p<0.01) decreases IR kidney adhesion (CPF: anti-VCAM-1 IR kidney: 
11.40±1.200; IgG IR kidney: 16.99±1.174; Figure 4.3.C).  VCAM-1 did not have a role in 
HPC-7 adhesion to the non-injured CL kidney (Figure 4.3.D).   
 
4.3.4 CD44 also has an important role in HPC-7 adhesion to the injured kidney 
Blocking HPC-7 surface expression of CD44 significantly (p<0.05) decreased HPC-7 
adhesion to the injured kidney (AUC: anti-CD44: 178.0±35.00; IgG: 282.3±20.69; Figure 
4.4.A).  There was no change in the number of HPC-7 trafficking through the injured 
microvasculature after anti-CD44 treatment (Figure 4.4.B).  Ex vivo analysis demonstrated 
a significant (p<0.05) decrease in HPC-7 adhesion to IR injured kidney only (CPF: anti-
CD44 IR kidney: 10.08±1.728; IgG IR kidney: 15.50±1.895; Figure 4.4.C).  HPC-7 adhesion 
to the non-injured CL kidney did not significantly change after blocking CD44 (CPF: anti-
CD44 CL kidney: 16.81±1.959; IgG CL kidney: 20.60±2.145; Figure 4.4.D).   
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Figure 4.3.  Recruitment and subsequent adhesion of HPC-7 to renal IR injury requires 
VCAM-1. An anti-VCAM-1 antibody was infused into the animal at 1 minute post-
reperfusion.  After 60 min post-reperfusion 2 x 106 naïve HPC-7 were introduced and 
their adhesion to the renal peritubular capillaries was examined using intravital 
microscopy.  HPC-7 adhesion to the injured vasculature is significantly decreased after 
blocking VCAM-1 compared to IgG controls (panel A; black line: IgG treated HPC-7; grey 
line: anti-VCAM-1).  The number of free-flowing cells was also quantified and there was a 
significant decrease in free-flowing HPC-7 at the point of infusion only (panel B).  Ex vivo 
analysis of the IR kidney confirms there is an overall decrease in the number of adherent 
HPC-7 after in vivo anti-VCAM-1 treatment (panel C) but no differences were seen in the 
non-injured right contralateral kidney (panel D).  Plots represent a mean adhesion ±SEM 
of at least 5 separate experiments; * p<0.05; ** p<0.01; *** p<0.001. Panel A: area under 
the curve calculation; panel B: two-way ANOVA with bonferroni post-tests; panels C and 
D: unpaired t-test.  
A B 
C D 
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Figure 4.4.  Adhesion of HPC-7 to renal IR injury requires CD44. Surface HPC-7 expression 
was blocked by incubating cells with 80μg/ml of a CD44 function-blocking monoclonal 
antibody for 30 minutes prior to administration into the animal model of renal IR injury.  
HPC-7 adhesion to the renal peritubular capillaries was examined using intravital 
microscopy.  HPC-7 adhesion to the injured vasculature is significantly decreased after 
blocking HPC-7 surface expression of CD44 compared to IgG controls (panel A; black line: 
IgG treated HPC-7; grey line: anti-CD44 treated HPC-7).  There were no differences in the 
number of free-flowing HPC-7 (panel B).  Ex vivo analysis of the IR kidney confirms there 
is an overall decrease in the number of adherent HPC-7 after anti-CD44 treatment (panel 
C) but not in the non-injured right contralateral kidney (panel D).  IgG controls were the 
same cohort as used in Figure 4.1 to reduce the number of animals used.  Plots represent 
a mean adhesion ±SEM of at least 5 separate experiments; * p<0.05.  Panel A: area under 
the curve calculation; panel B: two-way ANOVA with bonferroni post-tests; panels C and 
D: unpaired t-test.  
A B 
C D 
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4.3.5 HA is the counter-ligand for CD44 and helps HPC-7 adhere to the injured kidney 
The main endothelial counter-ligands to CD44 include HA and CD44 itself.  To decipher 
which counter-ligand is interacting with CD44 on the SC , an in vivo injection of either 
hyaluronidase, which breaks down HA, or a function blocking CD44 antibody was 
administered intra-arterially during reperfusion.  The major endothelial counter-ligand for 
CD44 on HPC-7 appeared to be HA, as digestion with hyaluronidase in vivo was associated 
with a significant (p<0.01) decrease in HPC-7 adhesion (AUC: PBS: 353.0±49.67; 
hyaluronidase: 190.9±24.53; Figure 4.5.A).  Blocking endothelial CD44 in vivo did not alter 
HPC-7 adhesion (Figure 4.5.B).  Removing either HA (p<0.001) or CD44 (p<0.001) activity 
causes a significant decrease in the number of free-flowing HPC-7 compared to the PBS 
and IgG controls respectively (CPF: hyaluronidase: 132.0±28.60; PBS: 197.5±18.62; anti-
CD44: 81.67±12.75; IgG: 134.29±15.00; Figure 4.5.C-D); this effect is only seen at the 
point of infusion.  Both in vivo HPC-7 adhesion results were confirmed during ex vivo 
analysis: hyaluronidase treatment significantly reduces HPC-7 adhesion in both the IR 
injured kidney and the non-injured CL kidney (CPF: hyaluronidase IR kidney: 8.714±1.206; 
PBS IR kidney: 22.33±0.7333; p<0.001; Figure 4.5.E; hyaluronidase CL kidney: 
12.37±1.601; PBS: 21.07±1.618; p<0.01; Figure 4.5.F); CD44 did not reduce HPC-7 
adhesion in either IR or CL kidneys (Figure 4.5.G-H).    
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Figure 4.5.  Recruitment and subsequent adhesion of HPC-7 to renal IR injury requires 
HA but not CD44. An in vivo injection of hyaluronidase or anti-CD44 was infused into the 
animal at 1 minute post-reperfusion.  After 60 min post-reperfusion 2x 106 naive HPC-7 
were introduced and their adhesion to the renal peritubular capillaries was examined 
using intravital microscopy.  HPC-7 adhesion to the injured vasculature is significantly 
decreased after digesting HA compared to IgG controls (panel A; black line: IgG treated 
HPC-7; grey line: hyaluronidase).  There was no difference in HPC-7 adhesion after anti-
CD44 in vivo treatment (panel B).  The number of free-flowing cells was also quantified 
and there was a significant decrease in free-flowing HPC-7 after hyaluronidase (panel C) 
and anti-CD44 (panel D) treatment, but only at the point of infusion only.  Ex vivo analysis 
of the IR and CL kidney confirms there is an overall decrease in the number of adherent 
HPC-7 after in vivo hyaluronidase treatment (panel E and F).  After anti-CD44 treatment 
ex vivo analysis confirms intravital results and no difference in HPC-7 adhesion to IR and 
CL kidneys are seen (panel G and H).  IgG controls were the same cohort as used in Figure 
4.3 to reduce the number of animals used.  Plots represent a mean adhesion ±SEM of at 
least 5 separate experiments; * p<0.05; ** p<0.01; *** p<0.001. Panel A: area under the 
curve calculation; panel B: two-way ANOVA with bonferroni post-tests; panels D and E: 
unpaired t-test. 
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4.3.6 The chemokines receptors CXCR2 and CXCR4 are expressed on HPC-7 
As KC is one of the first biomarkers of acute renal injury (Molls et al. 2006) and SDF-1α is 
known to be involved in BMSC homing (Togel et al. 2005), we decided to investigate if 
these chemokines had a role in HPC-7 recruitment to the IR injured kidney.  Flow 
cytometry was firstly conducted to detect if the main receptors for KC and SDF-1α, CXCR2 
and CXCR4 respectively, were present on HPC-7.  Both receptors were present on the 
HPC-7 surface (Figure 4.6.A-B). 
 
4.3.7 The chemokines KC and SDF-1α are involved in HPC-7 homing to the kidney 
To understand the specific roles of the chemokines KC and SDF-1α in HPC-7 trafficking to 
the kidney, the healthy kidney was bathed in either chemokine for 4 hours and then naïve 
HPC-7 were injected into the animal intra-arterially.  Renal HPC-7 recruitment was 
significantly increased when a healthy kidney was topically exposed to KC (p<0.05; Figure 
4.7.A) or SDF-1α (p<0.01; Figure 4.7.B) when compared to PBS controls (AUC: KC: 
457.2±79.55; SDF-1α: 393.5±26.87; PBS: 299.7±16.59).  When imaged at 4 hours post KC 
exposure, increased HPC-7 adhesion was observed.  However, this was not the case with 
exposure to SDF-1α, where the adhesion was a more gradual process peaking at around 
4½ hours post-SDF-1α exposure.  Ex vivo analysis confirmed the increases that are seen in 
one field of view after topical KC and SDF-1α treatment during the intravital studies are 
universal in different areas of the kidney (CPF: KC kidney: 32.85±4.118; p<0.05; Figure 
4.7.D; SDF-1α kidney: 26.73±2.536; p<0.05; Figure 4.7.E; PBS: 17.20±3.200).  No 
difference in HPC-7 adhesion was observed in the CL kidney (Figure 4.7.D-E).
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Figure 4.6. HPC-7 express chemokine receptors, CXCR2 and CXCR4, on their surface. Flow 
cytometry was used to determine if HPC-7 express the receptors to the chemokines KC 
and SDF-1α, CXCR2 and CXCR4 respectively.  Both CXCR2 (panel A; grey line and fill: IgG 
treated HPC-7; black line: CXCR2) and CXCR4 (panel B; grey line and fill: IgG treated HPC-
7; black line: CXCR4) are expressed on HPC-7.    
 
A 
B 
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Figure 4.7.  Chemokines KC and SDF-1α both help to recruit HPC-7 to the kidney.  
Healthy kidneys were exteriorised and immersed in a bath containing KC [200ng/ml] or 
SDF-1α [200ng/ml] for 4 hours (panel A).  Topical chemokine baths were removed and 2 x 
106 HPC-7 were injected intra-arterially into the animal and subsequent HPC-7 adhesion 
was monitored intravitally.  There was a significant increase in HPC-7 recruitment 
compared to the PBS control after both KC (panel B: black line: PBS treated kidney; grey 
line: KC treated kidney) and SDF-1α (panel C: black line: PBS treated kidney; grey line: 
SDF-1α treated kidney) topical treatments.  Ex vivo analysis of the kidneys post KC and 
SDF-1α topical treatment confirms there is an overall increase in the number of adherent 
HPC-7 after both treatments (panel D and E) but not in the non-treated right 
contralateral kidney.  PBS controls are of the same cohort in both KC and SDF-1α topical 
experiments.  Plots represent a mean adhesion ±SEM of at least 4 separate experiments; 
* p<0.05; ** p<0.01.  Panels B and C: area under the curve calculation; panels D and E: 
unpaired t-test. 
B C 
D E 
A 
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4.3.8 Both KC and SDF-1α topical treatments cause decreases in free-flowing HPC-7  
Interestingly, a significant decrease in the number of free-flowing HPC-7 after KC and 
SDF-1α topical treatments compared to the PBS-treated kidneys was observed (CPF: KC: 
123.5±31.26; p<0.001; Figure 4.8.A; SDF-1α: 49.75±7.878; p<0.001; Figure 4.8.B; PBS: 
174.4±22.72).  To decipher if these chemokines were having an effect on renal blood 
flow, perhaps through vaso-regulation, we utilised laser-speckle microscopy to monitor 
any changes in blood flow throughout the four hour topical exposure period and the 
following 45 minutes after HPC-7 were injected.  There was no change in blood flow in 
the kidney after SDF-1α treatment at any time point when compared to corresponding 
time point in the PBS control kidney (Figure 4.8.C).  However, blood flow does decrease 
in PBS (p<0.05) and SDF-1α (0.001) after 4 hour topical treatments when compared to the 
blood flow prior to PBS or SDF-1α treatment.  There was not a change in blood flow after 
exposure to KC compared to the blood flow prior to KC treatment.  In fact, blood flow 
was significantly sustained in the healthy kidney that received KC topical treatment when 
compared to the PBS control at 4 hours topical treatments, 5 min (the point of HPC-7 
infusion), 10 min and 15 min post-topical treatment (Figure 4.8.C).  The speed of the free-
flowing cells within the first 1 minute recording was also calculated in each of the treated 
kidneys: after SDF-1α topical treatment, HPC-7 moved slower in the first 1 minute 
recording, although this did not reach significance.  However, there was no difference in 
HPC-7 speed within the KC-treated kidney compared to the PBS control (Figure 4.8.D).  
Free flowing cells were defined as the total number of cells observed flowing through the 
field of view in a 1 minute time-frame of continuous observation; the blood circulation 
time for a mouse is approximately 4-6 seconds, thus meaning blood circulates 
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approximately 10 times during a 1 minute observation period.  To determine whether 
HPC-7 only passed once through the kidney or if they were re-circulated, numbers of 
freely flowing cells at 6 second intervals were determined for the first observation 
minute.  Less freely circulating HPC-7 were observed at each 6 second time point for the 
first minute following KC or SDF-1α topical treatment, suggesting more were lost to extra-
renal sites (Figure 4.8.E). 
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Figure 4.8.  Topical kidney treatment with KC and SDF-1α [200ng/ml] decreases free-
flowing HPC-7 to the kidney.  The number of free-flowing HPC-7 after topical treatments 
was quantified: KC (panel A) and SDF-1α (panel B) topical treatment of a healthy kidney 
significantly reduced the number of free-flowing HPC-7 (Black line: PBS treated kidney; 
grey line: chemokine treated kidney).  This effect only occurred at the point of infusion.  
There was no difference in blood flow at any time points when comparing SDF-1α and 
PBS treated kidneys (panel C; square black line: PBS treated kidney; black star grey line: 
SDF-1α treated kidney).  There was a decrease in blood flow after SDF-1α and PBS 4 hour 
topical treatments when compared to their blood flow prior to treatment.  KC 
A B 
C 
D E 
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significantly stabilised blood flow at 4 hours treatments and 5 min, 10 min and 15 min 
after KC treatment time points, compared to the same time points in the PBS treated 
kidney (panel C; square black line: PBS treated kidney; triangle grey line: KC-treated 
kidney).  There were no changes in HPC-7 speed in the first 1 minute recording after 
chemokine treatments (panel D).  Number of free-flowing HPC-7 within topically treated 
kidneys were analysed for each circulatory pass: significantly less HPC-7 were seen upon 
each circulatory pass after KC and SDF-1α topical treatments (panel E; square black line: 
PBS treated kidney; triangle grey line: KC-treated kidney; # p<0.05, ### p<0.001; black 
star grey line: SDF-1α treated kidney; * p<0.05; ** p<0.01, *** p<0.001).  Plots represent 
a mean adhesion ±SEM of at least 4 separate experiments; * p < 0.05, ** p < 0.01, *** p < 
0.001.  Panels A, B, C and E: two-way ANOVA with bonferroni post-tests; panel D: one-
way ANOVA with Dunnett’s post-tests. 
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4.3.9 A direct role of CXCR2 and CXCR4 in HPC-7 recruitment was confirmed in vivo 
A role for KC and SDF-1α in mediating HPC-7 recruitment to injured kidney was also 
demonstrated, as functionally blocking CXCR2 (p<0.05) or CXCR4 (p<0.01) on HPC-7 
significantly decreased adhesion within injured kidney in vivo compared to IgG control 
(AUC: anti-CXCR2: 212.3±20.94; anti-CXCR4: 150.0±22.96; IgG: 288.3±20.69; Figure 4.9.A-
B); this decrease was more pronounced when blocking CXCR4.  The results seen in vivo in 
the one field of view were again consistent to what was seen throughout the kidney, as 
demonstrated by our ex vivo data (CPF: anti-CXCR2 IR: 10.80±1.273; anti-CXCR4 IR: 
9.750±0.5439; IgG: 18.52±3.533; Figure 4.9.C-D).  HPC-7 adhesion to the non-injured CL 
kidney was also quantified; there were significantly less HPC-7 adherent to the CL kidney 
after blocking surface expression of CXCR2 and CXCR4 (CPF: anti-CXCR2 CL: 11.87±1.225; 
p<0.001; anti-CXCR4 CL: 11.60±1.995; p<0.01; IgG: 23.52±2.290; Figure 4.9.E-F).  There 
was also a significant (p<0.001) increase in the number of free-flowing HPC-7 after 
blocking CXCR2 and CXCR4 (CPF: anti-CXCR2: 89.00±3.571; anti-CXCR4: 103.3±15.39; IgG: 
73.00±10.37; Figure 4.9.G-H).  This effect occurred at the point of infusion only. 
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Figure 4.9.  Both CXCR2 and CXCR4 chemokine receptors are required for the adhesion 
of HPC-7 to renal IR injury. HPC-7 surface expression of CXCR2 and CXCR4 was blocked by 
A B 
C 
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D 
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incubating cells with 50μg/ml and 40μg/ml of function-blocking monoclonal antibodies 
respectively, for 30 minutes prior to administration into the animal model of renal IR 
injury.  Animals were subjected to 45 minutes ischaemia and 1 hour reperfusion, prior to 
receiving an intra-arterial bolus of 2 x 106 CFSE-labelled CXCR2/CXCR4-blocked HPC-7.  
One field of view was selected and 1 minute recordings every 5 minutes started from the 
point of infusion (60 minutes post-reperfusion).  After 2 hours reperfusion, recordings 
were taken for 1 minute every 10 minutes for the remaining 30 minutes.  HPC-7 adhesion 
to the renal peritubular capillaries was examined using intravital microscopy.  HPC-7 
adhesion to the injured vasculature is significantly decreased after blocking HPC-7 surface 
expression of CXCR2 (panel A) and CXCR4 (panel B) compared to IgG controls (black line: 
IgG treated HPC-7; grey line: anti-CXCR2/CXCR4 treated HPC-7).  Ex vivo analysis of the IR 
kidney confirms there is an overall decrease in the number of adherent HPC-7 after anti-
CXCR2 (panel C) and anti-CXCR4 treatment (panel D).  Similar decreases are also seen in 
the contralateral kidney after anti-CXCR2 (panel E) and anti-CXCR4 treatment (panel F).  
There were also decreases in the number of free-flowing HPC-7 when blocking CXCR2 
(panel G) and CXCR4 (panel H) on the HPC-7 surface.  IgG controls are from the same 
cohort as Figure 4.1 to reduce the number of animals used.  Plots represent a mean 
adhesion ±SEM of at least 5 separate experiments; * p<0.05.  Panels A and B: area under 
the curve calculation; panels C, D, E and F: unpaired t-test; panels G-H: two-way ANOVA 
with bonferroni post-tests. 
  
Chapter 4: Mechanisms that Govern HSC Recruitment to the Injured Kidney 
 
115 
 
4.4 Major Findings of Chapter 4 
 
FINDING HOW? 
1 
CD18 on HPC-7 surface is not needed for their 
recruitment to the IR-injured kidney 
In vivo and ex vivo: Intravital 
microscopy 
HPC-7 pre-treated with function 
blocking antibodies 
2 
CD49d and CD44 on HPC-7 surface is required for 
their adhesion to the IR-injured kidney 
In vivo and ex vivo: Intravital 
microscopy 
HPC-7 pre-treated with function 
blocking antibodies 
3 
Endothelial VCAM-1 is required for HPC-7 
adhesion to the IR-injured kidney 
In vivo and ex vivo: Intravital 
microscopy 
Intra-arterial injection of function 
blocking antibodies 
4 
Endothelial hyaluronan is required for HPC-7 
adhesion to the IR-injured kidney 
In vivo and ex vivo: Intravital 
microscopy 
Intra-arterial injection of function 
blocking antibodies 
5 
Endothelial CD44 is not required for HPC-7 
adhesion to the IR-injured kidney 
In vivo and ex vivo: Intravital 
microscopy 
Intra-arterial injection of function 
blocking antibodies 
6 
CD49d on HPC-7 and endothelial hyaluronidase 
govern HPC-7 adhesion to the CL kidney after renal 
IR injury 
Ex vivo: Intravital microscopy 
7 
Topical KC and SDF-1α can cause HPC-7 adhesion 
to a healthy kidney 
In vivo and ex vivo: Intravital 
microscopy 
8 
KC helps stabilise blood flow after topical 
treatment 
In vivo: Laser speckle contrast 
microscopy 
9 
CXCR2 and CXCR4 on HPC-7 govern HPC-7 
adhesion to the IR-injured kidney 
In vivo and ex vivo: Intravital 
microscopy 
10 
CXCR2 and CXCR4 on HPC-7 govern HPC-7 
adhesion to the CL kidney after renal IR injury 
In vivo and ex vivo: Intravital 
microscopy 
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4.5 Discussion 
Despite the general excitement about SC clinical trials, a major lack of understanding of 
how SCs home to injured tissues quite likely hinders their overall success.  To improve the 
potential regenerative efficiency of these rare cells, an increased understanding of 
homing mechanisms and in particular site-specific recruitment, would be of benefit.  HSCs 
are ultimately involved in generating blood cells and so their adhesion to injured 
vasculature might be similar to that of leukocyte adhesion.  Therefore, CD18, CD49d and 
CD44, which are well-established in playing critical roles in leukocyte adhesion, were 
investigated using our intravital model of renal IR injury.  We have shown that HPC-7 
adhesion within the injured kidney in vivo is dependent upon CD44 and CD49d 
interactions with endothelial HA and VCAM-1 respectively.  Both of these endothelial 
ligands are known to be up-regulated in IR injured kidney (Johnsson et al. 1996; Burne et 
al. 2001; Akhtar et al. 2010).  Interestingly, blocking these adhesion molecules or their 
endothelial counter-ligands only inhibited HPC-7 adhesion in the IR injured but not the CL 
non-injured kidney; it is possible that critical endothelial counter-ligands were only 
upregulated during high levels of oxidative stress and endothelial cell destruction, which 
would have occurred to a greater degree in the actual injured rather than CL kidney.   
 
A role for these particular adhesion pathways in a wide variety of other scenarios is well 
described.  The VLA-4 integrin (α4β1; CD49d/CD29) is also responsible for mediating 
tethering, rolling and firm adhesion of leukocytes to VCAM-1 (Springer 1994; Ley and 
Tedder 1995) and this pathway is used in homing exogenous HSCs to the BM in a lethally 
irradiated host.  We have previously shown a critical role for CD49d/VCAM-1 interactions 
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in mediating HSC recruitment to the liver and the cremaster muscle post IR injury 
(Kavanagh et al. 2010).  Furthermore, treating progenitor cells with a VLA-4 mAb causes 
less homing to the BM thus increasing the number of circulating cells (Papayannopoulou 
et al. 1995).  The VLA-4/VCAM-1 and CD44/HA pathways are also implicated in causing 
the adhesion of metastatic B-cells to endothelium (Okada et al. 1999).   
 
CD44 is also used by MSCs to migrate on and towards HA (Zhu et al. 2006; Herrera et al. 
2007).  With respect to endothelial counter-ligands, HA isn’t the sole partner for CD44, as 
it has been shown to interact homotypically with CD44 expressed on endothelial cells 
(Termeer et al. 2001).  However, while CD44 is up-regulated on renal capillary ECs after IR 
injury (Lewington et al. 2000), we found that CD44 homotypic interactions did not govern 
HSC adhesion in our renal IR injury model.  Although blocking endothelial CD44 in vivo did 
not affect adherent HSC numbers in our injury model, it may have other benefits as CD44-
/- mice have a reduced influx of neutrophils and improved kidney function after IR injury 
compared to WT mice (Rouschop et al. 2005).  Interestingly, studies suggest the CD44/HA 
pathway also governs MSC recruitment in the glycerol-induced model of AKI (Herrera et 
al. 2007).  This study utilised immunohistochemistry and electron microscopy to 
demonstrate that only CD44+/+ and not CD44-/- MSCs could be located within the renal 
cortex.  More importantly, it demonstrated that MSCs lacking CD44 could not be 
recruited to the kidney and that this directly resulted in a loss of therapeutic renal 
benefit, clearly demonstrating that the active local recruitment of SCs using surface 
adhesion molecules, such as CD44, is an essential pre-requisite for their beneficial effect. 
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The 2 integrin sub-unit CD18 was not involved in mediating HPC-7 recruitment to our IR 
injured kidney model.  Interestingly, CD18 has been implicated in governing HSC 
recruitment to injured gut and to IR injured cremaster muscle venules (Kavanagh et al. 
2013), which further supports previous data illustrating that the 2 integrin is important 
during HSC and progenitor cell adhesion to endothelial cells and their subsequent 
transmigration (Imai et al. 1999; Peled et al. 2000).  In contrast, studies by 
Papayannopoulou and colleagues have shown that HSC homing to the bone marrow is 
not dependant on CD18; although, the CD18-deficient mice in this study do have altered 
HSC homing when CD49d/CD29 functions are inhibited, suggesting that CD18 can 
contribute to BM recruitment but in a redundant fashion (Papayannopoulou et al. 2001).  
As it stands, the role of the β2 integrin in HSC recruitment to different sites is not clear-
cut, suggesting that there may be a degree of site specificity with regards to the adhesive 
mechanisms involved.  This further shows that understanding site-specificity is vital when 
developing strategies to target SC adhesion within specific organs.   
 
In the second part of this chapter we investigated whether chemokines, such as SDF-1α 
and KC, could also influence HPC-7 recruitment.  For chemokines to elicit chemotaxis in 
vivo these basic proteins are secreted by the endothelium and are bound and 
immobilised by particular glycoaminoglycans (GAGs) within the ECM or at the surface of 
vascular endothelium (Kuschert et al. 1999).  Chemokine presentation via GAGs forms 
chemokine gradients that can influence and interact with corresponding GAGS on passing 
leukocytes that express the chemokine counter-receptor.  Using a novel preparation that 
immerses the exteriorsed kidney in chemokine, we demonstrated that both SDF-1α and 
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KC could both promote HSC adhesion within a healthy kidney.  In agreement with our 
studies, Togel et al. (2005) observed that SDF-1α plays an important role in mediating the 
homing of CXCR4+ BM-derived cells in IR injured kidney.  Also, in the heart, SDF-1α 
expressing plasmids were transplanting into various ischaemic myocardial zones and this 
caused an increase recruitment of primary HSCs to the site of damage.  Conversely, Stroo 
et al. (2009) showed that manipulating the SDF-1α/CXCR4 axis, either by increasing local 
SDF-1α concentrations in the injured kidney or by blocking CXCR4 on HSCs, did not affect 
their migration; however, they injected recombinant SDF-1α into just one focal point in 
the kidney, which may explain this discrepancy.  Although SDF-1α is currently considered 
one of the most potent chemokines mediating SC homing both to the BM and to 
extramedullary tissues (Peled et al. 1999; Wright et al. 2002; Schulz et al. 2009), it was 
interesting to observe that HSC adhesion to the KC-exposed healthy kidney was more 
rapid than SDF-1α treatment.  This is the first time a novel role for this classical neutrophil 
chemoattractant has been directly demonstrated in mediating SC recruitment in a tissue 
bed. 
 
Topical exposure of SDF-1α to the healthy kidney did not elicit a change in blood flow 
compared to the PBS treated control; however after 4 hours topical exposure to both 
SDF-1α and PBS, there was a decrease in renal blood flow compared to the initial blood 
flow measurement prior to topical treatments.  During topical treatments, 1ml of fluid 
had to be replaced every hour and this could be due to the kidney absorbing the solution; 
this potentially could be leading to tissue swelling, which could influence blood flow by 
physically constricting or compressing the blood vessels.  It is well known that oedema, 
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which results from fluid loss from vessels into the interstitium, can compress capillaries; 
therefore what we may have inadvertently caused with these topical experiments is a 
kind of outside-in oedema.  A point to also make is that we have removed the tough 
fibrous kidney capsule to improve vascular imaging; one of its functions is to limit the 
expansion of the tissue spaces in response to oedemagenic stress.  What is important to 
note is that despite the reduced renal blood flow at the point of cell infusion after 4 hours 
topical treatment, increased adhesion of HPC-7 was still observed in SDF-1α treated 
kidneys and since this was not demonstrated in PBS treated kidneys, it suggests SDF-1α 
can actively prime circulating SCs to adhere.  It is also possible that the increased 
adhesion is because they are flowing through the kidney at a lower velocity and so the 
potential for adhesive interactions to take place is increased.    
 
After 4 hours of KC topical treatment, there was not a reduction in renal blood flow to 
such a great degree from resting starting blood flow, as seen in SDF-1α or PBS topical 
treatments.  Fluid was still lost from the bath during KC topical treatments, so it is likely 
that the kidney still absorbed the treatment but somehow topical KC treatment may have 
stabilised any changes in blood flow.  KC has been shown to stimulate mesangial cells of 
the kidney to release prostaglandin E2 (Tsai et al. 2004), which is an effective vasodilator 
at low concentrations and can increase blood flow to the kidney and other areas (Haylor 
and Towers 1982; Purdy and Arendshorst 2000; Nakatsuka et al. 2005; Rincon-Sanchez et 
al. 2005); this could likely explain the sustained blood flow seen in the KC topical treated 
kidneys.    
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The exposure of the healthy kidney to chemokines does highlight that they can induce SC 
adhesion, despite changes in renal blood flow.  Furthermore, both chemokines played a 
significant role in modulating adhesion in the injured kidney, as blocking CXCR2 and 
CXCR4 inhibited their recruitment.  Although the SDF-1α/CXCR4 pathway is well 
established regarding SC trafficking, this is the first time that KC and its main receptor 
CXCR2 have been shown to be involved in SC recruitment and was published this year 
(White et al. 2013).  KC can also interact with murine CXCR1 (Fan et al. 2007), but the role 
of this receptor in HSC recruitment was not investigated in this study.  CXCR2 has 
however been showed to be involved in other types of cellular recruitment: Morgan et al. 
(1997) used intravital microscopy to demonstrate that CXCR2-deficient mice exhibited a 
decrease in the adhesion of activated leukocytes (mainly neutrophils) and an increase in 
rolling leukocytes velocity in the cremaster venules: this demonstrates that this receptor 
may be involved in slowing down leukocytes so that then β2 integrins can cause full 
arrest.  We have shown that blocking CD18 does not affect adhesion of HSCs in renal IR 
injury, therefore it is unlikely that CXCR2 and CD18 are working cooperatively within our 
model.  CXCR4 and CXCR2 regulate neutrophil extravasation into the peripheral 
circulation by working antagonistically to each other (Eash et al. 2010).  The relationship 
between CXCR4 and HSCs is well characterised and a genetic deletion of CXCR4 in murine 
haematopoietic cells or an injection of AMD3100 (CXCR4 antagonist) actually increases 
their mobilisation into the circulation from the BM (Broxmeyer et al. 2005; Eash et al. 
2009).  Also, neutralising CXCR4 abrogated the migration of CD34+ cells towards injured 
kidney cells in vitro and in vivo (Togel et al. 2005).  CXCR4 is also involved in mediating 
cellular migration during development, homeostasis, inflammation and regeneration. 
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A better understanding of the basic biology underlying SC adhesion is needed if SC 
therapy is to be utilized to its optimum.  We have identified that KC/CXCR2 and SDF-
1α/CXCR4 pathways can regulate HSC adhesion to the kidney.  However, the clinical 
applicability of such topical chemokine techniques is debatable and may be associated 
with aggravated tissue injury due to the detrimental effects SDF-1α had on blood flow in 
our model and also SDF-1α-dependent lymphocyte recruitment (Liekens et al. 2010).  
Adhesion pathways governing HSC recruitment to sites of renal injury were previously 
scarce but we now know that the CD49d/VCAM-1 and CD44/HA adhesion pathways are 
essential for HSC adhesion to the IR injured kidney.  Understanding these recruitment 
mechanisms may enable the development of strategies that can further enhance this 
trafficking; one way could be to modulate the important adhesion molecules on the HSC 
surface, which could potentially lead to more rapid, efficient and longer lasting tissue 
repair.  Therefore, the following chapter will focus on ways of improving renal retention 
of HPC-7. 
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5 Methods of Enhancing Haematopoietic Stem Cell Adhesion to the IR Injured Kidney 
 
5.1 Introduction and Hypotheses 
5.1.1 Introduction 
A variety of chemical mediators are released from inflamed kidney, including cytokines 
and ROS: these can activate adhesion molecules on trafficking HSCs in a similar manner to 
leukocytes and subsequently initiate their adhesion to microvessels (Segerer et al. 2000).  
Hydrogen peroxide (H2O2) is known to be released by ischaemically injured tissues and 
sources include the damaged endothelium or the accumulating neutrophils upon 
reperfusion (Ardanaz and Pagano 2006).  Our group have recently examined the effects 
of pre-treating HPC-7 with H2O for 1 hour on HPC-7 adhesion to the IR injured gut 
(Kavanagh et al. 2012).  In vitro and in vivo experiments demonstrated that H2O2 could 
increase HPC-7 adhesion to the injured gut tissue and this was mediated through 
enhancing the ability of HPC-7 adhesion receptors to bind to their endothelial counter-
ligands.  This suggests HSC homing is not maximal and that enhancement of HSC 
recruitment may be possible.     
 
In Chapter 3, HPC-7 adhesion to injured kidney was increased compared to sham and this 
is most likely due to the injured kidney releasing factors that activate both the 
endothelium and the trafficking HPC-7.  Cytokines are well-known inflammatory 
mediators that are robustly activated during IR injury (Luster 1998) and is well 
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documented that they provide a powerful stimulus for neutrophil recruitment to the 
injured tissue (Mulligan et al. 1998; Burne et al. 2001).  However, how and if 
inflammatory cytokines/chemokines can cause HSC recruitment is less clear.  Local 
production of IL-1β, KC, TNF-α and SDF-1α has been shown to be increased soon after 
renal IR injury and many other tissues post IR injury (Furuichi et al. 2002): this can provide 
chemoattractant cues or activate cells to enhance neutrophil recruitment and their 
subsequent adhesion.  SDF-1α has been extensively studied with regards to SC homing, 
but the roles of other signalling molecules in SC recruitment are less well known.   
 
This chapter firstly investigates whether pre-treating SCs with media conditioned by an 
injured kidney can enhances HPC-7 adhesion compared the adhesion seen without pre-
treatment.  We further investigated which specific cytokines/chemokines could be 
involved in causing enhanced adhesion to the IR kidney.  The effects of HPC-7 pre-
treatment with H2O2 were also explored, as it has been previously shown by us to be 
effective at modifying adhesion in the similarly injured gut (Kavanagh et al. 2012).  
Mechanistic studies were conducted to determine how the cytokine/chemokine pre-
treatments could be enhancing SC adhesion; this involved looking at receptor expression 
and their localisation on the surface, as well as the deformability of SCs.    
 
5.1.2 Aims and Hypotheses 
The main aims and hypotheses of this chapter are: 
1. Hypotheses: Pre-treatment of HPC-7 with ICM enhances their adhesion.  
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2. Hypotheses: Cyto/chemokines, including IL-1β, TNF-α, KC and SDF-1α, are 
responsible for any increased HPC-7 adhesion.  
3. Hypotheses: Cyto/chemokines mediate HPC-7 adhesion by: increasing adhesion 
ligand expression; enhancing HPC-7 adhesion molecule affinity for its endothelial 
counter-ligand; increasing receptor clustering on the HPC-7 surface; and/or 
changing the deformability of HPC-7. 
4. Aims:  Investigate the effects of ICM and cyto/chemokine pre-treatment of HPC-7 
both in vitro and in vivo and use flow cytometry, static adhesion assays and 
confocal microscopy to determine the mechanisms of their action. 
 
5.2 Methods 
The methods used in this chapter are described in detail in Chapter 2.  Briefly, ICM and 
SCM were prepared from homogenised kidney subjected to 45 minutes ischaemia and 1 
hour reperfusion or sham surgery respectively.  HPC-7 were pre-treated with an ICM, 
SCM, SDF-1α, KC, IL-1, TNF-α or H2O2, for various durations, prior to determining their 
adhesion to renal sections or mouse renal endothelial cells in vitro or to the injured 
kidney in vivo.  For in vitro studies, 1 x 105 CFSE-labelled HPC-7 were added to each 
section/well and the average number of adherent cells within 5 fields of view was 
determined.  For in vivo studies, 2 x 106 CFSE-labelled HPC-7 were introduced via the 
carotid artery and one field of view was continually analysed for 90 minutes post-HPC-7 
administration.     
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For mechanistic studies, HPC-7 were analysed for changes in expression of adhesion 
molecules following pre-treatment with KC and SDF-1α for 5 minutes.  FACS analysis was 
conducted using fluorescently conjugated antibodies against CD49d and CD44; these 
were the important adhesion molecules for governing HPC-7 adhesion to the IR injured 
kidney, as shown in Chapter 4.  To investigate whether these chemokines enhanced the 
ability of HPC-7 to bind to the important endothelial ligands, pre-treated cells were added 
to VCAM-1 and HA, which were immobilised to plastic culture plates.  To visualise 
adhesion molecule distribution on the surface of HPC-7, pre-treated cells were fixed to 
preserve any changes in receptor localisation and then CD49d and CD44 were labelled 
with the corresponding primary antibody followed with a fluorescent secondary antibody 
prior to confocal imaging.  In order to understand any changes in the number of free-
flowing HPC-7 after pre-treatment, a micropipette assay was carried out to assess cell 
deformability; this involved applying suction pressure to pre-treated cells and recording 
the time taken for the cell to be fully aspirated into a glass pipette of a similar diameter 
to a capillary.  
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5.3 Results 
5.3.1 Media conditioned by the injured kidney can enhance HPC-7 recruitment in 
vitro 
Incubating HPC-7 with ICM for 5 and 10 minutes did not enhance their adhesion to frozen 
IR injured renal sections compared to SCM treated controls (Figure 5.1.A).  However, pre-
treating HPC-7 for 30 minutes with ICM caused a significant (p<0.001) increase in 
adhesion compared to SCM (CPF: 30 min ICM: 113.5±11.21; 30 min SCM: 26.67±6.741; 
Figure 5.1.A).  After 21 hours incubation, this effect was lost.  Interestingly, pre-treating 
HPC-7 with ICM also significantly (p<0.01) increased their adhesion to non-injured sham 
frozen kidney sections after 5 minutes incubation with ICM when compared to SCM 
treated cells (CPF: 5 min ICM: 18.14±3.04; 5 min SCM:  7.43±2.33; Figure 5.1.B).  After 
longer HPC-7 pre-treatments this increased adhesion was lost.  Also, HPC-7 adhesion to 
sham sections was to a lesser extent in comparison to what is observed with ICM on IR 
tissue sections. 
 
Immortalised renal endothelium was given to our lab as a kind gift from Dr. J. Steven 
Alexander, LSU-HSC, USA.  Pre-treating HPC-7 with ICM for 30 minutes also enhances 
their adhesion to PBS and TNF-α treated renal endothelium (CPF: 30 min ICM + PBS endo: 
27.08±2.313; 30 min SCM + PBS endo: 9.843±0.6639; 30 min ICM + TNF-α endo: 
17.54±4.714; 30 min SCM + TNF-α endo; 9.843±0.6639; Figure 5.1.C-D). 
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Figure 5.1.  Pre-treatment of HPC-7 with injured conditioned media (ICM) for 30 minutes significantly increases HPC-7 adhesion in vitro.  A 
significant increase in HPC-7 adhesion to frozen kidney IR injured sections compared to SCM pre-treated HPC-7 controls was only observed 
after 30 minutes pre-treatment with an ICM (panel A).  ICM pre-treatment for 5 minutes only enhanced HPC-7 adhesion to sham frozen 
kidney sections (panel B).  1 x 105 CFSE-labelled HPC-7 were pre-treated with ICM and SCM for 30 minutes and applied to PBS and TNF-α 
treated endothelium: pre-treating HPC-7 with ICM caused enhanced HPC-7 adhesion to both PBS (panel C) and TNF-α (panel D) treated 
murine renal endothelium. Representative images of HPC-7 adhesion to IR kidney sections with SCM (panel E) and ICM (panel F) are shown.  
Plots represent a mean adhesion ±SEM of at least 4 separate experiments; * p<0.05; *** p<0.001.  Panels A and B: one-way ANOVA with 
bonferroni post-tests; panels C and D: unpaired t-test. 
A B 
C D 
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5.3.2 Increased levels of small molecular weight proteins are within the IR injured 
kidneys 
Samples of the SCM and ICM were denatured, run through a 10% SDS polyacrylamide gel 
and subsequently stained with Coomaissie: this demonstrated that there were 
differences in protein expression levels between ICM and SCM (Figure 3.5.A).  However, 
as this 10% gel does not show the expression of smaller molecular weight proteins, a 15% 
polyacrylamide SDS gel was also prepared, as this denser gel allowed smaller proteins to 
be resolved.  Differences in proteins bands were again seen between the ICM and SCM: 
most notably there was a larger band between 7-19 kDa in the ICM compared to the SCM 
(Figure 3.5.B). The amount of protein loaded into each ladder was not quantified but an 
equal volume of each kidney conditioned media was applied to each lane.  
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Figure 5.2.  There is a greater presence of small molecular weight proteins in the injured 
kidney conditioned media. After injury, the kidney is known to release multiple soluble 
and pro-inflammatory factors that can activate both the endothelium and trafficking SCs 
resulting in increased HPC-7 adhesion.  Therefore, kidney homogenates from injured and 
sham kidneys were prepared and the same volume was applied to a SDS polyacrylamide 
gel to separate the proteins.  A protein ladder of known weights was also run down the 
left-hand side as a reference.  Initially a 10% SDS gel was used and there was a clear 
difference in the bands between the SCM (row i) and ICM (row ii). The ICM showed 
thicker bands, containing a higher amount of smaller proteins, when compared to SCM 
(panel A).  To resolve differences in smaller proteins than 19 kDa, such as cytokines, we 
increased the concentration of SDS to 15%, as this denser gel allows smaller proteins to 
resolve through more slowly.  There is a distinctly thicker band in the ICM column (row ii) 
in the 7-19 kDa weight range compared to SCM (row i; panel B).   
10% SDS 15% SDS 
A B 
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5.3.3 Pre-treating HPC-7 with low doses of SDF-1α enhances HPC-7 adhesion in vitro 
Most murine inflammatory cytokines have a molecular weight between 7-19 kDa.  It is 
therefore likely that a cyto/chemokine with a molecular weight in this range is mediating 
the pro-adhesive effects observed with the ICM.  SDF-1α is a chemokine that is well 
known to be increased after renal IR injury (Togel et al. 2005) and has a molecular weight 
of 8 kDa.  Therefore, HPC-7 were pre-treated with different concentrations of SDF-1α for 
5 minutes to determine any effective pro-adhesive concentrations.   
 
Pre-treating HPC-7 with 25ng/ml SDF-1α for 5 minutes significantly (p<0.05) increased 
adhesion to the injured kidney section compared to the PBS control (CPF: 25ng/ml: 
110.8±18.15; PBS: 19.00±5.132; Figure 5.4.A).  HPC-7 adhesion was not significantly 
different after 50ng/ml SDF-1α or 125ng/ml SDF-1α pre-treatments.  HPC-7 that were 
pre-treated with these three different concentrations of SDF-1α were also applied to 
TNF-α treated endothelium and again, 25ng/ml was the only pre-treatment to cause a 
significant increase in HPC-7 adhesion (CPF: 25ng/ml: 33.80±6.129; PBS: 7.560±3.438; 
Figure 5.1.B). 
 
5.3.4 SDF-1α pre-treatment is the only cytokine to enhance HPC-7 adhesion using 
the Stamper-Woodruff assay 
HPC-7 were also pre-treated with other well-known inflammatory mediators, such as IL-
1β, KC and TNF-α at 25ng/ml for 5 minutes before applying to renal IR injured tissue 
sections.  These cyto/chemokines are all within the 7-19 kDa range (IL-1β: 17 kDa; KC: 8 
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kDa; TNF-α: 17.4 kDa) and might well be contributing to the enhanced adhesion seen in 
the IR kidney and could be within the ICM.  The results were compared to a control pre-
treatment with PBS.  However, only SDF-1α induced a significant (p<0.01) increase in 
HPC-7 adhesion to injured kidney tissue (CPF: SDF-1α: 110.8±18.15; PBS: 19.00±5.132; 
Figure 5.5.A).  Pre-treated HPC-7 were also applied to sham renal tissue sections but no 
significant differences could be seen (Figure 5.5.B).  
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Figure 5.3.  Pre-treatment of HPC-7 with varying concentrations of SDF-1α for 5 minutes 
produces differences in HPC-7 adhesion in vitro.  Pre-treating 1 x 105 CFSE-labelled HPC-7 
with 25ng/ml of SDF-1α for 5 minutes significantly enhanced HPC-7 adhesion to frozen 
kidney IR injured sections, using the Stamper-Woodruff assay (panel A).  However, 
50ng/ml and 125ng/ml SDF-1α pre-treatments did not cause any significant differences in 
HPC-7 adhesion to frozen kidney IR injured sections compared to PBS pre-treated HPC-7 
controls (panel A).  1 x 105 CFSE-labelled HPC-7 were again pre-treated with 25ng/ml, 
50ng/ml and 125ng/ml of SDF-1α for 5 minutes and applied to TNF-α treated renal 
endothelium: pre-treating HPC-7 with the lowest dose of SDF-1α, 25ng/ml, caused 
enhanced HPC-7 adhesion to TNF-α activated endothelium (panel B).  Representative 
images of HPC-7 adhesion to TNF-α activated renal endothelium after PBS (panel C), 
25ng/ml SDF-1α (panel D), 50ng/ml SDF-1α (panel E) and 125ng/ml SDF-1α (panel F) 
HPC-7 pre-treatments.  Plots represent a mean adhesion ±SEM of at least 4 separate 
experiments; * p<0.05; ** p<0.01.  Panels A and B: one-way ANOVA with Dunnett’s post-
tests. 
A B 
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Figure 5.4.  Pre-treatment of HPC-7 with 25ng/ml of IL-1β, KC, SDF-1α and TNF-α for 5 
minutes produces differences in HPC-7 adhesion to IR injured renal sections.  Pre-
treating 1 x 105 CFSE-labelled HPC-7 with 25ng/ml of SDF-1α for 5 minutes significantly 
enhanced HPC-7 adhesion to frozen kidney IR injured sections, using the Stamper-
Woodruff assay.  However, IL-1β, KC and TNF-α HPC-7 pre-treatments did not cause any 
significant differences in HPC-7 adhesion to frozen kidney IR injured sections compared to 
PBS pre-treated HPC-7 controls (panel A; black fill: IR injured frozen renal sections).  1 x 
105 CFSE-labelled HPC-7 were again pre-treated with 25ng/ml of all cytokines for 5 
minutes and applied to sham renal sections: there were no significant differences with 
any cytokine pre-treatment compared to the PBS treated HPC-7 (panel B; grey fill: sham 
frozen renal sections).  Plots represent a mean adhesion ±SEM of at least 4 separate 
experiments; ** p<0.01.  Panels A and B: one-way ANOVA with Dunnett’s post-tests. 
A 
B 
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5.3.5 KC and SDF-1α HPC-7 pre-treatments enhance adhesion to TNF-α treated renal 
endothelium   
HPC-7 were pre-treated at 25ng/ml for 5 minutes as before and were then applied to 
TNF-α treated immortalised renal endothelium.  After IL-1β and TNF-α pre-treatments, 
there was a slight increase in HPC-7 adhesion, but this did not reach significance.  
However, unlike on frozen section, this time both KC and SDF-1α pre-treatments caused a 
significant (p<0.01) increase to TNF-α treated endothelium (CPF: IL-1β: 20.80±3.208; KC: 
39.16±4.281; SDF-1α: 33.80±6.128; TNF-α: 20.64±5.221; PBS: 7.560±3.438; Figure 5.5.A).  
Pre-treated HPC-7 were also applied to PBS treated endothelium and similar results were 
seen as with TNF-α treated endothelium.  HPC-7 adhesion increased after IL-1β or TNF-α 
but the values did not attain statistical significance.  However, following KC and SDF-1α 
pre-treatments there were significant (p<0.05 and p<0.01 respectively) increases in HPC-7 
adhesion compared to the PBS control (CPF: IL-1β: 18.74±2.960; KC: 25.96±3.687; SDF-1α: 
39.75±8.371; TNF-α: 22.03±2.947; PBS: 8.600±2.128; Figure 5.5.B). 
 
5.3.6 IL-1β pre-treatment does not enhance HPC-7 adhesion to the IR injured kidney 
in vivo 
The role of various cytokines in directly mediating HPC-7 adhesion was determined in vivo 
by pre-treating HPC-7 for 5 minutes with each cytokine, starting with 25ng/ml of IL-1β.  2 
x 106 CFSE-labelled IL-1β pre-treated HPC-7 were injected intra-arterially into a murine 
model of renal IR injury and the numbers of adherent and free-flowing cells were 
quantified.  There was no significant difference in the number of adherent HPC-7 after IL-
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1β pre-treatment compared to the PBS treated HPC-7 control (AUC: IL-1β: 300.3±25.62; 
PBS: 280.8±35.54; Figure 5.6.A).  Although there was no difference in adherent HPC-7 
after IL-1β pre-treatment, there was a significant (p<0.001) increase in the number of 
cells free-flowing in the injured mouse after IL-1β pre-treatment (Figure 5.6.B). 
 
5.3.7 KC pre-treatment enhances HPC-7 adhesion to the IR injured kidney in vivo 
There was a significant (p<0.01) increase in the number of adherent HPC-7 after KC pre-
treatment compared to the PBS-treated control (AUC: KC: 449.3±30.69; PBS: 
300.3±25.62; Figure 5.7.A). There were no significant differences in the number of free-
flowing HPC-7 after KC pre-treatment compared to PBS control (Figure 5.7.B). 
 
5.3.8 SDF-1α pre-treatment enhances HPC-7 adhesion to the IR injured kidney in vivo 
There was a significant (p<0.01) increase in the number of adherent HPC-7 after SDF-1α 
pre-treatment compared to the PBS treatment control (AUC: SDF-1α: 409.3±16.67; PBS: 
300.3±25.62; Figure 5.8.A). There was also a significant (p<0.001) difference in the 
number of free-flowing HPC-7 after SDF-1α  pre-treatment at the point of infusion only 
(60 minutes reperfusion) compared to PBS control (Figure 5.8.B). 
 
5.3.9 TNF-α pre-treatment enhances HPC-7 adhesion to the IR injured kidney in vivo 
There was a significant (p<0.05) increase in the number of adherent HPC-7 after TNF-α 
pre-treatment compared to the PBS treatment control (AUC: SDF-1α: 409.3±16.67; PBS: 
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300.3±25.62; Figure 5.9.A). There was also a significant (p<0.001) difference in the 
number of free-flowing HPC-7 after TNF-α  pre-treatment compared to PBS control 
(Figure 5.9.B). 
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Figure 5.5.  Pre-treatment of HPC-7 with 25ng/ml of IL-1β, KC, SDF-1α and TNF-α for 5 
minutes produces differences in HPC-7 adhesion to immortalised renal endothelium.  
Pre-treating 1 x 105 CFSE-labelled HPC-7 with 25ng/ml of KC or SDF-1α for 5 minutes 
significantly enhanced HPC-7 adhesion to TNF-α activated renal endothelium in vitro.  
However, IL-1β and TNF-α HPC-7 pre-treatments did not cause any significant differences 
in HPC-7 adhesion to the activated endothelium compared to PBS pre-treated HPC-7 
controls (panel A; black fill: TNF-α activated renal endothelium).  1 x 105 CFSE-labelled 
HPC-7 were again pre-treated with 25ng/ml of all cytokines for 5 minutes and applied to 
PBS treated renal endothelium: again, KC and SDF-1α were the only cytokine pre-
treatments to cause a significant increase in HPC-7 adhesion (panel B; grey fill: PBS 
treated endothelium).  Representative images of HPC-7 adhesion to TNF-α activated renal 
endothelium after PBS (panel C), IL-1β (panel D), KC (panel E) SDF-1α (panel F), TNF-α 
(panel G) HPC-7 pre-treatments.  Plots represent a mean adhesion ±SEM of at least 4 
separate experiments; * p<0.05; ** p<0.01.  Panels A and B: one-way ANOVA with 
Dunnett’s post-tests. 
A B 
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Figure 5.6.  HPC-7 pre-treatment with IL-1β does not increase adhesion but enhances 
the number of free-flowing HPC-7 in the injured kidney vasculature.  Kidneys were 
clamped for 45 minutes and allowed to reperfuse for 60 minutes prior to HPC-7 
administration.  2 x 106 HPC-7 were pre-treated with 25ng/ml of IL-1β for 5 minutes, 
washed and then injected intra-arterially into the IR injured animal.  Subsequent HPC-7 
adhesion and free-flowing numbers in the IR kidney were monitored intravitally.  There 
was no significant increase in HPC-7 adhesion compared to the PBS control after IL-1β 
treatment (panel A: black solid line: PBS treated HPC-7; grey dotted line: IL-1β treated 
HPC-7).   However the number of free-flowing cells at the point of infusion was 
significantly higher after cell IL-1β treatment (panel B: black solid line: PBS treated HPC-7; 
grey dotted line: IL-1β treated HPC-7).  Plots represent a mean adhesion ±SEM of at least 
4 separate experiments; *** p<0.001.  Panel A: area under the curve calculation; panel B: 
two-way ANOVA with bonferroni post-tests. 
A B 
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Figure 5.7.  HPC-7 pre-treatment with KC increases HPC-7 adhesion but do not enhance 
the number of free-flowing HPC-7 in the injured kidney vasculature.  Kidneys were 
clamped for 45 minutes and allowed to reperfuse for 60 minutes prior to HPC-7 
administration.  2 x 106 HPC-7 were pre-treated with 25ng/ml of KC for 5 minutes, washed 
and then injected intra-arterially into the IR injured animal.  Subsequent HPC-7 adhesion 
and free-flowing numbers in the IR kidney were monitored intravitally.  There was an 
increase in HPC-7 adhesion compared to the PBS control after KC treatment (panel A: 
black line: PBS treated HPC-7; grey line: KC treated HPC-7).  No changes in the number of 
free-flowing HPC-7 were seen after KC treatment (panel B: black solid line: PBS treated 
HPC-7; grey dotted line: KC treated HPC-7).  PBS controls are from the same cohort as 
Figure 5.6; this was to reduce the number of animals used.  Plots represent a mean 
adhesion ±SEM of at least 4 separate experiments; ** p<0.01.  Panel A: area under the 
curve calculation; panel B: two-way ANOVA with bonferroni post-tests.  
A B 
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Figure 5.8.  HPC-7 pre-treatment with SDF-1α increases HPC-7 adhesion and the number 
of free-flowing HPC-7 in the injured kidney vasculature.  Kidneys were clamped for 45 
minutes and allowed to reperfuse for 60 minutes prior to HPC-7 administration.  2 x 106 
HPC-7 were pre-treated with 25ng/ml of SDF-1α for 5 minutes, washed and then injected 
intra-arterially into the IR injured animal.  Subsequent HPC-7 adhesion and free-flowing 
numbers in the IR kidney were monitored intravitally.  There was an increase in HPC-7 
adhesion and free-flowing cell numbers compared to the PBS control after SDF-1α 
treatment (panel A and B: black solid line: PBS treated HPC-7; grey dotted line: SDF-1α 
treated HPC-7).  PBS controls are from the same cohort as Figure 5.6; this was to reduce 
the number of animals used.  Plots represent a mean adhesion ±SEM of at least 4 
separate experiments; ** p<0.01; *** p<0.001.  Panel A: area under the curve 
calculation; panel B: two-way ANOVA with bonferroni post-tests.  
A B 
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Figure 5.9.  HPC-7 pre-treatment with TNF-α increases HPC-7 adhesion and the number 
of free-flowing HPC-7 in the injured kidney vasculature.  Kidneys were clamped for 45 
minutes and allowed to reperfuse for 60 minutes prior to HPC-7 administration.  2 x 106 
HPC-7 were pre-treated with 25ng/ml of TNF-α for 5 minutes, washed and then injected 
intra-arterially into the IR injured animal.  Subsequent HPC-7 adhesion and free-flowing 
numbers in the IR kidney were monitored intravitally.  There was an increase in HPC-7 
adhesion compared to the PBS control after TNF-α treatment (panel A: black line: PBS 
treated HPC-7; grey line: TNF-α treated HPC-7).  There was also an increase in the number 
of free-flowing cells at the point of infusion after TNF-α treatment compared to PBS-
treated HPC-7 (panel B: black solid line: PBS treated HPC-7; grey dotted line: TNF-α 
treated HPC-7).  PBS controls are from the same cohort as Figure 5.6; this was to reduce 
the number of animals used.  Plots represent a mean adhesion ±SEM of at least 4 
separate experiments; * p<0.05; *** p<0.001.  Panel A: area under the curve calculation; 
panel B: two-way ANOVA with bonferroni post-tests. 
A B 
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5.3.10 Dual HPC-7 pre-treatment with KC and SDF-1α does not further enhance HPC-7 
adhesion  
2 x 106 CFSE-labelled HPC-7 were pre-treated with 25ng/ml of KC and SDF-1α together for 
5 minutes and injected intra-arterially.  There was a significant (p<0.01) difference in the 
number of adherent HPC-7 after KC+SDF-1α pre-treatment compared to the PBS 
treatment control (AUC: KC+SDF-1α: 427.3±27.92; PBS: 300.30±25.62; Figure 5.10.A).  
However this increase in adherent HPC-7 was not significantly different from KC or SDF-
1α treatment alone.  There was also a significant (p<0.01) difference in the number of 
free-flowing HPC-7 after SDF-1α  pre-treatment at the point of infusion only (60 minutes 
reperfusion) compared to PBS control (Figure 5.10.B). 
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Figure 5.10.  HPC-7 pre-treatment with KC+SDF-1α increases HPC-7 adhesion and the 
number of free-flowing HPC-7 in the injured kidney vasculature.  Kidneys were clamped 
for 45 minutes and allowed to reperfuse for 60 minutes prior to HPC-7 administration.  2 
x 106 HPC-7 were pre-treated with 25ng/ml of KC+SDF-1α for 5 minutes, washed and then 
injected intra-arterially into the IR injured animal.  Subsequent HPC-7 adhesion and free-
flowing numbers in the IR kidney were monitored intravitally.  There was an increase in 
HPC-7 adhesion compared to the PBS control after dual chemokine treatment (panel A 
and B: black solid line: PBS treated HPC-7; grey dotted line: KC+SDF-1α treated HPC-7).  
PBS controls are from the same cohort as Figure 5.6; this was to reduce the number of 
animals used.  Plots represent a mean adhesion ±SEM of at least 4 separate experiments; 
* p<0.05; *** p<0.001.  Panel A: area under the curve calculation; panel B: two-way 
ANOVA with bonferroni post-tests. 
A B 
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5.3.11 Hydrogen peroxide increases HPC-7 adhesion to activated renal endothelium 
only 
HPC-7 were pre-treated with 100μM for 5 or 60 minutes and then applied to TNF-α 
activated renal endothelium.  After both H2O2 treatments, there was an increase in HPC-7 
adhesion to the activated endothelium compared to the PBS treated control (CPF: H2O2 1 
hour: 29.32±4.611; H2O2 5 minutes: 29.27±2.373; PBS: 7.560±3.438; Figure 5.11.A).  Pre-
treated HPC-7 were also applied to PBS treated endothelium and similar results were 
seen as with TNF-α treated endothelium. 
 
Since no differences in adhesion were observed with a 5 or 60 minute incubation period, 
we decided to keep treatment time to a minimum and so incubated HPC-7 for 5 minutes 
with H2O2 for the in vivo experiments.  H2O2 HPC-7 pre-treatment does not increase HPC-
7 adhesion or the number of free-flowing cells in a renal IR injured model (AUC: H2O2: 
228.7±33.05; PBS: 300.3±25.62; Figure 5.11.B-C). 
 
Chapter 5: Methods and Mechanisms of Enhancing HSC Recruitment to the Injured Kidney 
 
147 
 
 
                       
 
Figure 5.11.  HPC-7 pre-treatment with H2O2 increases HPC-7 adhesion to activated renal endothelium in in-vitro experiments only.  Pre-
treating 1 x 105 CFSE-labelled HPC-7 with 100μM of H2O2 for 1 hour or 5 minutes significantly enhanced HPC-7 adhesion to TNF-α activated 
renal endothelium in vitro (panel A).  Kidneys were clamped for 45 minutes and allowed to reperfuse for 60 minutes prior to HPC-7 
administration.  2 x 106 HPC-7 were pre-treated with 100mM of H2O2 for 5 minutes, washed and then injected intra-arterially into the IR 
injured animal.  Subsequent HPC-7 adhesion and free-flowing numbers in the IR kidney were monitored intravitally.  There were no 
increases in the number of adherent of free-flowing HPC-7 numbers after H2O2 treatment compared to the PBS controls (panel B and C: 
black line: PBS treated HPC-7; grey dashed line: H2O2 treated HPC-7).  PBS controls are from the same cohort as Figure 5.6; this was to 
reduce the number of animals used.  Plots represent a mean adhesion ±SEM of at least 4 separate experiments; ** p<0.01.  Panel A: one-
way ANOVA with Dunnett’s post-tests; panel B: area under the curve calculation; panel C: two-way ANOVA with bonferroni post-tests.  
A B C 
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5.3.12 Cytokines, especially SDF-1α, significantly increase HPC-7 deformability 
As outlined above, pre-treating HPC-7 with some of the cyto/chemokines tested 
increased the number of free-flowing cells observed within the injured renal 
microcirculation immediately upon infusion.  Interestingly, this effect was not observed at 
any other time point.  Free-flowing cells were defined as the total number of cells 
observed flowing through the field of view in a 1 minute time-frame of continuous 
monitoring.  The blood circulation time for a mouse is approximately 4-6 seconds, 
meaning blood circulates approximately 10 times during a 1 minute observation period.  
To determine whether pre-treated HPC-7 only passed once through the kidney or if they 
were re-circulated, numbers of freely flowing cells at 6 second intervals were determined 
for the first observation minute.  More freely circulating HPC-7 were observed at each 6 
second time point for the first minute following IL-1β, SDF-1α, TNF-α and KC+SDF-1α pre-
treatments, suggesting more were continually re-circulated, with less being lost to extra-
renal sites (Figure 5.12.A-D respectively). 
 
No significant change in HPC-7 size was observed as a result of cytokine pre-treatment, as 
assessed by using a coulter counter (Figure 5.12.F).  The phalloidin levels within pre-
treated HPC-7 and the velocity of these free-flowing pre-treated cells in microvessels was 
also calculated using flow cytometry and the Slidebook analysis program respectively, but 
no significant changes were noted (Figure 5.12.G-H).  IL-1β (p<0.01), SDF-1α (p<0.01) and 
KC+SDF-1α (p<0.05) treated cells were significantly more deformable, as determined by a 
reduction in the time taken for cells to be fully aspirated into a glass micropipette, which 
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was of a diameter that was comparable to blood capillaries. (Figure 5.12.I-J).  SDF-1α 
alone caused a 61% reduction in entry time.  
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Figure 5.12.  The increased free-flowing HPC-7 numbers seen in the injured kidney 
vasculature after cytokine treatment due to changes in deformability.  The first one 
minute recording was broken down into 6 second intervals to illustrate each full 
circulatory pass.  With IL-1β, SDF-1α, TNF-α and KC+SDF-1α pre-treatments, more HPC-7 
continue to flow between 6-24 seconds suggesting less are lost to the circulation (panels 
A,C-E).  KC pre-treatment did not cause any increases in HPC-7 free-flowing cells (panel 
B).  There were no changes in HPC-7 size after pre-treatments (panel F).  The amount of 
phalloidin within HPC-7 and HPC-7 velocity in vivo was not affected by any pre-treatment 
(panel G-H). HPC-7 became significantly more deformable with SDF-1α and KC+SDF-1α 
pre-treatment as demonstrated by reduced time taken to aspirate into a glass capillary 
(panel I).  Photographs illustrating the method is shown and 50 cells were tested / group 
(panel H).  For all line graphs; black line: PBS treated HPC-7; grey dashed line: cytokine 
treated HPC-7.  Plots represent a mean adhesion ±SEM of at least 4 separate 
experiments; *p<0.05, **p<0.01.  Panels G-I: one-way ANOVA with Dunnett’s post-tests. 
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5.3.13 KC or SDF-1α HPC-7 pre-treatments do not alter adhesion molecule expression 
As KC and SDF-1α pre-treatments were most effective at increasing HPC-7 adhesion 
across the various assays, we further investigated the mechanisms mediating increased 
adhesion for these pre-treatments.  One way in which these chemokine pre-treatments 
could be causing an effect is by upregulating the number of important adhesion 
molecules on the HPC-7 surface.  To examine this, flow cytometry was utilised: 1 x 106 
HPC-7 were pre-treated with 25ng/ml of KC or SDF-1α for 5 minutes and were 
subsequently labelled for CD49d and CD44.  No significant upregulation of CD49d or CD44 
occurred after KC or SDF-1α (Figure 5.13.A-B). 
 
5.3.14 KC and SDF-1α pre-treatments enhances HPC-7 adhesion to both VCAM-1 and 
HA in vitro 
As we have shown CD49d and CD44, and their counter-ligands VCAM-1 and HA, are 
important in governing HPC-7 adhesion to the IR injured kidney we examined whether 
our chemokine pre-treatments could improve the ability of HPC-7 surface molecules to 
bind to their endothelial counter-ligands.  1 x 106 HPC-7 were pre-treated with 25ng/ml 
of KC or SDF-1α for 5 minutes and then applied to immobilised VCAM-1 and HA, adherent 
HPC-7 were then quantified.  Both KC (p<0.05) and SDF-1α (p<0.01) pre-treatments 
caused an enhanced adhesion of HPC-7 to both VCAM-1 and HA substrates compared to 
PBS-treated controls (CPF: VCAM: KC: 6.386±0.986; SDF-1α: 7.912±1.227; PBS: 
2.610±0.6038; Figure 5.14.A; HA: KC: 9.753±1.352; SDF-1α: 13.39±4.310; PBS: 
1.819±0.2791; Figure 5.14.B). 
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5.3.15 KC and SDF-1α pre-treatments alter CD44 and CD49d adhesion molecule 
distribution on the HPC-7 cell surface 
HPC-7 were pre-treated with 25ng/ml of KC or SDF-1α for 5 minutes and were then fixed.  
Treated cells were then exposed to fluorescent antibodies against CD44 and CD49d and 
any changes in adhesion molecule distribution were imaged using a confocal microscope.  
After pre-treating HPC-7 with SDF-1α, there was an increase (p<0.05) in the number of 
CD49d microclusters on the surface of the HPC-7 (Figure 5.15.A-B).  There were no 
changes in the number of CD44 clusters after SDF-1α treatment.  Conversely, after KC 
treatment there was an increase (p<0.05) in CD44 microclusters but no changes were 
seen to CD49d (Figure 5.15.C-D). 
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Figure 5.13.  The increased HPC-7 adhesion after KC and SDF-1α pre-treatments is not 
because of an increase in surface CD49d (A) or CD44 (B) expression. 1 x 106 HPC-7 were 
pre-treated with 25ng/ml of KC and SDF-1α for 5 minutes and any changes in adhesion 
molecules were examined using flow cytometry.  There wasn’t any upregulation of either 
CD49d (panel A) or CD44 (panel B) after KC and SDF-1α pre-treatments (grey fill: PBS 
control; blue line: KC pre-treated; orange line: SDF-1α pre-treated HPC-7). 
A 
B 
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Figure 5.14.  KC and SDF-1α pre-treatments enhance the ability of HPC-7 to adhere to 
10μg/ml VCAM-1 (A) and 0.5mg/ml HA respectively (B). 1 x 105 HPC-7 were pre-treated 
with 25ng/ml of KC and SDF-1α for 5 minutes and applied to 10μg/ml of immobilised 
VCAM-1 and 0.5mg/ml of immobilised HA in a 96-well plate.  Both KC and SDF-1α pre-
treatments caused an increase in HPC-7 adhesion to both VCAM-1 (panel A) and HA 
(panel B).  Plots represent a mean adhesion ±SEM of at least 4 separate experiments; * 
p<0.05; ** p<0.01.  Panel A and B: one-way ANOVA with Dunnett’s post-tests. 
A 
B 
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Figure 5.15.  KC and SDF-1α pre-treatments alter the distribution of CD49d (A-B) and CD44 (C-D) on the HPC-7 surface. 1 x 106 HPC-7 were 
pre-treated with 25ng/ml of KC and SDF-1α for 5 minutes, fixed and then labelled with antibodies against CD49d and CD44.  Cells were 
imaged using scanning confocal microscopy and areas of clustering were identified using the “Find Maxima” plugin in ImageJ.  Maxima plots 
were produced by identifying regions of maximal intensity within control determined tolerance level to separate clusters from background.  
CD49d adhesion molecule distribution is altered only after SDF-1α pre-treatment, there is no change with KC treatment (panel A; points of 
maximal intensity are highlighted in white).  SDF-1α increases the number of CD49d microclusters on the HPC-7 surface (panel B).  An 
increase in CD44 microclusters is seen after KC treatment only (panel C and D; points of maximal intensity are highlighted in white). Plots 
represent a mean number of microclusters ±SEM per cells of at least 50 HPC-7; * p<0.05.  Panel B and D: unpaired t-tests. 
C 
A B 
D 
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5.4 Major Findings of Chapter 5 
 
FINDING HOW? 
1 
30 minute HPC-7 pre-treatment with ICM 
enhanced HPC-7 adhesion to the IR-injured kidney 
compared to SCM 
In vitro: Stamper-Woodruff and 
renal endothelial assays 
2 
HPC-7 pre-treatment with  25ng/ml of SDF-1α for 
5 minutes, increased HPC-7 adhesion to the IR-
injured kidney 
In vitro: Stamper-Woodruff and 
renal endothelial assays  
In vivo and ex vivo: Intravital 
microscopy 
3 
HPC-7 pre-treatment with  25ng/ml of KC for 5 
minutes, increased HPC-7 adhesion to the IR-
injured kidney 
In vitro: Renal endothelial assays  
In vivo and ex vivo: Intravital 
microscopy 
4 
HPC-7 pre-treatment with  25ng/ml of TNF-α for 5 
minutes, increased HPC-7 adhesion to the IR-
injured kidney 
In vivo and ex vivo: Intravital 
microscopy 
5 
HPC-7 pre-treatment with 25ng/ml of KC + SDF-1α 
for 5 minutes, increased HPC-7 adhesion and 
number of free-flowing to the IR-injured kidney 
but not more so than using either chemokine 
alone 
In vivo and ex vivo: Intravital 
microscopy 
6 
HPC-7 pre-treatment with  25ng/ml of IL-1β, SDF-
1α or TNF-α for 5 minutes, increased the number 
of HPC-7 free-flowing through the IR-injured 
kidney at the point of infusion 
In vivo: Intravital microscopy 
7 
HPC-7 pre-treatment with  25ng/ml of IL-1β, SDF-
1α or TNF-α for 5 minutes caused an increase in 
HPC-7 deformability 
In vitro: Micropipette analysis 
8 
HPC-7 pre-treatment with  25ng/ml of KC causes 
an increase in the number of CD44 micro-clusters 
on the HPC-7 surface 
In vitro: Clustering protocol using 
confocal microscopy 
9 
HPC-7 pre-treatment with  25ng/ml of SDF-1α 
caused an increase in the number of CD44 micro-
clusters on the HPC-7 surface 
In vitro: Clustering protocol using 
confocal microscopy 
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5.5 Discussion 
Identifying the molecular adhesive mechanisms governing HSC adhesion to a damaged 
tissue bed is the first step to understanding how to enhance these rare but potentially 
clinically therapeutic cells to sites of injury.  The previous chapter identified CD49d and 
CD44, and their respective counter-ligands VCAM-1 and HA, as critical modulators 
governing HSC recruitment to the IR injured renal microcirculation.  Modulating the 
expression and/or binding ability of these specific adhesion molecules for endothelial 
counter-ligands might be an important approach to improving renal HSC homing.  In this 
chapter, we show a quick and effective pre-treatment strategy can increase HSC adhesion 
within the ischaemically injured kidney.  This novel data demonstrated that HSC 
recruitment to the kidney was an event that could be enhanced and that the adhesion 
brought about by the presence of an injury was not maximal. 
 
The use of an ICM demonstrated that soluble factors released by the injured kidney had 
the ability to modulate SC adhesion.  However, these were simply proof of principle 
experiments, as generating an ICM is not a likely therapeutic option.  Our Coomaisse-
stained gels demonstrated that ICM did contain proteins that were not present or were 
present at a lower concentration in healthy kidneys (SCM).  IL-1β, SDF1α, IL-8 and other 
pro-inflammatory cyto/chemokines are within the region of 7-19 kDa, which reflects the 
region of the proteins bands that were increased in ICM.  These cyto/chemokines are 
known to be secreted in abundance following renal IR injury and have a key role in 
mediating leukocyte recruitment (Olson and Ley 2002; Anders et al. 2003; Stroo et al. 
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2010).  Interestingly, inflammatory cytokines TNF-α and IL-1β have been shown to 
stimulate MSCs and enhance their migration in vitro (Ries et al. 2007).  It is likely that SC 
activation and subsequent adhesion is also mediated by similar soluble proteins.  We 
present data in this chapter that chemokine pre-treatment can significantly modulate the 
adhesion of HPC-7 cells within the renal microcirculation in vivo.   
 
This chapter identified HPC-7 pre-treatment with the chemokines SDF-1α and KC can 
substantially increase their adhesion to the IR injured kidney.  Interestingly, the 
inflammatory cytokine TNF-α also significantly increased HSC homing to the IR injured 
kidney.  The greatest amount of HPC-7 adhesion was seen with KC pre-treatment, 
whereas SDF-1α caused a greater number of freely circulating cells within the kidney.  
The importance of these particular chemokines is given further significance by the results 
from the previous chapter, in which topical exposure to SDF-1α and KC can also mediate 
homing to the healthy kidney.  We have provided additional data in a publication arising 
from the work in this chapter which demonstrates that these pre-treatment strategies 
could also enhance the adhesion of primary BM-derived Lin- cells in vitro (White et al. 
2013).  This importantly shows that chemokine pre-treatment modulates the HPC-7 cell 
line in a similar manner to primary stem/progenitor cells.     
 
SDF-1α is a well-known and thoroughly investigated chemoattractant with regards to SC 
homing (Peled et al. 1999; Wright et al. 2002; Togel et al. 2005); even platelet-released 
SDF-1α has been shown to aid in the recruitment of progenitor cells (Massberg et al. 
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2006; Stellos and Gawaz 2007).  Interestingly, Stroo et al. showed that manipulating the 
SDF-1α/CXCR4 axis, either by increasing local SDF-1α concentrations in the injured kidney 
or by blocking CXCR4 on HSCs, did not affect their migration (Stroo et al. 2009).  However, 
in these studies, they injected recombinant SDF-1α into just one focal point in the kidney, 
which may explain this discrepancy.  In this chapter, we demonstrated that only SDF-1α 
enhanced HPC-7 adhesion in all of the assays utilised: frozen tissue sections, renal 
endothelium and in vivo.  Although intravital microscopy only images the cortical 
peritubular capillaries of the kidney, the frozen tissue section S-W assay allowed adhesion 
to the deeper medullary regions to also be quantitated.  It is well-documented that the 
cortico-medullary areas are the most injured during renal IR injury (Sutton 2009) and SDF-
1α enhanced HPC-7 adhesion in these regions too.  Therefore, this particular chemokine 
would be a good molecule to use to target SCs to the most damaged regions of the 
kidney.  However, it is also important to note that the in vivo studies showed that KC 
produced the most HPC-7 adhesion to the peritubular capillaries.  This is the first time 
that KC has been implicated in HSC homing to any injured tissue. 
 
H2O2 is also increased during renal IR injury (Kim, 2009).  Recent studies in our lab have 
demonstrated that pre-treatment with this ROS could increase HPC-7 adhesion to IR 
injured gut through enhancing surface integrin clustering (Kavanagh et al. 2012)  This 
study demonstrated that  a 1 hour incubation with 100μM H2O2 did not induce any 
cytotoxic effects on HPC-7 cells.   For the renal studies presented in this chapter, we 
tested the same concentration but pre-treated for 5 minutes and 1 hour so as to keep 
incubation durations consistent with previous cyto/chemokine pre-treatment strategies.  
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Since significant increases in HPC-7 adhesion to TNF-α activated renal endothelium were 
observed after both pre-treatment durations, intravital studies were conducted using a 5 
minute protocol.  However, unlike our previous studies in the gut, no significant increases 
in HPC-7 adhesion to IR injured kidney were observed.  It is unclear why the same pre-
treatment would not universally improve SC adhesion in all injured organs, but may be 
related to the fact that site specific adhesion molecules govern SC homing.  For example, 
we presented in Chapter 4 the importance of CD44 and CD49d in mediating renal 
homing.  However, in the gut CD18 appears to be more critical (Kavanagh et al. 2012).  It 
is possible therefore, that H2O2 affects the affinity of these surface adhesion molecules 
differently and the modulation of those involved in renal homing is less efficient; this 
would require further detailed investigation.  Furthermore, HPC-7 are exposed to shear 
stress during in vivo experiments: The blood flow rate is a lot higher in the mouse kidney 
compared to that of the gut - 7.88mL/min/g vs. 2.79mL/min/g - so it is possible that H2O2 
does not facilitate changes in adhesion molecules that are strong enough to withstand 
the high shear in kidneys (Milia et al. 2001; Garrelds et al. 2002).  In agreement with 
these studies, Peled and colleagues demonstrated using in vitro studies that SDF-1α could 
rapidly activate the firm shear-resistant adhesion of human CD34+ cells to immobilized 
ICAM-1 and VCAM-1 (Peled et al., 2000).   
 
The second part of this chapter investigated whether KC and SDF-1α mediated increased 
adhesion through effects on CD49d and CD44 expression.  Others have shown, for 
example, that MSC homing to bone could be increased using cells genetically engineered 
to express higher surface levels of CD49d (Kumar and Ponnazhagan 2007).  However, 
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despite showing that both CD49d and CD44 governed HPC-7 adhesion to the IR injured 
kidney in vivo, neither KC nor SDF-1α pre-treatments enhanced CD49d or CD44 
expression on the HPC-7 surface: this could be due to HPC-7 not having intracellular 
stores of each receptor that can be quickly transported to the cell surface; or perhaps 5 
minutes stimulation is not long enough for receptor cycling to occur.  Montecucco and 
colleagues observed that neutrophils produced significant increases in both CD11b and 
CD18 subunits after a longer period (30 minutes) of TNF-α treatment (Montecucco et al. 
2008).  Primary human HSCs have been shown to contain CD44 intracellular stores; 
however, it has been noted that their adhesion is not dependant on the upregulation of 
CD44 numbers but actually due to altering the avidity of β1 integrins that work in 
conjunction with CD44 (Lundell et al. 1997; Pilarski et al. 1999).   
 
Another way of enhancing adhesion is through altering the receptor localisation on the 
cell surface.  Although conformational changes in adhesion molecules from an inactive to 
an active state are important for mediating cell adhesion, the dynamic reorganisation of 
adhesion molecules into clusters is also a major mechanism that regulates their binding 
capacity, acting to strengthen cell-cell adhesion (van Kooyk and Figdor 2000).  KC and 
SDF-1α induced an increase in the number of surface clusters of CD44 and CD49d 
respectively: this most likely contributed to the increased binding capacity that these 
adhesion molecules had for their counter-ligands HA and VCAM-1 respectively, as was 
demonstrated in vitro using immobilised substrates.  Various studies have actually stated 
that adherence of leukocytes post-chemokine treatment is not due to increases in VLA-4 
receptor numbers, but of alterations in both affinity and avidity of said receptor (DiVietro 
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et al. 2007), which is in agreement with our HPC-7 studies.  Grabovsky and colleagues 
(2000) demonstrated that the close proximity between chemokine receptors and surface 
integrins facilitates inside-out signalling events into rapid integrin clustering in leukocytes, 
which may also explain why the 5 minute incubation period was all that was required for 
adhesive events to be modulated.   
 
Using the micropipette aspiration technique, we have provided the first evidence that 
cytokines could also alter HSC deformability.  It is possible that this decreased resistance 
to deformation prevented circulating cells from becoming entrapped within non-renal 
sites and maintained their presence within peripheral blood.  Non-specific entrapment is 
a major obstacle for systemic SC delivery for regenerative purposes both experimentally 
and clinically (Fischer et al. 2009) and significantly reduces the pool of circulating 
transplanted HSCs available for recruitment.   At the time of infusion only, SDF-1α pre-
treated HSCs were observed to repeatedly circulate, unlike PBS pre-treated cells which 
were rapidly lost from the peripheral circulation.  IL-1β, TNF-α pre-treatments and 
KC+SDF-1α dual pre-treated cells continuously trafficked through the kidney throughout 
the duration of the experiment, with approximately 10-15 cells observed at each time 
point: this phenomenon may increase the chance of trafficking cells becoming adherent 
within injured renal microvessels and also contribute to the enhanced adhesion 
observed.  Interestingly, it is well accepted that cytokines, such as TNF-α and IL-1, 
generally reduce the deformability of circulating cells: for instance, leukocytes usually 
adopt a flatter and more rigid cellular structure post-cytokine exposure, which decreases 
their deformability (Skoutelis et al. 2000).  
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In conclusion, despite huge advances in the field of cellular therapy, a major limitation is 
their poor retention within target tissues on systemic delivery.  Modulation of HSC 
homing mechanisms may be used as a therapeutic strategy to improve the efficacy of 
potential SC therapy.  We provide a simple, quick and effective method for enhancing 
HSC adhesion into injured kidney using SDF-1α or KC.  These chemokines most likely 
mediate increased recruitment either through the modulation of CD49d and/or CD44, or 
by reducing HSCs clearance from the circulation.  Previous studies have enhanced SC 
recruitment by introducing genes encoding for SDF-1α within cardiac tissue (Tang et al. 
2005).  However, the clinical applicability of such techniques is debatable and may be 
associated with aggravated tissue injury due to side effects such as SDF-1α-dependent 
lymphocyte recruitment  (Liekens et al. 2010).  The current study benefits from 
identifying a strategy that increases recruitment without genetically manipulating the 
HSCs or the host tissue and thus has the potential to be used clinically.  Our data may 
therefore help in the design of future cellular therapies using HSCs for renal repair.  It is 
anticipated that enhancing HSC recruitment to injured kidney may expedite the recovery 
process and encourage greater therapeutic success clinically.  The vasculo-protective 
effects of these recruited HSCs forms the focus of the next chapter. 
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6 Beneficial Effects of Haematopoietic Stem Cells within the Injured Renal 
Microvasculature 
 
6.1 Introduction and Hypotheses 
6.1.1 Introduction 
In the previous chapters, the adhesion receptors governing HSC recruitment to the 
injured kidney and strategies to enhance this renal homing have been elucidated.  
However two pertinent questions remain - do these specific SCs confer any beneficial 
effects once within the injured kidney and does enhancing their local presence improve 
their therapeutic efficacy?   Inflammation is thought to play a major role in acute kidney 
injury (Bonventre and Zuk 2004; Friedewald and Rabb 2004).  Following an ischaemic 
insult, both the renal endothelial and proximal tubular cells produce cytokines and 
chemokines that lead to inflammatory cell infiltration.  The pathophysiology of AKI, 
particularly renal IR injury which is the major and most serious cause of AKI, is defined 
predominantly by inflammation and marked microcirculatory dysfunction (Bonventre and 
Yang 2011).  It is therefore reasonable to suggest that improvements in renal structure 
and function can be achieved if the marked inflammation and microcirculatory 
disturbances within the kidney can be resolved. 
 
The mechanisms by which HSCs could potentially produce beneficial effects may be 
through differentiation into functional resident renal cells or by stem, cell fusion with 
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local cells.  Early studies in the kidney focussed on the idea of differentiation; however 
the level of SCdifferentiation and fusion, and the number of newly generated cells, has 
been too low to explain the degree of improvement observed following 
SCtransplantation (Poulsom et al. 2001).    Recent studies have implicated a transient 
paracrine effect, whereby SCs secrete potent combinations of trophic factors and anti-
inflammatory factors that modulate the molecular composition of the environment to 
evoke responses from resident cells (Burdon et al. 2011).   This paracrine effect has been 
demonstrated for a variety of bone marrow-derived progenitor cells with most studies 
focussing on MSCs.  However, investigations into HSC paracrine activity remain limited 
although our group previously demonstrated a beneficial role for HSCs in reducing 
leukocyte accumulation in the IR injured gut.   
 
In this chapter we focussed on the vasculoprotective benefits that HSCs could confer 
within the injured kidney.  Improvements in the efficacy of these benefits following 
enhanced homing, and thus local renal presence of HSCs, were also assessed.  More 
importantly, we were able to quantitate for the first time the actual microvascular 
disturbances that took place in the IR injured mouse kidney.  The specific events 
monitored were neutrophil adhesion, microthrombus formation, vascular albumin 
leakage and overall renal blood flow.  High resolution intravital images were obtained 
using the spinning Nipkow based confocal microscope and by labelling endogenous cells 
using specific antibodies tagged with fluorescent dyes.  As explained earlier, direct 
intravital imaging of the mouse kidney in vivo has been challenging and therefore, in 
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comparison to other organs such as the liver and gut, there is no published study that has 
fully described these events.   
    
6.1.2 Aims and Hypotheses 
The main aims and hypotheses of this chapter are: 
1. Aim: Describe the microcirculatory disturbances associated with renal IR injury 
using Spinning Nipkow based confocal intravital microscopy 
2. Aim: Label endogenous platelets and neutrophils for confocal intravital imaging  
3. Hypotheses: Renal IR injury increases the presence of neutrophils and platelet 
within peritubular capillaries, the adhesion of which can be reduced using HSCs  
4. Hypotheses:  HSCs improve renal structure and function 
 
6.2 Methods 
The methods used in this chapter are described in detail in chapter 2.  To image the 
kidney using an upright confocal intravital microscope, the renal preparation was 
designed which was slightly more stationary.  Again, the ischaemia was induced for 45 
minutes and the tissue reperfused for up to 6 hours to induce substantial injury.  
Fluorescently conjugated antibodies to label endogenous platelets and neutrophils or 
FITC-BSA were via the carotid artery.   There were 4 treatment groups for these 
experiments: sham animals, IR injury alone; IR injury plus naïve HPC-7 injection 
introduced at 1 hour reperfusion; IR injury plus KC+SDF-1α treated HPC-7 injection 
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introduced at 1 hour reperfusion.  5 fields of view were taken at 1 hour, 4 hour and 6 
hour reperfusion time points and neutrophil and platelet microthrombi numbers were 
quantified.  At the end of the experiments, CL kidneys and lungs were removed to analyse 
platelet microthrombi and neutrophil infiltration immunohistochemically.  Serum was 
also removed for analysis of the renal injury markers, urea and creatinine.  IR kidneys and 
corresponding sham kidneys were snap frozen or fixed in formalin and then sectioned 
ready for histological analysis.  Additional experiments were conducted using Chandler 
loops, used to assess the weight of platelet thrombi in whole blood in the presence or 
absence of HPC-7 cells. 
 
6.3 Results 
6.3.1 HPC-7 reduce neutrophil numbers in a murine model of renal IR injury in vivo 
After renal IR injury, neutrophil numbers significantly (p<0.001) increased at 6 hours 
reperfusion compared to non-injured sham controls (CPF: IR only: 72.15±24.38; Sham: 
12.50±1.256; Figure 6.1.A-C).  These increases in neutrophil adhesion were not observed 
at 1 or 4 hours reperfusion.  As far as we can tell, the neutrophils were adherent within 
the peritubular capillaries.  Interestingly, infusion of either naïve HPC-7 (p<0.001) or 
KC+SDF-1α (p<0.001) pre-treated HPC-7 significantly reduced neutrophil accumulation 
within the IR injured kidney compared to IR injury without HPC-7 (CPF: IR + naïve HPC-7: 
21.48±9.053; IR + KC+SDF-1α HPC-7: 34.10±4.740; IR only: 72.15±24.38; Figure 6.1.A,C-E).  
There was significant difference in neutrophil adhesion at 6 hours between the two 
groups receiving HSCs.   
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6.3.2 HPC-7 also reduce the number of platelet microthrombi in the IR injured 
microvasculature in vivo 
After renal IR injury, platelet microthrombi numbers significantly (p<0.001) increased at 6 
hours reperfusion compared to non-injured sham controls (CPF: IR only: 63.80.±14.93; 
Sham: 18.50±6.900; Figure 6.2.A-C).  Similarly to neutrophils, these increases were not 
observed at 1 or 4 hours reperfusion.  The aggregates of platelets were observed 
adherent within the renal peritubular vessels and were sometimes large enough to impair 
the blood flow in that region.  Infusion of either naïve (p<0.001) or KC+SDF-1α (p<0.001) 
pre-treated HPC-7 significantly reduced platelet microthrombi accumulation within the IR 
injured kidney compared to IR injury without HPC-7 (CPF: IR + naïve HPC-7: 22.40±10.33; 
IR + KC+SDF-1α HPC-7: 17.10±9.948; IR only: 63.80.±14.93; Figure 6.2.A,C-E). There was 
significant difference in platelet microthrombi numbers at 6 hours between the two 
groups receiving HSCs.   
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Figure 6.1.  Naïve and KC+ SDF-1α pre-treated HPC-7 reduce neutrophil adhesion to an 
IR injured kidney at 6 hours reperfusion.  Neck surgery was performed and eFluor 660 
anti-Gr1 antibody was injected intra-arterially.  Kidneys were then clamped for 45 
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minutes and allowed to reperfuse for 60 minutes prior to HPC-7 administration.  Five 
fields of view were taken of the kidney at 1 hour, 4 hours and 6 hours reperfusion and 
neutrophil numbers were quantified.  There was a significant increase in the number of 
neutrophils at 6 hours reperfusion in the IR injured kidney compared to that of the sham 
(panel A: black line: IR injured; grey line: sham).  When injecting naïve and KC+SDF-1α 
treated cells at 1 hour reperfusion, there was a significant decrease in the number of 
adherent neutrophils compared to the IR injured kidney (panel A; green line: naïve HPC-
7; blue line: KC+SDF-1α treated HPC-7; black line: IR only). Representative images 
showing neutrophil numbers in: sham (panel B); IR only (panel C); naïve HPC-7 + IR (panel 
D); KC+SDF-1α HPC-7 (panel E; neutrophils: blue; HPC-7: green).  Plots represent a mean 
adhesion ±SEM of at least 5 separate experiments; *** p<0.001.  Panel A: two-way 
ANOVA with bonferroni post-tests. 
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Figure 6.2.  Naïve and KC+ SDF-1α pre-treated HPC-7 reduce platelet microthrombi 
adhesion to an IR injured kidney at 6 hours reperfusion.  Neck surgery was performed 
and Alexa 568 and anti-CD41 antibody was injected intra-arterially.  Kidneys were then 
clamped for 45 minutes and allowed to reperfuse for 60 minutes prior to HPC-7 
A 
IR only 
IR + HPC-7 
100μm 
100μm 
100μm 
IR + KC+SDF-1α HPC-7 
100μm 
B C 
D E 
Chapter 6: Beneficial Effects of HSCs upon the Injured Renal Microvasculature 
 
174 
 
administration.  Five fields of view were taken of the kidney at 1 hour, 4 hours and 6 
hours reperfusion and platelet numbers were quantified.  There was a significant increase 
in the number of platelet microthrombi at 6 hours reperfusion in the IR injured kidney 
compared to that of the sham (panel A: black line: IR injured; grey line: sham).  When 
injecting naïve and KC+SDF-1α treated cells at 1 hour reperfusion, there was a significant 
decrease in the number of adherent platelet microthrombi compared to the IR injured 
kidney (panel A; green line: naïve HPC-7; blue line: KC+SDF-1α treated HPC-7; black line: 
IR only). Representative images showing platelet numbers in: sham (panel B); IR only 
(panel C); naïve HPC-7 + IR (panel D); KC+SDF-1α HPC-7 (panel E; platelets: red; HPC-7: 
green).  Plots represent a mean adhesion ±SEM of at least 5 separate experiments; *** 
p<0.001.  Panel A: two-way ANOVA with bonferroni post-tests.  
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6.3.3 Platelet microthrombi decrease in size after HPC-7 administration in vivo 
As well as the number of platelet microthrombi, the average size and fluorescent 
intensity of each microthrombi at 6 hours reperfusion was also analysed.  There was a 
significant (p<0.001) increase in the size of the platelet microthrombi after IR injury 
compared to sham (Average Platelet Microthrombi Size (APMS): IR only: 43.88±10.23; 
Sham: 8.840±1.821; Figure 6.3.A). Both naïve HPC-7 or KC+SDF-1α pre-treated HPC-7 
cells significantly (p<0.001) reduced platelet microthrombi size within the IR injured 
kidney compared to IR injury without HPC-7 (APMS: IR + naïve HPC-7: 12.61±3.673; IR + 
KC+SDF-1α HPC-7: 19.64±5.20; IR only: 43.88±10.23; Figure 6.3.A).  The overall 
fluorescent intensity of the microthrombus, indicative of the density of platelets present, 
did not change between treatments (Figure 6.3.B). 
 
6.3.4 Fluorescent immunohistochemistry of frozen renal sections further confirms 
the in vivo observations that HPC-7 can reduce platelet microthrombi after IR 
injury 
Following intravital experiments, kidneys were removed, frozen in liquid nitrogen and 
sectioned to quantitate platelet numbers using histological techniques with an anti-
CD42b primary antibody and an Alexa 488 secondary antibody.  A significant (p<0.05) 
increase in platelet numbers was observed following renal IR injury compared to sham 
tissue sections (CPF: IR only: 47.84.±14.59; Sham: 13.34±2.815; Figure 6.4.A-C).  The 
presence of naïve HPC-7 or KC+SDF-1α pre-treated HPC-7 significantly (p<0.05) reduced 
platelet accumulation within the IR injured kidney compared to IR injury without HPC-7 
Chapter 6: Beneficial Effects of HSCs upon the Injured Renal Microvasculature 
 
176 
 
(CPF: IR + naïve HPC-7: 16.61±3.821; IR + KC+SDF-1α HPC-7: 17.10±9.948; IR only: 
47.84.±14.59; Figure 6.4.A,C-E). Again, there was no significant difference in platelet 
numbers between the two groups receiving HSCs. 
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Figure 6.3.  The size of platelet microthrombi is reduced in IR injured animals at 6 hours 
reperfusion when animals receive 2 x 106 naïve and/or KC+ SDF-1α pre-treated HPC-7.  
Five fields of view were taken of the kidney at 1 hour, 4 hours and 6 hours reperfusion 
and each microthrombus size and fluorescent intensity was quantified using Slidebook’s 
offline analysis program and the mean quantitated.  A significant increase in the size of 
microthrombi at 6 hours reperfusion in the IR injured kidney was observed compared to 
sham (panel A: black line: IR injured; grey line: sham).  Injecting naïve or KC+SDF-1α 
treated cells at 1 hour reperfusion, significantly decreased the size of each adherent 
platelet microthrombi (panel A; green line: naïve HPC-7; blue line: KC+SDF-1α treated 
HPC-7; black line: IR only). There were no changes in the microthrombus fluorescent 
intensity (arbituary units) between any of the treatments (panel B).  Plots represent a 
mean adhesion ±SEM of at least 5 separate experiments; ** p<0.01, *** p<0.001.  Panel 
A and B: two-way ANOVA with bonferroni post-tests. 
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Figure 6.4.  Fluorescent immunohistochemistry shows that naïve and KC+ SDF-1α pre-
treated HPC-7 reduce platelet microthrombi adhesion to an IR injured kidney at 6 hours 
reperfusion.  After intravital surgery, mice were sacrificed at 6 hours reperfusion and 
kidneys were snap frozen in liquid nitrogen ready for sectioning.  10μm sections were cut 
and fixed to glass slides ready for fluorescent immunohistochemistry. Platelet 
microthrombi numbers were proven by using a primary anti-CD42b platelet marker and a 
fluorescent Alexa 448 secondary antibody.  Five fields of view were taken from each 
different kidney and the numbers of platelets were quantified.  There was a significant 
increase in the number of platelet microthrombi in the IR injured kidney compared to 
that of the sham (panel A).  Kidney that had received naïve and/or KC+SDF-1α treated 
cells at 1 hour reperfusion showed a significant decrease in the number of adherent 
platelet microthrombi compared to the IR injured kidney (panel A). Representative 
images showing platelet numbers in: sham (panel B); IR only (panel C); naïve HPC-7 + IR 
(panel D); KC+SDF-1α HPC-7 (panel E).  Plots represent a mean adhesion ±SEM of at least 
4 separate experiments; * p<0.05.  Panel A: one-way ANOVA with Dunnett’s post-tests.
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6.3.5 Vascular albumin leakage is improved after HPC-7 administration 
Following systemic injection, FITC-BSA is normally contained within the microvessels, 
which appear white (false colour green) against a black background.  However, when the 
integrity of the vasculature is disturbed, FITC-BSA leaks out and appears as a flare in the 
interstitium.  Following renal IR injury, a substantial increase in the macromolecular 
leakage of FITC-BSA at 6 hours reperfusion was observed when compared to the sham 
controls at 6 hours reperfusion (Figure 6.5.A-B).  However, macromolecular leakage 
decreased in mice receiving naïve or KC+SDF-1α treated HPC-7 when compared to IR 
injured kidneys without HPC-7 (Figure 6.5.C-D). 
 
6.3.6 Using the Chandler loop, administration of HPC-7 reduces blood clot weigh  
Preliminary Chandler loop studies were conducted to determine whether the reduction in 
microthrobus formation was due to a direct effect of HPC-7 on the platelets themselves.  
Whole blood, isolated from the mouse descending aorta, was introduced into a Chandler 
loop in the presence or absence of 5 x 105 HPC-7 or just a vehicle (saline) control.  There 
was no significant change in the weight of blood clots at 4 hours although there was a 
trend for weight to decrease slightly in the presence of HPC-7 (Average weight (AW): 
Saline control: 115.8mg±36.08mg; HPC-7: 92.02mg±12.96mg; Figure 6.6.A).  After 24 
hours, there was a significant decrease in clot weight when treated with HPC-7 (AW: 
144.9mg±30.45mg; HPC-7: 75.67mg±19.58mg; Figure 6.6.B).   
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Figure 6.5.  Vascular macromolecular leakage of labelled albumin is decreased in an IR 
injured kidney when HPC-7 are injected.  Kidneys were clamped for 45 minutes and 
allowed to reperfuse for 6 hours prior to a 200μl intra-arterial bolus of FITC-BSA.  Five 
fields of view were taken of the kidney at 6 hours reperfusion.  There was a significant 
increase in the leakage of a macromolecule at 6 hours reperfusion in the IR injured kidney 
(panel B) compared to that of the sham (panel A).  Naïve and KC+SDF-1α treated HPC-7 
were injected at 1 hour reperfusion: there appears to be a visible decrease in the amount 
of vascular leakage in the IR injured kidneys after naive (panel C) and KC+SDF-1α treated 
HPC-7 (panel D) administration, compared to IR injury alone.  
 
Sham IR only
IR + KC+SDF-1α HSCIR + HSC
100μm 100μm 
100μm 100μm 
A B 
C D 
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Figure 6.6.  The mass of a thrombus is reduced when HPC-7 are present.  Blood was 
removed from murine donors into citrate coated tubes and then introduced into the 
chandler loop, along with calcium chloride and then this was allowed to rotate for 4 
hours in the presence of HPC-7 or a saline control.  After 4 hours, there was a decline in 
the weight of the blood clot with the presence of HPC-7, but this did not reach 
significance (panel A).  Clots were then put into HBSS and incubated for 24 hours and clot 
weights were measured again: There was a significant decrease in the weight of the 
thrombus when 5 x 105 HPC-7 were present (panel B).  Plots represent a mean adhesion 
±SEM of at least 3 separate experiments; * p<0.05.  Panel A and B: unpaired t-test.   
A B 
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6.3.7 Blood flow in IR injured kidneys is improved after HPC-7 administration 
Blood flow decreased in IR injured kidneys compared to sham, as determined by laser 
Doppler flux imaging (Figure 6.7).  When naïve or KC+SDF-1α pre-treated HPC-7 were 
injected, a significant improvement in blood flow was observed compared to IR injury 
alone at 6 hours reperfusion (Figure 6.7).   
 
6.3.8 Urea and creatinine levels are reduced, thereby function improves, after HPC-7 
administration 
Blood was removed from mice after 6 hours reperfusion from the descending aorta and 
serum was analysed for urea and creatinine.  After renal IR injury there was a significant 
(p<0.01) increase in the urea and creatinine compared to healthy shams (Urea: Sham: 
8.325±0.3250; IR only: 11.35±0.6739; Figure 6.8.A; Creatinine: Sham: 18.25±0.8539; IR 
only: 31.50±1.658; Figure 6.8.B).  IR injured mice receiving naïve HPC-7 had a significantly 
lower urea and creatinine level (p<0.001 and p<0.01 respectively) compared to non-
treated mice (Urea: IR + naïve HPC-7; 7.280±0.2990; Figure 6.8.A; Creatinine: IR + naïve 
HPC-7: 20.00±0.6325; Figure 6.8.B).   KC+SDF-1α HPC-7 treated IR injured animals also 
had a significantly lower urea and creatinine levels (p<0.001 and p<0.05 respectively) 
compared to non-treated IR only (Urea: IR + KC+SDF-1α HPC-7; 8.260±0.4739; Figure 
6.8.A; Creatinine: IR + KC+SDF-1α HPC-7: 24.80±2.417; Figure 6.7.B).  However there 
were no differences in urea and creatinine serum levels between naïve and KC+SDF-1α 
treated HPC-7. 
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Figure 6.7.  Blood flow is improved in IR injured kidneys when HPC-7 are injected.  
Kidneys were then clamped for 45 minutes and allowed to reperfuse for 6 hours prior to 
blood flow measurements.  Five fields of view were taken of the kidney at 6 hours 
reperfusion with the laser Doppler equipment.  There was a significant decrease in the 
flux at 6 hours reperfusion in the IR injured kidney compared to that of the sham.  Naïve 
and KC+SDF-1α treated HPC-7 were injected at 1 hour reperfusion: there is a significant 
increase in blood flow in the IR injured kidneys after naive and KC+SDF-1α treated HPC-7 
administration, compared to IR injury alone.  
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Figure 6.8.  Urea and creatinine serum concentrations were reduced with the presence of 
HPC-7.  Blood was removed from the murine models of renal IR injury after intravital 
monitoring and then centrifuged at 1000g for 10 minutes at 4°C.  The serum was 
removed from the pellet and frozen at -80°C ready for analysis by the Pathology 
department, Queen Elizabeth Hospital, Birmingham, UK.  There was a significant increase 
in the urea (panel A) and creatinine (panel B) serum concentrations after 45 minutes 
ischaemia and 6 hours reperfusion, compared to a sham animal.  When naïve or KC+SDF-
1α pre-treated HPC-7 were injected into an IR injured animal at 1 hour reperfusion, urea 
(panel A) and creatinine (panel B) serum concentrations were decreased, compared to IR 
injured animals without HPC-7.  Plots represent a mean adhesion ±SEM of at least 3 
separate experiments; * p<0.05, ** p<0.01.  Panel A and B: one-way ANOVA with 
bonferroni post-tests. 
 
 
 
A 
B 
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6.4 Major Findings for Chapter 6 
 
FINDING HOW? 
1 
Establish 6 hour reperfusion IR injury model to 
image inflammatory cell recruitment 
In vivo: Confocal intravital 
microscopy 
2 
After renal IR injury, increased neutrophil 
numbers were observed at 6 hours reperfusion 
compared to a sham animal 
In vivo: Confocal intravital 
microscopy 
3 
When HPC-7 are injected into an IR-injured animal, 
they decreased the number of neutrophils at 6 
hours reperfusion, compared to an untreated IR 
control 
In vivo: Confocal intravital 
microscopy 
4 
After renal IR injury, increased platelet 
microthrombi numbers were observed at 6 hours 
reperfusion compared to a sham animal 
In vitro: Fluorescent 
immunohistochemistry 
In vivo: Confocal intravital 
microscopy 
5 
When HPC-7 are injected into an IR-injured animal, 
they decreased the number of platelet 
microthrombi at 6 hours reperfusion, compared to 
an untreated IR control 
In vivo: Confocal intravital 
microscopy 
6 
HPC-7 improved blood flow and vascular leakage 
in the IR-injured animal compared to a no cell IR-
injured control 
In vivo: Confocal intravital 
microscopy and laser Doppler 
microscopy 
7 
There is increased urea and creatinine injury 
markers after 6 hours reperfusion in a renal IR-
injured model compared to a sham control 
In vitro: Blood serum analysis 
8 
HPC-7 reduced injury markers at 6 hours 
reperfusion in the IR-injured animal compared to a 
no cell IR-injured control 
In vitro: Blood serum analysis 
9 
HPC-7 pre-treatment with 25ng/ml of KC + SDF-1α 
for 5 minutes does not appear to confer any 
greater benefit to inflammatory cell numbers or 
injury 
In vitro: Fluorescent 
immunohistochemistry and blood 
serum analysis 
In vivo: Confocal intravital 
microscopy and laser Doppler 
microscopy 
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6.5 Discussion 
This chapter presents novel data obtained using confocal IVM demonstrating that 
significant neutrophil and platelet adhesion occurs following mouse renal IR injury in vivo, 
and that these events are key contributors to microcirculatory and tissue damage.  
Adherent platelet microthrombi could subsequently block blood flow, further 
exacerbating the injury.  Additional microcirculatory disorders included marked albumin 
leakage, an indicator that vascular integrity had been disturbed, and an overall decrease 
in renal blood flow.  Considering these observations, it is essential therefore, that the 
development of new strategies to treat AKI must involve approaches that improve renal 
microcirculatory haemodynamics.  This study demonstrated that HSCs could confer quite 
remarkable vasculoprotective effects within the injured kidney, which is incredibly 
remarkable.  Novel labelling methodologies for imaging within the kidney were utilised 
for these studies, generating images of renal microcirculatory disturbances not previously 
seen. 
 
Numerous studies have previously demonstrated infiltration of neutrophils into IR injured 
tissues.  Increased renal distribution of leukocytes has also been shown histochemically, 
often as early as two hours post-reperfusion (Willinger et al. 1992).  Our intravital data is 
consistent with these findings.  Clearly blocking neutrophil adhesion is beneficial as 
antibodies against renal ICAM-1 prevented neutrophil adhesion, which subsequently 
protected from AKI (Kelly et al. 1996).  Although an anti-inflammatory role for MSCs is 
well described, the ability of HSCs to modulate neutrophil presence in inflamed tissue has 
received little attention (Schwarting et al. 2008).  However, our novel intravital data 
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indicates HSCs can indeed reduce neutrophil adhesion in mice undergoing renal IR injury.  
The role of platelets in the mouse kidney following IR injury has not previously been 
investigated directly.  In an early study in rats, radio-labelled donor platelets accumulated 
in the kidney 30 minutes post-reperfusion  (Chintala et al. 1994).  Similarly, within the IR 
injured gut, platelet adhesion increases at 30 minutes post-reperfusion (Holyer 2010).  
These pro-thrombotic events take place much earlier than what we have observed in the 
current study in which the number of microthombi increased most significantly at 6 hours 
post-reperfusion.  In intestinal IR injury, platelet rich microthrombi predisposes the 
animal model to organ failure (Kalia et al. 2001; Salter et al. 2001); therefore reducing 
platelet microthrombi would be extremely advantageous.  Our novel imaging 
methodology has allowed us to generate exciting data that shows HSCs also markedly 
modulate platelet adhesion.  
 
Although potent anti-platelet drugs are available for clinical use, there are advantages in 
using SCs to potentially inhibit platelets.  Although the anti-thrombotic / anti-aggregatory 
effects of well known drugs (eg. aspirin, GPIIBIIIA antagonists) are described, there is little 
direct evidence from in vivo studies that these drugs also prevent platelet-endothelial (P-
E) interactions. Indeed, Schulz and colleagues demonstrated intravitally, that although 
aspirin, in combination with clopidogrel, reduced platelet thrombus formation following 
rupture of an atherosclerotic plaque in vivo, they did not prevent adhesion of platelets to 
dysfunctional endothelial cells (Schulz et al. 2008).   
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Although a role for neutrophils is recognised in ischaemic disorders, there is increasing 
evidence that implicates a pathological role for adherent platelets on activated 
endothelium in IR injury.  Platelets have been shown to recruit inflammatory leukocytes 
to sites of IR injury and further aggravate endothelial damage.  Studies in the heart 
(Kupatt et al. 2002; Gawaz 2004), kidney (Singbartl et al. 2001) and liver (Khandoga et al. 
2002; Khandoga et al. 2003) have all shown that platelets mediate leukocyte adhesion 
during the reperfusion stage.  In our intravital studies, the microthrombi are generally 
observed earlier, and therefore they may be promoting the neutrophil recruitment in our 
model.  Furthermore, activated platelets can support the rolling and adhesion of 
leukocytes to the injured endothelium (Buttrum et al. 1993; Yeo et al. 1994) but also bind 
leukocytes via P-selectin-PSGL interactions (Palabrica et al. 1992).  Indeed, several 
studies, including our own research, have demonstrated that targeting leukocytes is not 
sufficient and preventing platelet-endothelial interactions is also needed.  Since adherent 
platelets on activated endothelium can recruit inflammatory cells (neutrophils, 
monocytes) and further exacerbate pathology, any strategy that simultaneously inhibits 
platelet and leukocyte adhesion will be desirable, particularly in IR injured tissue.  In 
addition, since SCs become adherent within the injured tissue microcirculation, their 
beneficial paracrine effects are localised within the immediate vicinity in which they are 
present i.e. in the disturbed microvessels.  This prevents any systemic effects being 
mediated and as such avoids unwanted side effects associated with pharmacological anti-
platelet agents e.g. bleeding complications.   
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It is unclear how HSCs mediate anti-platelet and anti-neutrophil effects and this will need 
to be investigated further. They could have direct effects on platelets and neutrophils 
themselves and/or on other cells, such as the endothelium, in the surrounding 
environment. Indeed, many functions have been postulated that HSCs can act beyond 
their role in haematopoiesis.  Circulating HSCs have been shown to fight against bacterial 
infection by releasing cytotoxic cytokines, such as TNF-α, act as readily available 
precursors of mature blood leukocytes, or release anti-inflammatory and pro-growth 
factors at sites of inflammation (Granick et al. 2012).   Evidence does suggest that 
commonly used anti-platelet drugs may not just work on the various actions on platelets, 
but also influence endothelial function (Zhao et al. 2006).   
 
Our preliminary data obtained using the Chandler loops suggests HSCs may directly 
modify platelet aggregation, as no endothelium was present in these assays; this effect 
was only significant after 24 hours.  The thrombi were stringy and brittle and were even 
more so when HPC-7 were present.  The appearance of these thrombi were different to 
how we expected, even though the shear rates were calculated to be similar to those 
experienced within a mouse renal arteriole, yet the clots resembled were more so of 
venous structure.  These are however very early studies and we cannot speculate further 
as to any potential protective mechanism.   
 
Interestingly, Abou-Saleh (2009) has shown that endothelial progenitor cells (EPC) and 
their supernatant can also inhibit platelet activation and aggregation through releasing 
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PGI2 and upregulating COX-2 production, thereby promoting an anti-thrombotic 
phenotype.  This effect was abolished when treated with a COX inhibitor, indomethacin.  
Using an in vivo model of arterial injury, Saleh and colleagues also showed that when 
EPCs or their supernatant was introduced intra-arterially 15 minutes before a FeCl3-
induced injury, it could effectively reduced thrombus mass by 33% and subsequently 
improved blood flow.   
 
It was originally hypothesised that any vasculoprotective effects would be proportional to 
the degree of HSC recruitment.   However, quite surprisingly, we demonstrated that HSCs 
recruited simply by injury alone were capable of reducing inflammation to levels 
observed in sham animals.  This is the opposite to what was observed by Kavanagh and 
colleagues (2013), as HPC-7 only reduced leukocyte adhesion in the IR injured gut when 
pre-treated with SDF-1α to enhance their recruitment.  This may be explained by the fact 
that physiologically, the renal blood flow (RBF), or the volume of blood delivered to the 
kidneys, is higher than in other organs.  Approximately 34% of the cardiac output in mice 
is delivered to the kidneys and 19% to the gut; calculated from the following published 
data in mice: CO=14.9ml/min ; RBF=5.1ml/min;  Small intestinal BF= 2.79ml/min  (Broulik 
et al. 1973; Garrelds et al. 2002).  This would mean that in ‘first passes’, more HSCs are 
delivered to the kidneys compared to other organs.  Hence the degree of HSC 
recruitment within gut may not be sufficient to confer a therapeutic effect.  Also, the 
intestinal mucosa is incredibly susceptible to ischaemic injury, which possibly does not 
affect the renal cortex (region viewed) to the same degree.  Therefore, more SCs may be 
required to aid in the repair of a severely damaged intestinal environment. 
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An increase in vascular permeability to albumin was also observed in renal IR injured 
microcirculation as shown by macromolecular leakage of FITC-BSA.  Leakage from vessels 
can occur as a result of direct injury to endothelium but has been demonstrated to be 
highly correlated with the number and location of adherent and emigrated leukocytes 
(Kurose et al. 1993).  Blockage of microvessels with microthombi, adherent leukocytes 
and/or platelet-leukocyte aggregates can reduce blood flow in the IR injured tissue 
(Frenette et al. 1998).  The additional advantages of inhibiting leukocyte and platelet 
adhesion using HSCs are therefore the reduction in macromolecular leakage and also the 
restoration of blood flow.  Several studies have shown that treatments aimed at reducing 
the trapping of RBC, leukocytes and also promoting the anticoagulant state significantly 
improved kidney morphology and function (Hellberg et al. 1990; Rabb et al. 1994; Kelly et 
al. 1996; Druid et al. 1998).   
 
Data presented in this chapter also showed improvements in renal function.  During renal 
injury, the glomerular capillaries are unable to filter blood efficiently due to a reduction in 
blood flow – this results in an increase in both urea and creatinine.  Serum urea and 
creatinine concentrations were elevated in renal IR injured mice compared to sham, 
indicating a malfunction in kidney function.  Even small increases in creatinine result in 
worsened long-term outcomes and an associated greater mortality risk (Coca et al. 2007).  
However, improvements in these parameters were observed in HSC-treated mice 
indicating this cellular therapy can also improve renal function.  This is in contrast to data 
presented recently by Burst and colleagues (2013) who demonstrated that rat-derived 
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HSCs, characterised as being Lin- CD90+, could not ameliorate renal function or structure 
after damage to their IR injury model; however, this study was conducted in rats in which 
fewer cells were injected than in this work.   
 
Future studies would need to determine the long term benefits of HSCs in the kidney, as 
this study only observed a relatively short period of reperfusion in the acutely injured 
kidney.  Although no therapeutic advantage was demonstrated in enhancing SC presence 
in this injury mode, it may be that increased SC presence becomes essential in more 
chronic models of renal injury.  Thus strategies that enhance renal HSC adhesion may be 
necessary for their vasculoprotective benefits to be apparent and is thus a worthwhile 
pursuit.   
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7 General Discussion 
7.1 Summary of Main Findings 
Although HSCs are potentially beneficial for a variety of renal disorders, their efficacy may 
depend on successful local recruitment (Lin et al. 2003; Li et al. 2010; Li et al. 2011; Li et 
al. 2012).  HSCs are rare cells constituting <0.05% of the BM and this scarcity has 
hindered their clinical use.  Improving their therapeutic efficacy may therefore depend on 
identifying adhesive mechanisms that underpin SC trafficking.  However, no studies have 
previously described the molecular adhesive mechanisms governing renal HSC 
recruitment.  Therefore, one of the primary aims of this thesis was to understand the 
adhesion mechanisms involved in HSC recruitment to the IR injured kidney and to utilise 
the information to develop strategies to improve renal homing.  We developed an 
intravital imaging methodology to obtain valuable insights into the kinetics of SC homing 
within the mouse renal microcirculation in vivo immediately following their infusion.  This 
study not only generated data on renal SC homing, but also provided novel data on some 
of the microcirculatory disturbances that are associated with renal IR injury.  The major 
findings from this study include the following: 
 
 HSCs are recruited to injured and non-injured CL kidney post-renal IR injury, with 
increased free-flowing HSCs numbers observed in injured kidneys at the point of 
infusion.  This increased adhesion is despite the fact that blood flow is reduced in 
the injured kidney upon reperfusion. 
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 Topical application of chemokines KC or SDF-1α can recruit HSCs to a healthy 
kidney and their receptors, CXCR2 and CXCR4, are expressed on the HSC surface. 
 Blocking studies have shown CD49d, CD44, CXCR2 and CXCR4 are responsible for 
governing HSC adhesion to the injured peritubular capillaries in vivo.  VCAM-1 and 
HA are the endothelial counter-receptors for CD49d and CD44 and are important 
in mediating recruitment following renal ischaemic damage. 
 HSC pre-treatment with KC or SDF-1α enhanced adhesion to renal endothelium in 
vitro, whereas IL-1β or TNF-α did not.  However, all tested cytokine pre-
treatments enhanced HSC adhesion to IR injured kidney in vivo.  IL-1β, SDF-1α, 
TNF-α or KC+SDF-1α treatments also increased the number of free-flowing HSCs.   
 Enhanced adhesion can be explained by various mechanisms: these included that 
after IL-1β, SDF-1α and KC+SDF-1α pre-treatments HSCs were more deformable 
when moving through (glass) capillaries.  Also, KC or SDF-1α increased HSC 
adhesion to both VCAM-1 and HA, indicating an increased binding capacity of 
HSCs adhesion molecules for their respective counter-ligands.  Furthermore, an 
increase in the number of CD49d and CD44 micro-clusters after SDF-1α or KC pre-
treatment was observed, most likely explaining the increases in adhesion to their 
immobilised counter-receptors in vitro. 
 A longer perfusion model of renal IR injury showed an increase in platelet 
microthrombi and neutrophils at 6 hours reperfusion in injured peritubular 
capillaries compared to sham.  Additional microcirculatory disturbances include 
increases in vascular permeability and decreased blood flow within the kidney.  
Most strikingly, HSC injection at 1 hour reperfusion reduced both platelet and 
neutrophil numbers at 6 hours reperfusion in an IR injured kidney in vivo, as well 
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as reducing renal vascular permeability and increasing renal blood flow; this 
resulted in an overall improvement in kidney function at 6 hours reperfusion. 
 
Intravital studies monitoring HSC trafficking in vivo to sites of injury have been limited 
due to difficulties in isolating sufficient numbers for detection following systemic 
infusion.  We and others have found that approximately 5000 primary murine HSCs (KSL 
cells) can be obtained from one adult mouse (Orlic et al. 2001); this is too low for 
intravital or even in vitro adhesion assays and pooling cells from mice would require an 
unacceptable number of donor mice to be culled for individual intravital experiments.  A 
murine HSC line, HPC-7, was therefore used.  Many studies have used these HPC-7 to 
model primary HSCs in detailed molecular, cellular signalling and homing studies (Pinto 
do et al. 1998; Pinto do et al. 2001; Pinto do et al. 2002; Kavanagh et al. 2010; Kavanagh 
and Kalia 2011; Kavanagh et al. 2012).  However, it is essential to point out that our pre-
treatment strategies also enhanced the adhesion of primary SCs in a similar manner 
when using an activated renal endothelium adhesion assay (White et al. 2013).  This 
repertoire of information validates the use of HPC-7 as a HSC alternative. 
 
The body of work contained in this thesis firstly presented data showing that acute 
inflammation of the kidney results in increased adhesion of exogenously administered 
HPC-7 cells.  Both in vitro and in vivo data demonstrates that renal IR injury acts as a 
stimulus to promote the recruitment and adhesion of HPC-7 to the injured 
microvasculature.  This stimulus could be in the form of small molecular weight proteins, 
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which were identified in a greater concentration within the ICM compared to the SCM.  
We initially demonstrated that pre-treating cells with this ICM resulted in increased HPC-
7 adhesion in vitro; these proof-of-concept experiments clearly demonstrated that HSC 
adhesion can be modified and this is the first time this has been demonstrated within an 
injured kidney.  However, this strategy does not have the potential to be applied 
clinically, and so more translational approaches were identified.   
 
Although we speculated and identified a critical role for SDF-1α and other 
cyto/chemokines such as KC, we would need to perform detailed analysis of the ICM to 
identify any additional chemical and biological factors within the ICM.  There may be 
more potent modulators of SC behaviour than those identified in this study; powerful 
cellular activators such as leukotrienes and complement factors are also known to be 
released in abundance following IR injury and can influence circulating blood cell 
adhesion.  Furthermore, these molecules may be unique to tissue or injury type and may 
offer the potential to further refine the targeting process to specific sites.  This is 
particularly important since not all studies have identified SDF-1α as a critical homing 
molecule: Ip and colleagues (2007) have shown that blockade of CXCR4 on MSCs did not 
reduce their recruitment to the ischaemic myocardium; this could be due to a lower 
expression of CXCR4 on MSCs compared to HSCs.  Although many studies have 
highlighted a key role for SDF-1α in mediating HSC recruitment and homing (Lapidot 
2001; De Falco et al. 2004; Porecha et al. 2006), we present novel data that KC is equally 
as potent at enhancing HSC adhesion.  Identifying more than one effective strategy is 
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important, as it is not clear which pre-treatment, if any, will be effective when used in 
translational studies in humans.   
 
The VLA-4/VCAM-1 pathway has previously been implicated in SC homing to different 
tissues (Mazo et al. 1998; Zhang et al. 2007; Kavanagh et al. 2010).  This is not surprising 
as the trafficking of leukocytes is also somewhat dependant on this pathway (Woodside 
et al. 2006).  The α4 but not β1, on MSCs has been showed to be essential for MSC 
recruitment and engraftment to the heart after myocardial infarction (Ip et al. 2007).  We 
have shown the α4 subunit is essential for HSC recruitment to the IR-injured kidney but 
whether the β1 subunit is also responsible for this adhesion is yet to be investigated.  As 
well as being important in acute injuries, the VLA-4/VCAM pathway has been proposed to 
be of importance in chronic disease states (Yusuf-Makagiansar et al. 2002); this suggests 
strategies that modify the interactions of this pathway may also improve their homing in 
more chronic renal diseases.  The molecular adhesive mechanisms’ governing HSC 
homing to experimental models of CKD have yet to be determined and is certainly 
important area to pursue in future studies.   
 
The final part of this work focussed on the inflammatory environment during renal IR 
injury.  Neutrophil infiltration is heightened at 6 hours reperfusion: CD18 on their surface 
is the primary adhesion molecule responsible for their adhesion and its endothelial 
counter-ligand ICAM-1 is heavily upregulated after 24 hours of renal IR injury (Burne et al. 
2001).  Therefore, as AKI is split into several stages, it is conceivable that CD18 could 
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become predominant in HSC trafficking in the later stages of kidney injury.  This could 
also be true of endothelial CD44: we have shown HPC-7 require their CD44 expression to 
adhere to injured renal endothelium and  although CD44 can interact with itself (Isacke 
1994) and is expressed on capillary endothelial cells after renal IR injury (Rouschop et al. 
2005), in our model of renal IR injury HSC adhesion to the peritubular endothelium was 
not governed by endothelial CD44.  After renal IR injury, CD44 expression on capillary 
vasculature has been shown to peak at 24 hours (Lewington et al. 2000), whereas HSC 
adhesion in our model was examined at 1-2 hours reperfusion.  We have shown that HA 
was the endothelial counter-ligand for CD44 on HSCs and is required for HSC homing to 
the injured renal microvasculature.  This reiterates that another important pathway for 
HSC adhesion has a role in leukocyte rolling and firm adhesion to endothelium 
(DeGrendele et al. 1997; Gal et al. 2003).  Collectively this data provides sufficient 
evidence that the kinetics of HSC adhesion follows a similar process to that of the 
leukocyte-endothelial cascade.  From a clinical perspective, one of the major areas of 
debate for cellular therapy is which would be the best and most effective route for 
delivery: intra-arterial injection of SCs is the preferred method of delivery of cellular 
therapy in patients; this current study (and others from our group) demonstrates that 
these cells can be delivered systemically, that they are capable of circulating in the 
bloodstream and can home to and be captured by inflamed renal vasculature.   
 
Peled and colleagues (2000) suggested that HSC receptor activation could be modulated 
by the inflammatory environment the cells are exposed to within an injured organ and 
this activation can happen within minutes.  They showed that more CD34+ cells adhered 
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to ICAM-1 and VCAM-1 after 1 minute stimulation with SDF-1α, compared to untreated 
control; therefore a 5 minute HSC treatment with individual cytokines was used to pre-
activate HSCs to enhance adhesion.  KC and SDF-1α are known to be released by the 
injured kidney (Togel et al. 2005; Molls et al. 2006) and both of these chemokines cause 
an increase in the number of CD44 and CD49d receptor micro-clusters and subsequently 
enhance their binding to their endothelial counter-ligands, HA and VCAM-1.  Wards and 
colleagues (1994) have shown that the cooperative effects of more receptor clusters 
actually increases the resistance of the bond breaking, thereby enhancing firm adhesion.  
Other studies have shown that small patches of adhesion receptors, known as point 
contacts, contribute to cell attachment and spreading on ligand-coated substrates 
(Streeter and Rees 1987; Tawil et al. 1993).  These studies support our hypothesis that 
HSC pre-treatments enhance adhesion through modulating receptor localisation.  Overall, 
our data suggests that modulating the binding capacity and/or cluster number of surface 
adhesion molecules provides a relatively easy and effective means by which to modify SC 
recruitment and that such strategies are a worthwhile pursuit.  
 
The final part of this work focussed on characterising the inflammatory environment 
during renal IR injury.  Although neutrophil infiltration has been demonstrated following 
renal IR injury, no previous studies have directly reported increased platelet thrombus 
presence within peritubular capillaries in vivo, noted at 6 hours reperfusion.  These can 
contribute to microvascular congestion, poor blood flow and exacerbation of the 
inflammatory injury.   There are currently few treatments specifically aimed at inhibiting 
the root cause of IR injury, which has been hypothesised to be the reduction in blood 
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flow due to reduced NOS activity and microvascular congestion.  These have been 
hypothesised to be the main cause of sustained AKI (Regner and Roman 2012).  Increased 
platelet and neutrophil presence has also been implicated in the pathophysiology of a 
number of other kidney conditions.  Studies have suggested that platelet activation and 
leukocyte-endothelial interactions may be important in early post-transplantation renal 
failure and rejection in humans and clinical trials using PAF antagonists have shown to be 
beneficial in ischaemic AKI (Haug et al. 1993; Grino 1994).  In the glomeruli of 
transplanted human kidneys, increased platelet and neutrophil deposition has been 
correlated with higher serum creatinine levels (Koo et al. 1998) and their presence 
immediately after transplantation of a renal allograft is indicative of a non specific, 
inflammatory event that is potentially detrimental to long-term graft function.  
Therefore, methods such as targeted HSC delivery to the kidney, which can effectively 
reduce both platelet and neutrophil infiltration would be extremely important long-term 
and in may confer therapeutic benefit in many other renal disorders in which platelets 
and neutrophils contribute to the pathology. 
 
Sutton and colleagues (2002) stated that in ischaemic AKI, there is a short therapeutic 
window in which administered treatments will be useful for prevention of tissue injury.  
Studies have shown this window of opportunity to be a real phenomena, as angiogenic 
therapy following CKD is only useful in reducing injury when administered at certain time 
points (Long et al. 2012).  In our studies, we have shown in our longer perfusion model of 
renal IR injury that HSC infusion at 1 hour reperfusion can reduce platelet microthrombi 
and neutrophil infiltration and also improved blood flow.  We speculate that this 
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improvement in blood flow and reduced inflammatory cell number underlies the 
observation of decreased urea and creatinine levels are decreased, thus improving GFR 
and the kidneys capability to filter nitrogenous substances.  Urea and creatinine levels are 
brought down to similar levels to those seen in a non-injured sham-operated animal.  This 
is the first study to show that HSCs can confer vasculoprotective and functional benefits 
within such a short period of time.  Ratajczak and colleagues (2012) suggest that 
paracrine signals from a variety of SCs results in similar therapeutic benefits: Ren et al. 
(2008) and Abou-Saleh et al. (2009) have shown that MSCs and EPCs release NO after 
exposure to pro-inflammatory molecule and additional studies involving MSCs, HSCs or 
EPCs administration after myocardial injury have shown similar therapeutic effects on 
ventricular function (Orlic et al. 2001; Kucia et al. 2004; Quevedo et al. 2009).  We 
hypothesise that once HSCs are within the injury site, they are exposed to many 
inflammatory factors and could be acting in a paracrine action, similar to MSCs and EPCs 
in the above studies by releasing immunosuppressive factors and NO, which would 
explain decreases in neutrophil and platelet adhesion, altering the injured environment 
from a pro-inflammatory phenotype to a more anti-inflammatory one (Figure 7.1).
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Figure 7.1.  HSC anti-inflammatory hypothesis.  Renal IR injury causes an upregulation in adhesion molecules.  This promotes subsequent 
adhesion of leukocytes and platelets, which reduces blood flow. Blood flow is worsened due to endothelial cell swelling because of altered 
eNOS activity (panel A).  We hypothesise that HSCs adhere to the injured environment and release a concoction of anti-inflammatory factors, 
which would act to reduce cytokine and leukotriene secretion.  In addition, we believe HSCs could be releasing NO, which is an important 
protective molecule, as it can also reduce platelet and leukocyte activation and adhesion (panel B). 
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7.2 Future Work 
Even though the literature on HSC recruitment to injured or diseased tissues is 
expanding, there are still questions which remain to be answered.  Therefore there are 
several ways in which the work detailed in this thesis could be expanded.  If we anticipate 
taking our pre-treatment strategies into the clinic, we would need to conduct studies 
using human HSCs to determine whether similar modifications in human HSC homing can 
be made.  Furthermore, the vasculoprotective effects of human cells would also need to 
be investigated in similar in vivo experimental studies.   
 
The paracrine factors released from the HPC-7 that are responsible for the 
vasculoprotective effects clearly need to be identified.  Cytokines are heavily upregulated 
in IR injury and their production can worsen IR injury and several anti-cytokine agents 
have been tested to determine whether they ameliorate AKI (Eason et al. 1996).  
Neutrophils predominate in IR injuries and it has been shown that reducing CXC 
chemokines can reduce neutrophil infiltration.  It is possible that HSCs create an anti-
inflammatory environment by reducing the release of such chemokines, which may 
explain the decrease in neutrophils we have observed after HSC administration.  
Therefore detailed analysis of the releasate from HSCs when exposed to an inflammatory 
environment needs to be determined.  We have collected serum from IR injured animals 
that received HPC-7 which will be compared using ELISAs with serum from injured mice 
without cells and will compare their cytokine profiles.  Schwarting and colleagues 
demonstrated that Lin− HSCs reduced infarct size and reduce inflammation in a mouse 
model of stroke; they analysed gene transcript levels of a variety of trophic factors 
Chapter 7: General Discussion 
 
205 
 
including brain-derived neurotrophic factor, glial-derived neurotrophic factor, VEGF and 
TGF-β.  However, although no changes in the presence of growth factors were observed, 
RT-PCR analysis of pro-inflammatory cytokines in spleens 24 hours after HSC injection 
demonstrated decreased gene transcripts of pro-inflammatory cytokines TNF-α and IL-1β 
(Schwarting et al. 2008).  This study is the first to demonstrate that HSCs are capable of 
modulating gene expression of inflammatory markers.   
 
The body of literature studying paracrine-mediated effects of SCs is quickly increasing, 
especially regarding their anti-inflammatory properties.  MSCs have been shown to 
express high levels of iNOS and release various chemokines such as CXCL9 and CXCL10 
after IFN-γ and TNF-α pre-treatment (Ren et al. 2008).  These leukocyte-recruiting 
chemokines can enhance inflammatory cell homing towards MSCs, but instead of 
exacerbating the damage, pro-inflammatory cytokine treated MSCs release large 
quantities of NO, which acts to locally suppress the adhesion of immune cells.  This NO 
elevation is continued days after the treatment is removed; this could also be of use in 
later stages of regeneration as NO is known to propagate new blood vessel growth. 
Ratajczak and colleagues (2012) hypothesised that different types of SCs may have similar 
anti-inflammatory paracrine effects to each other, therefore studies would need to be 
conducted to understand if our HSCs released similar compounds.   
 
In addition to HSCs, accumulating evidence now suggests that MSCs may be protective in 
animal models of IR injury including following renal IR injury (Wise and Ricardo 2012).  
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Current interest has focussed heavily on using MSCs primarily because of their ability to 
avoid rejection and their relative ease of expansion in culture.  Interestingly, a recent 
study has shown that MSCs can improve kidney function after renal IR injury by 
enhancing regulatory T cell infiltration and provided beneficial effects at 72 hours (Hu et 
al. 2013).  It is unknown whether MSCs share the potential to elicit reductions in platelet 
and neutrophil numbers post IR injury and would be worthy of experimentation.  Within 
the previous study, MSCs did not need to home to the injury site to confer beneficial 
effects; currently, the molecular mechanisms that govern the recruitment of MSCs to the 
kidney post IR injury are also unknown but if these were understood, would increasing 
their homing to sites of injury enhance their regenerative capacity? 
 
Although we have shown that HSCs were vasculoprotective at 6 hours post-injury, it is 
not known whether these beneficial effects would be sustained if animals were allowed 
to recover.  Crockett and colleagues (2006) reduced liver IR injury in the early stages of 
reperfusion by administering acetylcholine receptor (AChR) agonists  prior to ischaemia 
as acetylcholine is known to bind to macrophages and inhibit their cytokine release.  
Although these agonists reduced the early elevation in plasma cytokines and injury 
markers, after 6 hours reperfusion these beneficial effects slowly diminished and by 24 
hours the results were negligible.  In our lab, experiments are underway to understand if 
HPC-7 can reduce pro-inflammatory cytokine plasma concentrations.  However we have 
yet to determine to determine whether HPC-7 are also protective in the later stages of 
reperfusion. 
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7.3 Concluding Remarks 
In conclusion, despite huge advances in the field of cellular therapy, a major impediment 
remains their poor retention within target tissues on systemic delivery.  This is the first 
time that the main adhesive and cytokine pathways governing HSC recruitment to an IR-
injured kidney have been detailed.  Manipulating such mechanisms that target these cells 
to the site of injury is essential to realising their full potential.  We provide a simple, quick 
and effective method for increasing HSC adhesion into injured kidney using cytokine pre-
treatments, with KC and SDF-1α eliciting maximal enhancement.  Previous studies have 
enhanced SC recruitment by introducing genes encoding for SDF-1α within cardiac tissue 
(Tang et al. 2005); however, the clinical applicability of such techniques is debatable and 
may be associated with aggravated tissue injury due to side effects, such as SDF-1α-
dependent lymphocyte recruitment (Liekens et al. 2010).  The current study benefits 
from identifying a strategy that increases recruitment without genetically manipulating 
the HSCs or the host tissue and thus has the potential to be used clinically.  It is 
anticipated that enhancing HSC recruitment to injured kidney may expedite the recovery 
process and encourage greater therapeutic success clinically.  There are currently no 
clinical trials using HSCs in AKI; our data may therefore help in the design of future clinical 
studies that use HSCs for renal repair.  HSCs have been shown to improve kidney function 
within a short period of time and the study of these beneficial effects using naïve/pre-
treated HSCs in recovery models will need to be carried out. 
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